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ABSTRACT 
Core temperature (Tc) regulation is fundamental to mammalian survival, since hypothermia (Tc ≤ 
35°C) and hyperthermia (Tc ≥ 40°C) are major risk factors for health and wellbeing. The purpose 
of this thesis was to determine if acetaminophen, an analgesic and antipyretic drug, increased the 
onset of hypothermia or hyperthermia during passive cold and heat stress, respectively. It was 
later investigated if acetaminophen induced inhibition of cyclooxygenase mediated these side-
effects.  
In Study 1a, the plasma acetaminophen response to a dose of 20 mg·kg-1 of lean body mass was 
determined through enzyme linked immunosorbent assay. In Study 1b, the effect of 
acetaminophen administration on internal temperature (rectal; Tre) during a passive 2-hour mild 
cold (20°C, 40% relative humidity) exposure was examined. Study 1a showed that the plasma 
response was homogenous between subjects, reaching peak concentrations between 80-100 
minutes (14 ± 4 μg·ml-1). In Study 1b, acetaminophen reduced Tre in all participants compared 
with baseline, and the average peak reduction was 0.19 ± 0.09°C. In contrast, Tre remained stable 
when participants ingested a sugar placebo. Study 1 is the first experiment which confirms a 
hypothermic side-effect of acetaminophen in healthy humans.  
Study 2 investigated whether acetaminophen augmented the rate of Tre rise during exposure to 
passive dry (45°C, 30% r.h.) and humid (45°C, 70% r.h.) heat stress for 2-hours and 45-minutes, 
respectively. This study showed that the rate of Tre rise in the dry (0.005 vs 0.006°C∙min-1) and 
humid (0.023 vs 0.021 °C∙min-1) conditions were similar between the acetaminophen and 
placebo trials (p > 0.05). Study 2 is the first experiment which confirms acetaminophen has no 
meaningful effect on thermoregulation during passive dry or humid heat exposure. Study 3 
determined how the hypothermic effect of acetaminophen changes during exposure to a 
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thermoneutral (25°C, 40% r.h.) and cold (10°C, 40% r.h.) environment for 2-hours. In summary, 
there was no hypothermic effect of acetaminophen in a thermoneutral environment (p > 0.05), 
whereas Tre fell by 0.40 ± 0.15°C compared with baseline during cold stress (p < 0.05). 
Compared with the placebo, Tre was ~0.35°C lower at 120 minutes, but was significantly lower 
from 70-minutes. Study 3 confirmed that there is a relationship between the level of cold stress 
and magnitude of the hypothermic effect of acetaminophen.  
Study 4 determined whether ibuprofen (400 mg), a cyclooxygenase inhibitor, reduced Tre during 
2-hour passive cold stress (10°C, 40% r.h.) to a level comparable with acetaminophen. Ibuprofen 
administration did not influence Tre, vastus medialis shivering, or energy expenditure compared 
with a placebo throughout the cold exposure (p > 0.05). Taken together, this renders it unlikely 
that cyclooxygenase activity is required for thermogenesis induced by skin cooling. Study 4 
provides evidence that acetaminophen induced hypothermia is not exclusively mediated by 
cyclooxygenase inhibition.  
In Summary, this series of experiments has shown that acetaminophen has a hypothermic side 
effect in healthy humans, which is amplified during acute cold stress. Ibuprofen had no such 
effect on thermoregulation during cold exposure, so it is unlikely that cyclooxygenase inhibition 
mediates the hypothermic side-effect of acetaminophen. 
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CHAPTER 1: GENERAL INTRODUCTION 
Human internal/core temperature (Tc) is tightly regulated at an optimum of 37°C. At the lower 
extremes of Tc (≤35°C), ion fluxes, increases in membrane fluidity, and decreases in enzyme 
performance and post-translational protein synthesis can occur. While protein denaturation 
looms at the higher extreme of Tc (>41°C), an event which can be life threatening. In 
environments that are not considered thermally stressful (i.e. those that do not acutely change the 
global temperature of the skin), Tc is regulated entirely through subtle changes in cutaneous 
blood flow (Romanovsky, 2014). This method incurs virtually no metabolic cost, so is a suitable 
first line of defence against threats to heat balance. As the ambient temperature falls below 18°C, 
less fuel-efficient mechanisms are utilised for active thermogenesis (heat production), which are 
partitioned into shivering (skeletal muscle) and non-shivering (brown adipose tissue and skeletal 
muscle) mechanisms (Blondin et al., 2014). During heat stress, humans rely on heat loss 
mechanisms to maintain heat balance. Most notably, homo-sapiens are able to evaporate sweat 
from the skin surface, and raise the skin temperature for convective heat transfer with the 
environment (Marino 2008a). The autonomic adaptations described above will only arise in the 
absence of sufficient behavioural adaptations which are mediated if thermal comfort is 
compromised. These include changing clothing, adjusting the thermostat, and seeking a warmer 
or cooler environment (Havenith and Fiala 2015). Nevertheless, there are scenarios where these 
thermoregulatory adjustments are insufficient, noted by an uncompensable increase or decrease 
in Tc.  
Heat stress is seen during exercise, occupational settings, and of course during heat waves. A 
simple definition may be that heat stress arises when active heat loss mechanisms are required to 
maintain heat balance, or a Tc of 37°C. Heat stroke, a condition caused when Tc reaches upper 
2 
 
extremes of ~41°C and beyond (Leon and Helwig 2010; Simpson and Abelsohn 2012), is a rare 
occurrence regarding mortality. In the USA, heat stroke caused 125 deaths per million people 
(NOAA 2013), yet there are thousands of excess deaths during heat waves (Kenney et al. 2014). 
A poignant example is that of the 2003 Europe heat wave which caused over 15,000 excess 
deaths in France and 70,000 excess deaths across Europe (Robine et al. 2008). Most of these heat 
wave related deaths occur in elderly people who have pre-existing cardiovascular or respiratory 
illnesses. For example, the Chicago heat wave in 1995 caused approximately 1,686 excess deaths 
in the period July 14th to July 20th where the ambient temperature peaked; only 4.7% of these 
deaths were linked to hyperthermia, while over 93% were due to an underlying cardiovascular 
cause (Kaiser et al. 2007). Occupational health and productivity is also negatively impacted by 
heat stress. There are many studies which show an increased risk of workplace injuries in people 
are exposed to excessive heat, and this is primarily due to an inability to concentrate in times 
where sensory input is dominated by an increased skin temperature and wittedness (Tawatsupa et 
al. 2013). These cognitive responses are also met with reductions in workplace productivity 
which is perpetuated by a greater frequency in recovery breaks. Such productivity losses have 
been shown to incur annual losses of ~£5 billion GBP in Australia and ~£618 million GBP in 
Germany (Hübler et al. 2008; Zander et al. 2015). Without question, climate change will be, and 
has been, paralleled by an increased frequency of hot weather events. In the last 20 years, 16 of 
20 winters and 19 of 20 summers have been above average in ambient temperature (Hansen et al. 
2010), and record high temperatures have been documented two-fold more often than record low 
temperatures since the year 2000 (Meehl et al. 2009). Even if Europe achieves their goal of 
reducing CO2 emissions to 20% below the level shown in 1990 by 2020, the effects of climate 
change will persist for at least a further 50 years (Monjon 2016).  
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On the other hand, exposure to cold carries even greater risk to human health, at least at the time 
of writing this thesis. In the United Kingdom, the hospital admissions in which hypothermia is a 
primary or secondary cause outweigh that of hyperthermia. In fact, admission rates seem to be 
rising in this region. The National Health Service (NHS) hospital episode statistics for 2013/2014 
indicate that there were 3,780 admissions to NHS hospitals where hypothermia was the primary 
diagnosis, and nearly 18,000 where hypothermia was the secondary diagnosis. In 2005/2006, 
admission numbers were 2,010 and 7,069 for primary and secondary diagnoses, respectively. 
The very young (0 to 4 years) and the elderly (≥ 65 years) accounted for 80% of these 
admissions, highlighting an impaired ability of these age groups to regulate their Tc during 
physiological stressors. Hypothermia is associated with many symptoms depending on the 
magnitude of Tc decline, which Brown et al. (2012) categorised into four stages [I (35 to 32°C), 
II (<32 to 28°C), III (<28 to 24°C), IV (<24°C)]. At stage I, the patient is normally responsive 
with a maximal increase in metabolic rate to fuel shivering thermogenesis, however, 
consciousness is obscured and blood pressure becomes difficult to read as Tc approaches 32°C 
(Parsons, 2014). At stages II and beyond, there is a high risk of cardiac abnormalities, 
particularly ventricular fibrillation. In stage II-IV hypothermic patients, an Osborn wave 
(positive deflection of the ‘J’ point) is normally present during echocardiography analysis 
(Osborn, 1953; Omar, 2016). This is an abnormality closely related to risk of fibrillation (i.e. 
larger Osborn wave indicates greater cardiac rhythm dysfunction). The risk of cardiovascular 
failure is positively correlated with decreases in Tc (Filippi et al., 2014), and survival from 
accidental hypothermia is unlikely when stage IV hypothermia is attained (Parsons, 2014).  
There is evidence that the use of some over-the-counter drugs may impair Tc regulation during 
thermal stress. The Vigibase adverse drug reaction database was founded by the World Health 
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Organisation in 1975 and is a useful tool for initial inspection of specific drugs and risk of 
hypothermia or hyperthermia. In this thesis, the drugs in question (acetaminophen and ibuprofen) 
are known as cyclooxygenase (COX) inhibitors, since their mechanism of action stems from 
blocking the activity of this enzyme. The sole function of the COX enzyme is to convert 
arachidonic acid to an intermediate named PGH2 (Dubois et al. 1998). Thereafter, cell specific 
enzymes convert PGH2 to a number of prostanoids (TXA2, PGI2, PGE2) which serve as lipid 
hormone like molecules. For example, TXA2 synthase is present in the platelet and converts 
PGH2 to TXA2 since it is required for platelet aggregation and thrombus formation (Yokoyama 
et al. 1991). Endothelial cells contain PGI2 synthase which convert PGH2 to produce both PGI2 
for vasodilatory effects (Spisni et al. 1995). Hypothalamic endothelial cells contain PGE2 
synthase which converts PGH2 to PGE2, a hormone which increases neuronal drive for 
thermogenesis during fever (Wilhelms et al. 2014). There are many known roles for prostanoids 
in human biology since COX is present in almost all cell types; these are only examples which 
are most relevant to thermoregulation. It should be noted early on that COX inhibitors are used 
to treat pain, inflammation, and fever (COX is involved in the pathophysiology in each process). 
However, there exists no conclusive evidence that these drugs impact any aspect of Tc in healthy, 
non-febrile individuals.  
Nonetheless, Vigibase indeed shows an interaction between the use of COX inhibitors and 
hypo/hyperthermia (Lindquist 2008). Acetaminophen has been associated with 340 cases of 
hypothermia and 45 cases of hyperthermia, while ibuprofen is linked with 184 cases of 
hypothermia and 20 cases of hyperthermia. These numbers are low relative to the volume of 
users worldwide, but there are no studies which have investigated this potentially adverse 
reaction in humans, at different ambient temperatures, and at non-toxic doses. A drug induced 
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depression of thermogenesis during cold exposure could lead to accidental hypothermia, 
particularly within the elderly and new-borns who are commonly administered over-the-counter 
analgesics and are most vulnerable to cold stress (Koponen et al. 2013; Liukas et al. 2011; 
Ohlsson and Shah 2016). Equally, these populations are most at risk during exposure to 
excessive heat since the very young and elderly make up a large percentage of morbidity and 
mortality rates during heat waves (Kenney et al. 2014). The first goal of this thesis is to 
determine whether acetaminophen interacts with human Tc during heat stress and cold stress. If a 
potentially adverse reaction is seen in healthy adults, follow up work will determine whether 
these effects are at least in part mediated through COX inhibition. In the preliminary 
experiments, acetaminophen was chosen over ibuprofen or other COX inhibitors since it is the 
most commonly administered drug in the world and has a stronger evidence base to support an 
influence on non-febrile thermoregulation. In the final study, Ibuprofen was ingested prior to 
cold exposure as it is a potent non-selective COX inhibitor that it not known to have any other 
actions which may affect thermoregulation (Wong et al., 2013).  
1.1 Objectives of this thesis 
The primary objective of this thesis is to investigate whether two of the most common over-the-
counter drugs in the world carry a hypothermic side effect when ingested at therapeutic doses. 
The secondary objective is to determine if the same dose elicits a greater hypothermic response 
in severe compared with a mild cold exposure. The final objective is to determine whether COX 
bioactivity is required for non-febrile thermogenesis.   
The purpose of this thesis can be summarised in three experimental aims: 
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1. To validate whether acetaminophen administered at therapeutic doses has a hypothermic 
action in healthy humans. This will be achieved through the completion of Study 1 
(Chapter 4). 
2. To investigate if acetaminophen administration influences thermoregulatory responses to 
dry and humid passive heat stress. This will be achieved through the completion of Study 
2 (Chapter 5). 
3. To use the information gained from Study 1 and 2 and elucidate the therapeutic or 
pathological potential of acetaminophen during extreme heat or cold stress. This will be 
achieved through Study 3 (Chapter 6). 
4. To investigate the pharmacodynamics behind the responses shown in Study 1, 2 and 3 
using a non-selective cyclooxygenase inhibitor. This will be achieved through the 
completion of Study 4 (Chapter 7).   
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CHAPTER 2: LITERATURE REVIEW 
2.1 Methodology and structure  
A thorough search of the literature relevant to thermal physiology, and its potential interaction 
with acetaminophen and cyclooxygenase was undertaken. Key words and key authors were 
entered into Pubmed, Google Scholar and Web of Science. The reference list of relevant articles 
were also scanned for the purpose of finding appropriate content for the literature review.      
In section one, the topic of thermoregulation is introduced. Here, there will be a specific focus 
on why core Tc is regulated at 37°C, and the biology of how this is achieved. Attention will be 
paid to the neuronal pathways regulating autonomic heat production and heat loss effectors.  
Section two focuses on the COX enzyme and prostanoids. In this section, the biology of the 
enzyme is discussed in addition to its known roles in the pathophysiology of fever generation. 
This will be followed by a review of the evidence supporting a novel role for cyclooxygenase in 
non-febrile thermoregulation (heat and cold responses).  
Finally, section three details the pharmacokinetics and pharmacodynamics of acetaminophen 
and ibuprofen. These two over-the-counter drugs were administered in experiments detailed in 
this thesis and have differential potencies of COX inhibition and tissue distribution.  
2.2 Thermoregulation  
Thermoregulation is a topic that receives considerable attention in the context of human health 
and performance. In a thermal neutral zone where active heat loss and heat producing 
mechanisms are not at play, Tc is regulated solely by subtle changes in vasomotor tone 
(Romanovsky 2014). Human Tc is used as a proxy to describe the extent an individual is losing or 
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gaining body heat, and can be measured in tissue such as the rectum (Colin et al. 1971), 
oesophagus (Saltin and Hermansen 1966), tympanic membrane (Brinnel and Cabanac 1989), 
aural (Cross and Stratton 1974), visceral (O'brien et al. 1998), and arterial blood (Pennes 1948). 
Since most of these sites represent only one tissue location in the body, the arterial blood 
temperature is considered the gold standard Tc measurement since it reflects a global temperature 
of the body (Pearson 2012). That-being said, arterial blood temperature is highly invasive and 
difficult to measure, so the rectal temperature is most often used to reflect Tc. Indeed, rectal 
temperature is used and an index of Tc in each experiment within this thesis.  
Heat balance can be predicted from several known parameters which form the heat balance 
equation, which reads simply as (Kenny and Jay, 2013):  
(M – W) = (Hdry + Hevap + Hresp) + S [Watts]                                    (1)            
Where M is the metabolic rate and W is the external work performed. M – W is the efficiency in 
which the energy produced is used on performing that specific task. The term mechanical 
efficiency defines the amount of energy expended to do a given amount of external work 
(Wasserman et al. 1967). The human body is inefficient in this manner, and 80 to 100% of any 
external work performed will be released as heat. The external work (W) depends on the 
mechanical efficiency of the task. For instance, if an individual cycled at an external workload 
200 Watts, metabolic heat production would be ~800 Watts because the gross mechanical 
efficiency of cycling is 20% (Whipp and Wasserman, 1969). Hdry is the rate of dry heat transfer, 
incorporating heat transfer by convection, conduction and radiation. Convection defines heat 
transfer from a solid surface to a fluid medium (i.e. water, air and blood), and the rate of heat 
transfer is dependent on the velocity, heat capacity, and volume of surrounding medium. 
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Conduction defines diffuse heat transfer through direct contact of the skin surface with another 
solid surface. In most situations, this is negligible, but is an important parameter when the body 
is in contact with a highly conductive material for an extended period i.e. the application of ice 
packs prior to exercise in the heat, warming blankets in the perioperative setting, or when an 
individual has fallen unconscious on a cold floor (Rollstin and Seifert 2012; Ross et al. 2013; 
Torossian et al. 2016). Radiative heat transfer defines heat exchange between bodies with 
different surface temperatures. The mean radiant temperature can be used to estimate total 
radiative heat transfer within the heat balance equation. Hevap is the rate of evaporative heat 
transfer from the skin. Evaporation of sweat at the skin surface is a powerful driver of heat loss, 
but can incur a large degree of total body water loss if fluid replacement is inadequate. Hresp is 
heat transfer from respiratory pathways, describing heat exchange between the respiratory tract 
and the external environment. Each of these variables are reported in Watts (W) or Watts 
corrected for body surface area (W·m-2). An extended background of each of these components 
are available below and in recent reviews (Cramer and Jay 2016; Kenny and Jay 2013). 
Metabolism always represents a source of heat gain, and the rate of metabolic heat production is 
determined from the amount of energy released from catabolism of carbohydrates, fat, and amino 
acids. This process is required for the regeneration of adenosine triphosphate (ATP), an organic 
chemical which serves as an energy source for all cellular and molecular activities, making it 
critical for almost all physiological processes. It stands to reason that metabolic rate increases in 
line with the level of physical activity because ATP turnover is elevated. Metabolic rate is 
normally expressed in Watts (W) corrected for body surface area (i.e. W/m-2) in the thermal 
physiology literature (Parsons, 2003), but it can also be expressed in kilojoules per minute (1 
kJ/min-1 is ~ 17 W), kilocalories per minute (1 kcal/min-1 is ~ 70W), or metabolic equivalents 
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(1 MET = 58.2 W/m-2). Typical metabolic rates for various activities are displayed below. The 
conversion of VO2 values into heat production is as follows: Energy equivalent is calculated as 
(ISO 8996): 
EE = (0.23RER + 0.77) × 5.88  
Based on this information, metabolic rate can be calculated as (Parsons, 2003):  
M = EE × V̇O2 × 1/BSA [W/m-2] 
Where V̇O2 is oxygen consumption in l/hour-1, and BSA represents the body surface area in m2. 
The rate of metabolic heat production is proportional to the increase in V̇O2, because the demand 
for O2 (particularly from skeletal muscle tissue) increases in order to fuel the activity. During 
cold stress, neuronal drive from the CNS causes autonomic rhythmical skeletal muscle 
contractions (i.e. increasing M), a process required for the maintenance of Tc if voluntary activity 
is not possible.  
Thermal conduction defines the transfer of heat between solid surfaces in contact with one-
another. The rate of heat transfer between solid surfaces is defined by three factors, i) the 
temperature gradient between the two objects in question i.e. the higher the gradient, the faster 
rate of heat transfer, ii) the thermal conductivity of the material, and iii) the thickness of the 
material i.e. heat will transfer slower in thicker materials due to its greater volume for heat 
storage. In most heat-exposure studies, thermal conduction is considered zero as individuals are 
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Table 2.1. Heat production values for different tasks and types of activity. W/m-2 values are 
generated for a reference body surface area of 1.7 m2. 
Activity  Rate of heat production 
Rest W W/m-2 
Sleeping 75 44 
Seated 85 50 
Standing 100 59 
Occupational tasks   
Walking at 5 km/h 313 184 
Light industrial work 125-453 74-266 
Heavy industrial work 132-677 78-398 
Very heavy industrial work 293-1108 172-652 
Cycling   
150 W external load 600 353 
Data compiled from Andersen (1978). 
rarely in contact with solid objects that affect their heat balance (Cramer and Jay, 2016). Some 
medical applications are based on thermal conduction however, such as ice-packs for the 
treatment of inflammation or warming blankets to prevent  accidental hypothermia in neonates 
(Fallis et al., 2006).  
Thermal radiation describes the process of heat exchange in the form of electromagnetic waves, 
and occurs between bodies of different surface temperature. Waves which form the 
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electromagnetic spectrum include X-rays, light, and radio-waves (Parsons, 2003). Like 
conduction, there is a net heat flow from hot to cold, and there are several factors which 
influence radiative heat transfer, including i) the temperature gradient between the body and 
surrounding surfaces, ii) the effective surface area of the body which changes in line with the 
body orientation, iii) clothing properties i.e. insulation level (Clo value) and the amount of 
radiation it reflects or absorbs (influence primarily by the colour). The level of thermal radiation 
is normally expressed as the mean radiant temperature; the temperature in the centre of a black 
globe which absorbs the radiation within the environment (Havenith and Fiala, 2015). If exposed 
to thermal radiation, the temperature inside the globe will rise, and the radiant temperature will 
be close to the ambient temperature in environments with minimal radiation sources (Hodder and 
Parsons, 2008). The sun is the most common source of radiant heat in the outdoor environment, 
but boilers, furnaces, and radiant warming lamps are common sources of thermal radiation in the 
indoor environment (Parsons, 2003).  
Convection defines heat transfer from a solid surface to a fluid medium (i.e. water, air and 
blood), and the rate of heat transfer is determined by the velocity, heat capacity, and volume of 
surrounding medium. It is also heavily influenced by the level of clothing insulation (i.e. higher 
Clo, lower convection) and the temperature of the skin (Parsons, 2003). For example, humans 
will gain heat from convection if the temperature of the fluid medium (air or water) exceeds the 
mean skin temperature. Conversely, convection can provide a strong cooling source if the 
medium has a lower temperature than the skin temperature. It is also important to consider that 
each fluid medium has a different capacity to transfer heat. For example, water has a greater 
specific heat capacity (4.19 vs 1.01 kJ·kg-1·K-1) and thermal conductivity (579 vs 25 mw·m-
1·K-1) than air, so water is a more powerful source of convective heat transfer. Consequently, 
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cold water immersion is employed to rapidly cool individuals suffering from heat stroke (Epstein 
et al., 2015), and perfusion of warm water through a water perfused suit is used to rapidly 
increase skin temperature  in laboratory studies (Rowell et al., 1969).  
Evaporation of sweat from the skin surface to the ambient environment the primary natural 
source of heat loss in humans. If the ambient temperature exceeds that of the skin (creating a 
source of convective heat gain), evaporative heat loss is the only avenue by which humans can 
dissipate heat (Cramer and Jay, 2016). That-being-said, evaporation is dependent on the gradient 
between the water vapour pressure of the ambient air and the water vapour pressure at the skin. If 
the water vapour pressure in the air exceeds that at the skin, the environment is fully 
uncompensable, a situation where humans will gain all heat generated through metabolism. 
Evaporation involves a phase change of sweat on the skin surface from liquid to a water vapour, 
which will diffuse into the ambient air (Parsons, 2003). To that-end, it is worth noting that 
unevaporated sweat (i.e. sweat that drips from the skin) is not a source of heat loss and only 
serves to decrease total body water. The rate of evaporative heat loss is also influenced by the air 
flow, evaporative resistance of clothing, wettedness of the skin, and the skin surface area (Jay et 
al., 2015).  
Heat exchange through respiration is the final component of the heat-balance equation, 
describing thermal exchanges between the respiratory tract and the ambient environment. The 
respiratory tract heats inspired air close to the Tc and becomes saturated with moisture drawn 
from the surface of the airway (Parsons, 2003). Like convection, conduction, and radiation, the 
rate of respiratory heat lost to the environment depends on the temperature gradient between the 
internal and external environment (Cramer and Jay, 2016). It also has an evaporative component, 
where moisture content of the expired air is a pathway for evaporative heat loss. To that end, 
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respiratory heat loss is greatest in a cold dry environment, and becomes negligible when i) there 
is no temperature gradient (convective component) and ii) when there is no vapour pressure 
gradient (evaporative component). It should be noted that respiratory heat exchange is small due 
to the very low thermal conductivity of air. For example, respiratory heat transfer at an air 
temperature of 0°C provides only 10 W more heat loss compared with an air temperature of 
20°C. 
2.2.1 Why do we regulate core temperature at 37°C?  
Prior to understanding the processes that regulate our Tc, it is first important to address what Tc 
defines, and some important considerations when using this terminology. Thermal physiologists 
often use the phrase “Tc” to define the internal temperature of an organism, and the skin 
temperature (Tsk) to define the temperature of the shell (Kenny and Jay, 2013). Each of these 
components can be incorporated into a two-compartment model which produces a metric known 
as mean body temperature. Mean body temperature is most commonly used for the estimation of 
heat storage during exercise, but appears seldom in this thesis due to the limitations associated 
with using the two compartmental prediction (Kenny and Jay, 2013). Throughout the literature 
review, Tc is generally used to define the internal temperature of the species under investigation, 
but the specific tissue site measured in each study (rectal temperature, Tre) is used throughout the 
experimental chapters. Other measurement sites include oesophageal, axillary, tympanic, 
visceral, arterial blood, and sublingual temperature (Havenith and Fiala, 2015), but the Tre was 
chosen for reasons related to logistics, accuracy, and to allow comparisons with prior studies in 
which most use Tre.  
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Homeostatic regulation of Tc is a key feature of mammalian survival; reductions in Tc result in 
dysregulated ion channel function (Milburn et al. 1995), enzyme performance (Sizer 2006), and 
a suppression of protein synthesis (Frerichs et al. 1998). In contrast, significant increases in Tc 
are associated with severe protein denaturation (Lepock 2003) and systemic inflammatory 
response syndrome (Leon and Helwig 2010). Although subject to considerable variation, the 
human Tc survival limits are in the region of 27 to 42°C (Epstein and Roberts 2011; Stocks et al. 
2004; Taylor et al. 2008), which represents a 10°C decrease and 5°C increase in basal Tc (37°C), 
respectively. This shows that in general, humans have an increased Tc survival limit during cold 
exposure, despite our ancestry arising from Africa. Mechanistically, this is because proteins can 
begin to denature at temperatures as low as 40°C (Ritchie et al. 1994), whereas hypothermia 
decreases metabolism, and by reducing excitotoxicity, can even be used as a therapeutic tool to 
improve survival rates after traumatic head injury, provided the patient’s vital signs are 
continuously monitored (Cao et al. 2014). As mammalian Tc is such a powerfully regulated 
variable, deviations of more than ± 2°C are rarely witnessed in healthy individuals capable of 
normal behavioural and autonomic thermoregulation. However, there are many scenarios in 
which thermoregulatory mechanisms fail, such as in uncompensable heat and cold stress 
(Cheung et al. 2000; Sloan and Keatinge 1973), severe head injury (Badjatia 2009), stroke 
(Ginsberg and Busto 1998), and drug overdose (Ritter and Eskin 1998; Rollstin and Seifert 2012; 
Yapakci et al. 2001).  
Understanding why humans autonomously regulate their Tc close to 37°C is fundamental for the 
thermal physiologist. It underpins why thermal homeostasis is critical, and is best illustrated by 
examining the atomic events that arise following significant deviations from this desired 
temperature (as in hypothermia, when Tc falls below 35°C). Firstly, any physiological change 
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mediated by a change in temperature does not occur without prior alteration in the biophysical 
properties of a molecule. The reaction rate of enzymes depends on molecules effectively 
colliding together, and the kinetic energy of molecules increases in line with the intracellular or 
blood temperature (Tattersall et al. 2012). Thus, the likelihood of molecules colliding with 
sufficient energy to react increases as a product of Tc, which explains why hypothermia 
decreases cellular metabolism (Tupone et al. 2016) and hyperthermia increases it (Streffer 1988). 
Again, decreasing brain temperature following traumatic head injury is protective since it 
substantially reduces metabolism, and thus excitotoxicity within the brain (Tymianski et al. 
1998).  
Of importance to reaction rates is the activation energy (also known potential energy) of the 
substrate/reactant molecule, a term which defines how much energy is required for a specific 
chemical reaction to occur. The Maxwell-Boltzmann distribution shows that the number of 
molecules that meet the activation energy threshold increases in line with temperature, such that 
there is a positive linear relationship (Starzak 2010). Diffusion (a physical property) requires a 
very low activation energy of ~2.5 kJ·mole-1, whereas it is roughly 50-90 kJ·mole-1 for chemical 
reactions. An adaptation of the Arrhenius equation is used to calculate the temperature 
dependence/thermal sensitivity of enzymes, ion channels, and physiological functions (i.e. heart 
rate, muscle contractility, and oxygen consumption to name but a few). This temperature 
coefficient is known as the Q10 because the equation quantifies the difference in reaction rates for 
a theoretical 10ºC shift in temperature. This does not describe the ambient temperature an 
organism is exposed to, it describes the temperature of the internal environment a molecule, cell, 
or tissue is exposed to. Therefore, the Tc of an organism must be regulated at an optimal 
performance temperature for biophysical regulation, which for humans is ~37°C. Because a 
17 
 
thermal physiologist seldom examines temperature dependence in such large internal increments 
(i.e. every 10°C), the equation is constructed as follows:  
Q10 = (k2/k1)10/(t2-t1)                                                                    (2) 
Where ‘k’ is the theoretical reaction rate and ‘t’ is the measured temperature. The equation can 
be applied to determine the effect of temperature on many molecular and physiological 
functions. For example, one may be interested in the temperature dependency on heart rate at 37 
and 40°C, where the heart rate was 65 and 85 b·min-1, respectively. In this case, the equation 
would read Q10 = (85/65)10/(40-37), yielding a Q10 value of 2.44, which means there will be a 2.44-
fold increase in heart rate for every 10ºC increase in Tc. This is somewhat accurate given cardiac 
pacemaker cells are temperature sensitive (Haverinen and Vornanen 2007), but heart rate it also 
influenced by interplay of sympathetic and parasympathetic nerve activity (Brodde 1991; Brodde 
and Michel 1999). For example, the sympathetic nervous system drives tachycardia when Tc falls 
to ~35°C (Gurabi et al. 2014), so the Q10 should be interpreted with caution for whole 
physiological systems that require input from the nervous system. 
The Q10 is best utilised ex-vivo or in-vitro since this eliminates any confounding nervous activity. 
For example, Burdyga and Wray (2002) extracted guinea pig and rat ureteric smooth muscle to 
calculate the influence of cooling (transfer from 35 to 21°C) on the force amplitude arising from 
spontaneous contraction. Using electrophysiological techniques, they demonstrated that 14°C 
cooling decreased guinea pig urethra overall mechanical activity by 20.5 ± 7.5%, but this was 
increased by 105 ± 11.5% in the rat ureteric tissue. Use of Q10 temperature coefficients revealed 
that it was the rate of relaxation which contributed to the differences in mechanical activity 
described above. In the guinea pig, a high Q10 of 5.1 markedly decreased the rate of relaxation, 
whereas a slightly lower Q10 of 3.7 in the rat allowed more time for the inflow of calcium ions, 
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overriding any cooling induced kinetic lag of force development. Here, the lack of any nervous 
interference renders any Q10 change attributable to a direct influence of temperature on 
physiological outcomes. Although the methods employed are not directly relatable to this Ph.D. 
project (here, in-vivo methods are used), it is a valuable reminder of the temperature sensitivity 
in various biological pathways.  
2.2.2 The thermoneutral zone  
The thermoneutral zone is a simple but important concept in thermoregulation. It was first 
defined as “the range of ambient temperatures within which metabolic rate is at a minimum, and 
within which temperature regulation is achieved by nonevaporative physical processes alone” 
(Bligh and Johnson 1973). Thus, a thermal neutral zone is not accepted if metabolic pathways 
are recruited for thermogenesis, or evaporation of sweat is required for heat loss. Subtle 
vasomotor changes incur virtually no metabolic cost, whereas shivering and non-shivering 
thermogenesis require significant substrate utilisation and increases in metabolic rate (discussed 
further in sections 2.6.3 and 2.6.4, respectively). Furthermore, a prolonged increase in Tsk 
(40.5°C for 45 minutes) places significant strain on the cardiovascular system, marked by a 
125% increase in cardiac output (Rowell et al. 1969). In unclothed humans, an air temperature of 
23 to 26°C, or a water temperature of ~34 to 36°C is generally thought to satisfy thermal 
neutrality, based on the resulting Tsk. In a clothed human, the thermal neutral zone would shift to 
a lower temperature depending on the insulation value of the clothing. In the heat, thermal 
neutrality cannot be achieved at an air temperature above 26°C unless the skin is cooled 
artificially. For instance, Kingma et al. (2014) produced a thermoregulatory model to delineate 
what specific combinations of Tc, Tsk, and ambient temperature are required for the attainment of 
a thermal neutral zone. The model demonstrates that the thermal neutral zone is dynamic and 
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shows a high degree of plasticity. Based on this model, the mean Tsk must be in the range of 30.6 
to 36.8°C and Tc in the range of 36 to 38°C to satisfy the requirements for a thermal neutral zone.  
The detection thresholds required to trigger cold and warm thermal sensations depend on the 
starting Tsk and the body region in question. For example, 70 kg human exposed to an ambient 
temperature of 24°C, local Tsk can range between 30 and 34°C while the subject is in a perceived 
state of sensory thermal neutrality (Gagge et al. 1967). Specifically, this means that there are no 
prevailing sensations of warm or cold, so the sensation is neutral. In fact, work in primates 
suggest that there is a balanced firing of both cold and warm thermoreceptors when local Tsk is 
between 30 and 34°C (Hensel and Iggo 1971). Indeed, this thermosensory zone is used as a 
neutral Tsk when diagnosing cutaneous sensory disorders such as hypoesthesia (Rolke et al. 
2006). Filingeri et al. (2017) determined the properties of thermal neutral zone, examining its 
width and whether this changes as a dynamic function of the starting Tsk. Using a circular 
thermal probe on the palm starting at three distinct temperatures (26, 31, and 36°C), they showed 
that the thermal neutral zone was dynamic and shifted depending on the starting temperature of 
the probe. For example, at a starting Tsk of 31°C, the threshold for warm sensation was ~+2°C, 
whereas the cold threshold was found to be ~-0.4°C. At 36°C starting temperature, and compared 
with the 31°C condition, the threshold for warm sensation was ~1.62°C and the threshold for 
cold sensation was ~1.4°C larger (p < 0.05). For a resting Tsk of 26, 31, and 36°C starting 
temperature, the thermal neutral zone fell within a range of 2.36°C (25.7 to 28°C), 2.47°C (30.6 
to 33.1°C), and 2.25°C (34.2 to 36.5°C), respectively. The limitations of this study are that it is 
only valid in a small skin area (the palm) and may be misleading for whole body thermal 
neutrality. For instance, a range of mean Tsk required to satisfy thermal neutrality have not been 
as well defined. 
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As humans, we spend most of our lives in a thermal neutral zone through clothing and 
perceptually avoiding environments below the thermal neutral zone. However, there are many 
scenarios in which thermal stress might not be avoided, such as the cold stress of birth, in a 
poorly insulated home during extreme heat or cold, or during exercise. In situations where the Tsk 
falls below or above the inter threshold zone, active thermogenic or heat loss mechanisms are 
initiated from within the pre-optic anterior hypothalamus. In the next section, the biology 
involved in Tc stability during skin cooling is described in detail. 
2.3 Mechanism of core temperature stability 
The following 3-step feedback loop is required for Tc regulation during cold exposure: 
1. Feedforward afferent signals of skin and gut temperature directed towards the central 
nervous system.  
2. Neuronal integration of the signal in the pre-optic anterior hypothalamus.  
3. Autonomic thermoregulatory responses.  
In the following sections, the neuronal pathways responsible for autonomic thermoregulation are 
discussed. Prior to this discussion, it is important to address translation issues from animal work 
to human physiology.  
Due to ethical and practical issues associated with human experimentation, there are many 
references drawn from animal work throughout this thesis. In the present literature review, 
animal work has provided important mechanistic information related to central mechanisms of 
thermoregulation, and acetaminophen induced hypothermia. While results from animal studies 
are often used to explain physiological responses in humans, it is erroneous to assume perfect 
inter-species translation, especially in clinical trials. Despite successful animal testing, 85% of 
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novel drugs fail when tested on humans in pre-clinical trials, and those that reach a phase III trial 
(Arrowsmith, 2011), only 50% become FDA approved (Ledford, 2011). Although there is no 
alternative to using this approach if the studies cannot be performed in humans, it is important to 
identify the limitations of animal to human translations, with special reference to 
thermoregulation.  
There are several issues of importance when translating work from animals into humans. Besides 
general physiological complexity, the most obvious limitation is the enormous difference in body 
characteristics; the first issue is that of body mass. A commonly used mouse as a model for 
human physiology is the C57BL/6 mouse sub-strain which has a body mass of ~20 grams, but a 
reference adult human may have a body mass of 70 kg, 3,500 times heavier than the C57BL/6 
mouse. In the heat and at fixed workloads, the rate of heat storage is directly proportional to 
body mass, where there is a negative association (Havenith et al., 1998). In the cold, the rate of 
heat loss is also negatively associated with body mass i.e. heat loss is slower in heavier 
organisms (Taylor et al., 2014). There is also a matter of skin surface area and its relation with 
body mass (i.e. surface to mass ratio). Rodents have a very large surface area to mass ratio 
compared with humans, and this ratio has an independent effect on heat stress and cold stress 
responses and vulnerabilities. In the heat, the rate of heat storage is positively associated with the 
surface area to mass ratio (Havenith, 2001). In the cold, the rate of heat loss is also positively 
associated with a high ratio i.e. organisms with a high surface area to mass ratio with lose heat 
faster than those with a low ratio (Allen, 1877). Based on these principles, it is reasonable to 
assume that the physiological responses to the same heat and cold stimulus are not the same 
between different species. Indeed, the hypothermic response to acetaminophen may be 
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exacerbated in mice due to their high surface area to mass ratio, even if doses are corrected for 
absolute body mass (Ayoub et al., 2004).  
A second characteristic of mice that is problematic for human translation is the reliance on 
brown adipose tissue for thermogenesis. Although the functional efficiency of BAT is similar 
between mice and humans (Porter et al., 2016), the relative contribution of BAT to total body 
mass is far greater in the mouse (Porter et al., 2016). In contrast, adult humans rely more on heat 
production through shivering thermogenesis during acute cold exposure, and little on BAT 
thermogenesis (Blondin et al., 2014). A major component of this thesis is an attempt to 
demonstrate acetaminophen induced hypothermia in humans, and to uncover the underlying 
mechanisms which mediate this side effect (cyclooxygenase inhibition is one possibility). If 
acetaminophen’s hypothermic action in mice is through suppression of cyclooxygenase and BAT 
function (for which there is already strong evidence), the effect might not be mirrored in adult 
human beings i.e. because they do not rely heavily on BAT function for thermogenesis. 
Another consideration is the difference in thermal neutral zones between humans and rodents. In 
nude adult humans, an ambient temperature between 24-26°C is considered thermoneutral i.e. it 
will not induce metabolic heat loss (increasing skin blood flow) or heat gain (shivering, BAT 
activation) responses (Kingma et al., 2012). In rodents, the thermal neutral zone is close to 30°C 
to compensate for their greater surface area to mass ratio (Speakman and Keijer, 2013). Despite 
this difference in preferred thermal neutral zones, experimental mice are often housed at an 
ambient temperature which optimises comfort for the researcher i.e. ~18 to 21°C (Speakman and 
Keijer, 2013). This type of environment is below neutral for a mouse, which means they are in a 
consistent state of mild to moderate cold stress. The fact that mice may constitutively produce 
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more heat than if they were in a neutral environment has implications for metabolic studies, 
especially if they are to be translated to human research. 
Repeated exposure to cold ambient temperatures has an impact on the mouse (and human) 
phenotype and genotype. It is well known that mice rely on BAT formation for Tre maintenance, 
but it is often ignored that mice may adapt in this way because of long term cold exposure. 
Attention to this key variable, the ambient temperature, has a broad transformative impact on 
translation to human trials (Ledford, 2011). Specific to the present thesis, studies inducing 
hypothermia in mice with acetaminophen should be approached with caution because this effect 
may be dependent on mice being exposed to cold. Unfortunately, there are no trials which have 
investigated acetaminophen’s hypothermic effect in mice housed in their thermal neutral zone. 
Such a study would help determine if acetaminophen reduces body temperature by inhibiting 
heat production or activating heat loss mechanisms. 
2.3.1 Skin region and thermal sensitivity  
The human skin is a ~2 m2 large organ that forms a barrier between our internal and external 
environment. It protects us from exogenous pathogens and allows us to detect noxious 
temperatures, chemicals and mechanical influences. The human skin is critically involved in 
thermoregulation, since thermosensory nerve endings project to the brain for us to discriminate 
and initiate an autonomic response to variable ambient and skin temperatures. As such, human 
Tsk is a useful marker of thermoregulatory stress, either as a global mean or on a specific 
anatomical region. Rowell et al. (1969) used a water perfused garment to raise the Tsk of five 
young males to 40.5ºC for ~40 minutes. They demonstrated that cardiac output increased up to 
125%, while hepatic blood flow and peripheral resistance fell up to 60%. In cold exposure 
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experiments, water perfused suits are commonly used to clamp Tsk at a value which yields a 
reliable increase in resting metabolic rate (Blondin et al. 2010; Haman et al. 2005). For example, 
an exposure to mild cold, resulting in a Tsk of 27.4°C, elicited a 2.5-fold increase in metabolic 
rate (Haman et al. 2005). When the mean Tsk is reduced to 19°C, this is met with a 3.5-fold 
increase in metabolic rate (Martineau and Jacobs 1989). These responses show the importance of 
the skin in initiating cold and heat defence responses.   
The specific role of the skin in thermoregulation is not homogenous throughout each anatomical 
region, as reflected by large variations in thermal sensitivity and sweat output. Indeed, the non-
hairy skin (palms, soles of the feet, ear and some areas of the face) acts as a radiator because it 
has a large surface area to volume ratio and contains many arteriovenous anastomoses 
(Romanovsky 2014). As the name suggests, arteriovenous anastomoses form connections 
between arterioles and venules, and their innervation by the sympathetic nervous system can 
greatly influence skin blood flow to that area, regulating heat exchange (Walløe 2016). In 
response to cold stress, sympathetic innervation by vasoconstrictor nerves can reduce blood flow 
to almost zero, whereas a lack of innervation (stimulated by heat stress) has been shown to 
increase finger blood flow by ~500% compared with baseline (Nagasaka et al. 1987). In the non-
hairy skin, arteriovenous anastomoses can reach diameters of up to 150 µm, whereas a typical 
capillary is only 10 µm (Elstad et al., 2014). These features permit very high ranges of blood 
flow requirements which either dump large volumes of heat from the skin to the environment or 
reduce blood flow to ~0% i.e. in response to skin cooling. The hairy skin contains fewer 
arteriovenous anastomoses, but a greater concentration of cutaneous thermoreceptors 
(Romanovsky 2014). For example, Cotter and Taylor (2005) showed that the face shows greater 
thermal sensitivity to skin cooling and skin warming than the forearm, thigh, leg, and foot. 
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Interestingly, the authors also showed that the extremities were the least sensitive to local hot and 
cold exposure, supporting the notion the role of the hand and feet as thermal radiators. Moreover, 
stimulation of the cold receptors by menthol (discussed in the next section) produced no cooling 
sensation when applied to the hand, but did produce cold defence responses when applied to the 
abdomen (Almeida et al, unpublished observation). 
2.3.2 Thermoreceptors 
The ability to discriminate between different skin, core, and brain temperatures is a key feature 
of the somatosensory nervous system. It allows reactive avoidance of noxious (painful) heat or 
cold and is crucial for behavioural (voluntary) and autonomic (involuntary) thermoregulatory 
adaptations. For behavioural thermoregulation (conscious discrimination of a change in 
temperature), thermosensory inputs are delivered to the somatosensory cortex (Craig 2002), 
while inputs are delivered to the pre-optic anterior hypothalamus for autonomic responses 
(Nakamura and Morrison 2008a). Changes in skin and core temperature excites nerves of the 
trigeminal and dorsal root ganglia (DRG), allowing thermal discrimination from sensation 
arising from the face and other areas of the body, respectively. When stimulated, action 
potentials from these nerves synapse with neurons in the spinal cord, which then activate second 
order relay neurons in the lateral parabrachial nucleus (Nakamura and Morrison 2008a, 2011). 
Based on the initial thermosensory input (hot or cold), neurons in the lateral parabrachial nucleus 
activate, or inhibit, distinct neuronal populations in the pre-optic area (Nakamura and Morrison 
2010). Based on this signal, mechanisms for heat production or heat loss will be activated.  This 
pathway is described in depth later in section 2.4.3.  
There are two types of somatosensory nerve fibres required for thermosensory inputs; thinly 
myelinated Aδ (A delta) fibres which have moderate conduction velocities, and the non-
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myelinated C fibres which exhibit slow conduction velocities (Vriens et al. 2014). Each fibre 
type has a small but consistent action potential firing rate even at a thermoneutral Tsk [32-33°C 
(Fowler et al. 1988; Schepers and Ringkamp 2009)]. Early work from Darian-Smith et al. (1973) 
reported that, in monkeys, innocuous cold caused electrical activity in nerves firing in the 5-30 
m·s-1 range, which is indicative of Aδ fibre activity. Later work by Fowler et al. (1988) estimated 
conduction velocity using reaction times of cold sensation in humans, which yielded slower 
velocities of 2.1 ± 0.8 m·s-1, which is at the lower end of the Aδ range. Later, Campero et al. 
(2001) used microneurography to further identify and define thermosensory afferents. 
Microneurography is an invasive technique, which involves the insertion of a needle electrode 
(100-200 µm diameter) into intact nerves in awake human participants. The conduction 
velocities of the functional nerve units which responded to innocuous cooling included those in 
the C fibre range (< 2 m·s-1), a finding that conflicted with the notion that cold thermosensory 
inputs were mediated exclusively by Aδ fibres (Fowler et al. 1998). The increased specificity of 
microneurography when compared with estimates of conduction velocity from reaction times 
likely explain these findings. The discharge rates of each of these fibres are transient i.e. the 
action potentials reduce to a steady state level once they have reached a discharge rate 
proportional to the intensity of the cold stimulus. This type of activity explains the transient 
nature of some cold sensations i.e. initial submersion in cold water invokes an immediate cold 
sensation, but this decreases in intensity as the stimulus continues despite no change in water 
temperature.  
Given that Tc is the critically regulated variable in thermoregulation, it follows that there are 
thermosensory nerves excited by hypothermia and hyperthermia residing in the body core, but 
there is a lack of evidence in this regard. Ruan et al. (2005) recorded the activities of afferent 
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vagal pulmonary C fibres in anaesthetised rats whose pulmonary temperature was maintained at 
37, 38.5, and 41ºC for 3 minutes. They demonstrated that the baseline activity did not increase at 
38.5ºC, but was elevated 5-fold when the temperature reached 41ºC. The fact that vagal afferent 
nerves are more responsive at 41ºC suggest that they are activated closer to the noxious 
temperature ranges. Gupta et al. (1979) studied the responsiveness of left splanchnic nerves to 
cooling in anaesthetised cats. They exposed single fibre preparations to water temperatures 
regulated between 12 and 38ºC, and showed that no cold sensitive afferents were found in the 
vagal nerve, but afferents arising from the stomach were particularly sensitive to 12ºC. In 
support for visceral thermosensitive afferents, a recent study studied the effect of cold (7ºC), cool 
(22ºC), neutral (37ºC) and warm (52ºC) fluid ingestion (3 ml·kg-1 body mass) in already cold 
exposed humans (Morris et al. 2017). Compared with 37ºC, metabolic rate increased by ~25% 
with 7 and 22ºC fluid, but fell by ~17% following administration of 52ºC fluid. This 
demonstrates a role for thermosensitive afferents originating in the stomach which respond to a 
wide range of temperatures (at least 7 to 52ºC). The water temperatures used in that study are 
supraphysiological because an internal temperature of 7 or 52ºC would be fatal (Parsons 2014). It 
remains to be elucidated whether the upper and lower extremes of Tc elicit similar metabolic 
responses (i.e. 35 to 41ºC). 
The channels that regulate in the inflow of cations (positively charged ions) are well described, 
although the precise mechanisms by which they open in response to cold is still under debate.  
Transient receptor potential cation channels (TRP channels) are present on the membrane of 
these thermosensory neurons in the skin, gut, and brain, and regulate the inflow of sodium and 
calcium ions through the cell membrane. These ions are required for the generation of action 
potentials in response to changes in temperature, although they are also activated by a variety of 
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chemical agents. The molecular activation mechanisms of temperature responsive TRP channels 
(thermoTRPs) are not completely defined, but the notion that there is a temperature mediated 
shift in the voltage-dependent gating process is now undisputed. The theory that shifts in 
temperature induce an intrinsic conformational change in the channel is the most likely, since 
heat and cold sensitive ion channels exhibit the same thermosensitive characteristics following 
reconstitution into artificial lipid membranes (Zakharian et al. 2010). Since thermoTRP channels 
are highly temperature sensitive, they have Q10 values of between 10-50, which is far greater 
than values of 2-7 seen in other ion channels (Voets 2012). The reader is directed to section 2.3.1 
for an overview of the Q10 temperature coefficient. The currently known subfamilies which are 
involved in thermoregulation are melastin (TRPM), acyrin (TRPA), and vanniloid (TRPV). The 
thermosensory channel activated by innocuous heat is most likely TRPV3. The TRP channel that 
appears to be activated by innocuous cold temperatures is TRPM8, while TRPV1 and TRPA1 
are involved in noxious heat and cold sensations, respectively (Denda and Tsutsumi 2011; Kwan 
and Corey 2009). TRPM8 was first characterised in 2002 by Peier et al. (2002a). The authors 
used DNA databases to identify potential exons from the TRPM8 gene (based on the known 
TRPV1 gene), and yielded a full-length sequence by using prediction software alongside 
polymerase chain reaction (PCR) techniques. To determine the role of TRPM8, the gene was first 
transfected into Chinese hamster ovary cells, and intracellular calcium concentrations (indicative 
of channel opening) were quantified in response to chemical agonists and changes in incubation 
temperature. For the first time, it was shown that TRPM8 was sensitive to a low ambient 
temperature (15°C) and the organic compound menthol, indicating that TRPM8 may act as a 
molecular sensor to subneutral temperatures. Using similar techniques in Chinese hamster ovary 
cells, Peier et al. (2002b) discovered a role for TRPV3 for innocuous heat. They showed that 
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these cells displayed no calcium influx when exposed to low temperatures, but this was maximal 
when the temperature was between 33 and 45ºC. This shows that TRPV3 is responsive to 
innocuous heat sensations, but does not cause calcium influx at low temperature or that above 
45ºC. The authors also showed that TRPV3 is expressed in epidermal keratinocytes. 
The two methods most commonly used to elucidate the roles of specific TRP families in 
thermoregulation are knockout mouse models and the use of specific agonists and antagonists. 
Additionally, some authors have investigated the thermosensory role of TRP channels in the 
human embryonic kidney cell line, where the genetic insertion of thermoTRPs induces high 
temperature sensitivity. The knockout mouse model (where the deleted gene is denoted as -/- in 
most genetic literature) is carefully bred to not express a specific gene of interest, whereas 
agonists and antagonists chemically activate or deactivate the target protein, respectively. 
Moqrich et al. (2005) demonstrated that TRPV3-/- mice showed an impaired ability to 
thermoregulate when transferred to a warm environment. In a 2-hour protocol where the time 
spent in specific temperature zones (15 to 55ºC) was recorded, they showed that wild type mice 
showed a preference toward the zones where the temperature was 30 to 37ºC, evidenced by a 
significantly increased time spent within that zone. In contrast, the TRPV3-/- mice showed no 
preference for the warm zone, indicating that TRPV3 is required for innocuous warm sensations. 
Camphor is an oil extract from the wood of an Asian tree called camphor laurel, and is a potent 
TRPV3 agonist (Sherkheli et al. 2013). Kotaka et al. (2014) applied camphor at various strengths 
(5, 10, and 20%) to the medial forearm of 9 middle-aged adults in a thermoneutral environment 
(~25ºC). At all strengths, camphor increase skin blood flow 1.5-fold, reaching a peak only 10 
minutes after the application.  
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The use of TRPM8-/- mice in thermoregulation research has significantly advanced our 
understanding of the role this ion channel has in innocuous cold thermosensation. Dhaka et al. 
(2007) demonstrated that mice (C57Bl/6 strain) lacking the TRPM8 gene had profound 
differences in cold ambient temperature (15ºC) avoidance compared with wild-type mice. In that 
experiment, mice could move freely between different temperature zones ranging from 15-53ºC, 
and time spent in each zone was used as an index of cold thermosensory function. Wild type 
mice showed a greater preference for ambient temperatures of 30 to 38ºC (which is their normal 
preferred temperature range), whereas TRPM8-/- mice spent significantly more time in colder 
areas (< 30ºC). This indicates that the TRPM8 protein is indispensable for adequate sensation of 
cold ambient temperatures (15-25ºC). More recently, Tajino et al. (2011) demonstrated that wild-
type and TRPM8-/- mice exert significantly different Tc and thermogenic responses during 
exposure to 10ºC, but not at 25ºC. For example, staining of harvested brown adipose tissue (a 
heat producing organ described in section 2.6.4) after cold exposure indicates that 
phosphorylated nuclear factor kappa B and uncoupling protein-1 [UCP-1 (markers of brown 
adipose tissue activation)] are vastly decreased in TRPM8 -/- mice. However, brown adipose 
tissue heat production was not completely inhibited, suggesting that 1) other pathways are 
involved in cold thermosensation which are yet to be established or 2) TRPM8 was not fully 
inhibited. Nonetheless, the inhibitory effects on brown adipose tissue thermogenesis resulted in a 
significant 1ºC Tc reduction in TRPM8-/- mice when exposed to 10ºC, compared with wild-type 
mice.  
An alternative method used to examine TRPM8 function is through use of menthol as a selective 
agonist. Major benefits to using menthol application (as opposed to knockout mouse models in 
combination with cold air) are that it can be applied specifically to thermosensitive regions on 
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the skin, and it can safely be applied to humans (in spray or gel form).  When its thermosensory 
effects were examined on human skin (Yosipovitch et al. 1996), it only produced a cooling 
sensation in 12 out of 18 participants, and the duration of the cooling ranged from 5-70 minutes 
(mean, 32 minutes). The use of ethanol as a solvent for menthol may account for the large 
between subject variation for two reasons. Firstly, ethanol itself is a TRPV1 agonist (Gazzieri et 
al. 2006), and activation of TRPV1 substantially decreases thermogenic responses to 
environmental cooling in mice (Feketa et al. 2013). Secondly, ethanol has an inhibitory effect on 
TRPM8 function via interaction with the membrane lipid phosphatidylinositol 4,5-bisphosphate 
(PIP2). In human embryonic kidney cells, the addition of PIP2 reverses the inhibitory effect of 
ethanol on TRPM8, whereas the addition of a PIP2 antagonist enhanced the inhibitory effect of 
ethanol (Benedikt et al. 2007). Given that ethanol is not an appropriate solvent in this regard, 
Valente et al. (2015) prepared menthol by mixing 10 mL of warm water and l-menthol crystals 
(10 mg·kg body mass-1) for five minutes to form a gel which was immediately applied to the 
neck, right arm and leg. Application of the menthol gel caused a mild but significant increase in 
Tc (~0.2ºC) and decreased skin blood flow (~20 perfusion units), which is indicative of an acute 
thermogenic response. These effects appeared to deteriorate 3-hours after application of the 
menthol gel. For a description of the perfusion unit (an arbitrary unit which indicates blood flow 
alterations during laser Doppler flowmetry), the reader is directed to the work of Cho et al. 
(2009). Finally, Gillis et al. (2015) mapped responses to menthol spray for five days to 
investigate if its thermogenic effects altered by repeated exposures. The subjects were separated 
into three independent treatment groups (control, 0.2 and 0.5% menthol spray), where 
thermogenic responses to each treatment were examined during exercise [45% cycling at peak 
power output (day 1 and 5)] and at rest (day 2, 3 and 4). At rest, 0.2% menthol spray (upper 
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body) induced a small but significant increase in Tc across a 60-minutes period when compared 
with control and 0.5% menthol (0.1°C increase). This effect was not lost on the fourth day of 
treatment, indicating a lack of habituation effect after repeated exposures to menthol spray. 
There were no differences in thermoregulation when treatments were administered during 
cycling exercise, indicating that the heat loss mechanisms activated during exercise outweigh 
any thermogenic effect of menthol spray.  
Despite significant differences in Tc induced by menthol, the scale of the response is small. One 
would expect that if cold exposure was fully stimulated by menthol in a thermoneutral 
environment, Tc would rise almost immediately due to the autonomous activation of 
thermogenesis. One reason why menthol doesn’t elicit a strong thermogenic response in humans 
could be due to the mechanism by which it acts as a TRPM8 agonist, so it is important to 
consider how menthol influences TRPM8 gating. Until recently, the precise mechanism of 
TRPM8 agonists were unknown. Using calcium imaging within a human embryonic kidney cell 
line, Janssens et al. (2016) studied how the gating kinetics of TRPM8 change when exposed to 
menthol and allyl isothiocyanate (mustard oil). They found that menthol ‘activates’ TRPM8 by 
preventing the channel from closing, whereas mustard oil causes the channel to open faster than 
it normally would. More specifically, menthol inhibits normal deactivation because it allows for 
a more stable “open” conformation of the channel. In contrast, mustard oil amplifies TRPM8 
activation by destabilising the “closed” conformation. Given that menthol does not force TRPM8 
to open, it is unsurprising that its thermogenic side-effects in humans are unreliable in 
thermoneutral conditions (Gillis et al. 2015; Valente et al. 2015; Yosipovitch et al. 1996).  Of 
note, mustard oil is not advised as a replacement for menthol because it also activates TRPV1 
and TRPA1, the respective sensors for noxious heat and cold. 
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2.3.3 Interaction of dorsal root ganglia nerves with dorsal horn cells  
When DRG nerves are activated by thermal information, a process which may be partly 
regulated by TRP channels, a signal is projected to the spinal cord, where a synapse occurs 
between thermosensitive neurons and temperature specific spinal and trigeminal dorsal horn cells 
(Craig 2002). The use of retrograde neural tracers and c-Fos staining techniques have greatly 
advanced our understanding of both afferent (ascending) and efferent (descending) neural 
pathways involved in autonomic thermoregulation. c-Fos is a protein expressed in individual 
neurons immediately after their activity (Hoffman et al. 1993), such that staining c-Fos with an 
antibody allows researchers to map the neuronal activation pathways in response to cold and 
warm environmental temperatures. These techniques have been used to map the afferent 
pathways which project to the pre-optic area during acute cold (4ºC), heat (36ºC) or 
thermoneutral (26ºC) exposure in mice (Nakamura and Morrison 2008b, 2010, 2011). The 
authors also use various chemical agents to identify what neurotransmitters mediate these 
responses (Table 2.1).  
The authors revealed that glutamatergic projections from lateral parabrachial nuclei (LPB) 
transmit thermosensory signals directly to pre-optic area. The LPB acts a relay centre for sensory 
information (temperature, mechanical, chemical) and thus receives an enormous amount of 
projections from dorsal horn cells (Cechetto et al. 1985). c-Fos staining demonstrated that 
neurons in the external lateral sub-region of the LPB (LPBel) were activated only in response to 
cold exposure (Nakamura and Morrison 2011), whereas there was a large c-Fos expression in the 
dorsal subregion of the LPB (LPBd) during heat exposure (Nakamura and Morrison 2010). 
When the Tsk decreases, thermosensory signals projecting from the LPBel to the pre-optic area 
are eliminated following nanoinjection of a GABA receptor agonist (muscimol) or a glutamate 
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receptor antagonist (AP5/CNXQ), demonstrating that dorsal horn cells provide glutamatergic 
inputs to LPBel neurons in order to regulate Tc (Nakamura and Morrison 2008b). The 
thermosensory pathway within the pre-optic area which mediates autonomic responses to cold 
begins with initial neuronal inputs delivered to the median pre-optic nuclei (MnPO) from the 
LPBel. In a recent experiment, it was demonstrated that the thermogenic responses to LPBel 
stimulation with NMDA are reversed after nanoinjection of AP5/CNXQ in the MnPO 
(Nakamura and Morrison 2008b). In addition, direct stimulation of MnPO glutamate receptors 
with NMDA triggers brown adipose tissue thermogenesis, shivering thermogenesis, and 
tachycardia (Nakamura and Morrison 2008a).  
Table 2.2. Chemicals commonly used to determine the role of specific pre-optic area 
neurotransmitters in thermoregulation. 
Chemical Action 
Muscimol GABA receptor agonist 
Bicuculline GABA receptor antagonist 
Methysergide Serotonin receptor antagonist 
AP5/CNXQ Glutamate receptor antagonists 
NMDA Glutamate receptor agonist 
 
2.3.4 The pre-optic area 
The subsequent topic of this literature review concerns the mapping of thermosensory neurons 
within the pre-optic area. At this point, the afferent pathway involving skin cooling, to dorsal 
root cells, to the LPB, to the MnPO has been described. But how is this information integrated to 
form an appropriate physiological response? To answer this question, it is necessary to briefly 
35 
 
skip past the MnPO and describe the function of nuclei within the medial pre-optic area (MPO). 
A prior explanation of MPO neuronal projections is required when explaining the relationship 
between the MnPO and the MPO.  
During heat and thermoneutral exposure, the MPO plays a crucial part in regulating efferent 
responses by sending GABAergic inhibitory projections to the dorso-medial hypothalamus 
(DMH) in warm and thermoneutral environments (Nakamura and Morrison 2010). These 
inhibitory projections are vital for the regulation (or elimination) of thermogenesis in hot 
environments, such that nanoinjection of bicuculline (a GABA receptor antagonist) into the 
MPO results in a substantial increase in brown adipose tissue and shivering thermogenesis 
(Osaka 2004). This evidence renders it likely that, in response to cooling, the MnPO (described 
above) transmits its own inhibitory projections to the MPO, which in turn eradicates the tonic 
inhibition from the MPO to the DMH. In support of this view, activation (with NMDA) or 
disinhibition (by bicuculline) of MnPO neurons drives cold defensive thermogenesis (Nakamura 
and Morrison 2011). The view that MPO provide tonic inhibitory projections to the DMH (and 
thus inhibits thermogenesis) is cemented by evidence that nanoinjection of muscimol (a GABA 
receptor agonist) into the MPO also results in thermogenic activation (Zaretsky et al. 2006). As 
previously stated, MPO neurons tonically inhibit premotor neurons with the DMH and rostral 
medullary raphe region (rMR). During cold exposure, it is most likely that inhibited MPO 
neurons can no longer block glutamatergic DMH neurons to the rMR. For example, activation of 
neurons in the DMH evokes c-Fos expression in regions of the rMR that mediate cold defence 
responses (Zaretskaia et al. 2008). Additionally, muscimol injection into the DMH blocks brown 
adipose tissue, shivering, and tachycardia during cold exposure (Nakamura and Morrison 2011).  
2.3.5 Efferent neuronal pathways  
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The rMR contains several pre-motor neuronal populations which are activated when MPO 
neurons are inhibited by GABAergic projections from the MnPO. These populations include the 
rostral raphe pallidus nucleus and the raphe magnus nucleus. Given that injection of muscimol 
into the rMR elicits brown adipose tissue activation, shivering, vasoconstriction and tachycardia, 
it appears that these pre-motor neurons receive tonic GABAergic projections in thermoneutral 
conditions (Nakamura and Morrison 2008a, 2011). Equally, thermogenesis is blocked through 
injection of glutamate receptor antagonists into the rMR following NMDA induced glutamate 
excitation of neurons in the DMH. These findings support the notion that pre-motor rMR 
neurons are stimulated directly by glutamatergic projections from the DMH. Although, inhibition 
of DMH neurons does not block the veno-vasoconstrictor response to skin cooling, indicating 
that alternative projections to the rMR mediate this response. This neuronal pathway has not 
been fully elucidated, but there is evidence to suggest that some neurons from the MnPO bypass 
the MPO and DMH, eliciting thermogenic responses (Tanaka et al. 2011). 
The rMR directly activates ventral root motor neurons in the spinal cord. We know this not only 
because the rMR has many projections to preganglionic neurons in the spinal cord (Yoshida et 
al. 2009), but also because antagonising the cells within the spinal cord blocks the thermogenic 
effects of rMR excitation (Yoshida et al. 2003). Moreover, excitation of preganglionic ventral 
root cells with glutamate stimulates thermogenic responses identical to that of skin cooling. 
Interestingly, the neurotransmitter serotonin may play a key role in core body temperature 
defence against the cold. Using mice, Madden et al. (2010) injected a serotonin receptor 
antagonist (methysergide) in the intermediolateral cell column (T2 to T5) and decreased Tsk by 
~6°C. Injection of methysergide decreased brown adipose tissue activation by 64% compared 
with the responses with saline injection. Subsequently, the authors repeated the experiment with 
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specific antagonists for the serotonin 7 and 1A receptor, and reported decreases in brown adipose 
tissue sympathetic activation by ~53%, respectively. This work demonstrates that the activity of 
serotonin is critical for full thermogenesis during cold exposure. The DMH also mediates the 
release of adrenocorticotropic hormone (ACTH) from the hypothalamic pituitary axis in 
response to cold stress. ACTH release is stimulated from the paraventricular nucleus within the 
hypothalamus, such that blockade of neurons in this region blunts any rise in plasma ACTH 
during cold stress (Hunt et al. 2010). The presence of ACTH increases the production of 
glucocorticoids, hormones that activate lipolysis and the breakdown of glycogen in the liver (Xu 
et al. 2009). These responses enhance substrate availability for brown adipose tissue metabolism 
and shivering thermogenesis.  
In summary, this section has described the neuronal network involved in cold induced autonomic 
thermogenesis. In the later sections, evidence suggests that acetaminophen, a hypothermic agent, 
may interact with this pathway to depress cold-defence response. The use of glutamate and 
GABA agonists and antagonists have greatly advanced our understanding of these pathways 
during cold exposure. However, as described in section 2.3, the translation from animal work 
should be interpreted with care. In the next section, the physiological responses to cold stress are 
described in detail. 
2.3.6 Cutaneous vasomotion  
Control of skin blood flow is an important facet of the human thermoregulatory system. During 
thermoneutrality or heat exposure, the MPO provides glutamatergic projections to pre-motor 
neurons in the DMH and rMR, tonically inhibiting efferent signals which would normally result 
in veno/vasoconstriction. As described earlier, these pre-motor neurons are “disinhibited” 
through GABAergic projections from the MnPO to the MPO when Tsk is reduced below a 
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thermoneutral threshold. Venoconstriction occurs more rapidly than vasoconstriction because 
veins have a greater thermal sensitivity than arteries (Webb-Peploe and Shepherd 1968), and 
because these changes in vasomotor tone do not require substrates to function efficiently, it is the 
first line of defence in response to a reduction in Tsk, in the aim of preserving thermoneutrality. 
As previously discussed, the stability of Tc in thermoneutral conditions is solely dependent on 
changes in vasomotor tone. In thermoneutral conditions (~25°C in a nude, resting human), the 
skin receives up to 10% of cardiac output, equating to approximately 350 ml·min-1 skin blood 
flow (Romanovsky 2014). Because the mammalian body continuously produces heat from 
normal metabolic processes, it is not surprising that such a large blood volume is purposely 
directed to the skin for heat dissipation, even in thermoneutral conditions. During extreme heat 
stress, cutaneous blood flow can reach ~8 litres·min-1, and entirely cease during extreme cold 
exposure (Rowell et al. 1969). This demonstrates the remarkable capacity of the cutaneous 
circulation to facilitate a wide range of blood flow requirements, a feature made possible by the 
arteriovenous anastomoses described earlier in this thesis (section 2.4.1). However, this is not 
homogenous for all skin regions, evident by a cold-induced vasodilation in areas of the skin with 
very large surface area to volume ratio (i.e. the palms, fingers, toes, and soles of the feet). 
Although this response seems paradoxical, cold induced vasodilation in these regions is 
necessary to delay tissue damage/frostbite and improve dexterity in the extremities (Tyler et al. 
2015). Vasoconstriction is necessary for the redistribution of heat to the central compartments 
(preserving organ temperature), and to limit heat transfer from the skin to the environment. There 
are two arms which mediate cutaneous vasoconstriction in response to skin cooling; reflex 
(autonomic) and local responses to a fall in Tsk. 
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The human skin is indispensable for proper thermoregulatory function owing to its ability to 
redistribute heat to the external environment. It can receive almost no blood flow during cold 
stress and up to 8 litres·min-1 during severe heat stress, which equates to ~60 % of cardiac 
output. In normothermic conditions, the sympathetic nervous system controls skin blood flow 
through balanced release of vasoconstrictor (norepinephrine, peptide y) and vasodilator (nitric 
oxide, histamine, prostaglandin) substances, such that it receives ~250 mL·min-1 in these 
conditions (Brengelmann and Savage 1997). In section 2.4.1, evidence that the sympathetic 
response is primarily dictated by Tsk during cold exposure, and the Tc during heat exposure was 
put forward. The skin blood flow will be almost zero during severe cold stress, even if Tc is well 
regulated. In contrast, maximal skin blood can only be achieved through a raised Tc (~39.5°C). 
Cutaneous veno and vasoconstriction is the first line of Tc defence during acute cold stress. The 
effectiveness of this response is especially apparent when observing an initial increase in Tc 
shortly after exposure to cold, reflecting a redistribution of warm blood from the skin to the 
central compartments (Study 3). The complex neuronal pathway from the thermoreceptor to the 
brain, and from the brain to the cutaneous veins and arteries was described in section 2.5.1.  
During heat stress, evaporation of sweat from the skin surface is the main avenue for heat loss 
(Parsons, 2003). An increase in skin blood flow is required for elevated levels of sweat secretion 
to the skin, and cutaneous vasodilation mediates this response (Bruning et al. 2012). Warm 
sensitive neurons in the skin and core synapse with neurons in the spinal cord, which project to 
relay neurons in the LPBd. Activation of neurons from the LPBd project to the MnPO, activating 
the MPO, an area which send inhibitory projections to premotor neurons within the rMR 
(Nakamura and Morrison 2008b). When rMR neurons are inhibited, cutaneous arteries relax, 
allowing an elevation in skin blood flow and thus heat loss. These nerves are cholinergic, in that 
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they release acetylcholine onto the vasculature to stimulate relaxation of the vessel. In addition to 
acetylcholine, there are co-factors released from endothelial cells which permit full vasodilation, 
and the best known vasoactive molecules are nitric oxide and prostacyclin. Skin microdialysis 
infusion of nitric oxide synthase and cyclooxygenase antagonists have been used to determine 
the roles of these products in vasodilatory responses to heat stress, where they act in a paracrine 
manner (Melikian et al. 2009). In thermoneutral conditions, Kellogg et al. (1998) demonstrated 
that local antagonism of nitric oxide synthase by NG-nitro-L-arginine methyl ester (L-NAME) 
reduces the cutaneous vascular conductance (CVC) response to heat stress by ~14% compared 
with a control. Briefly, CVC is an index of vasodilation, and is relative to the CVC achieved by a 
potent vasodilator assumed to cause maximal vasodilation (CVCmax), normally nitroprusside. In 
the control trial, %CVCmax rose to ~44% during heat stress (1°C rise in Tc), while CVC reached 
~30% max following L-NAME microdialysis. Importantly, there is a greater reliance on nitric 
oxide for full vasodilation in older subjects. Holowatz et al. (2003) used a water perfused suit to 
raise the Tc  of seven young adult subjects by 1°C. During this level of hyperthermia, CVC rose 
to ~80 of max in young males, but microdialysis infusion of L-NAME reduced this by ~22%, 
suggesting that nitric oxide is only partly involved in the vasodilatory response to heat stress. 
Prostacyclin (PGI2) is a key vasodilatory mediator, and its role in this regard is explained in 
section 2.4.3 because it is a product of COX bioactivity. 
In a thermal neutral zone, the reflex responses to 2°C skin cooling are so efficient that local 
mechanisms do not contribute to vasoconstriction (Savage and Brengelmann 1996). Reflex 
vasoconstriction, triggered by skin thermoreceptors, is mediated by α-adrenergic receptors 
present on the membrane of endothelial cells. The use of pharmacological methods alongside 
measurements of cutaneous blood flow have been a useful tool in this field for the identifying the 
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chemical modulators involved. For instance, Stephens et al. (2001) used a combination of 
intradermal yohimbine (α-adrenergic receptor inhibitor), propranolol (α and β-adrenergic 
receptor inhibitor), bretylium tosylate (blocks release of noradrenaline from axon terminals) and 
saline (control) to specify which receptors are involved in cutaneous vasoconstriction in response 
to skin cooling. Although β-adrenergic receptors are not directly involved in vasoconstriction, 
their inhibition was necessary to block the potential confounding effects of their receptor 
activation. When the mean Tsk was progressively decreased to 30.5ºC across a 15-minute period, 
cutaneous vascular conductance (CVC) was reduced by ~50% of baseline CVC in the saline 
treated sites, whereas it was only reduced to ~82% of baseline CVC in the yohimbine + 
propranolol treated site. Because intradermal yohimbine partially inhibited the cold induced 
decrease in CVC, it was clear that α-adrenergic receptors had a role in the reflex responses to 
cold stress. The combination of yohimbine and propranolol did not completely block cutaneous 
vasoconstriction in response to skin cooling, but did block a norepinephrine induced 
vasodilation, so it is likely that co-transmitters are involved in this process. In a later study, the 
same group investigated if neuropeptide y acted as a co-transmitter in this regard (Stephens et al. 
2004). In response to graded skin cooling, microdialysis infusion of BIBP-3226 (a neuropeptide 
Y antagonist) reduced the normal CVC response to skin cooling by ~11% (55 and 66% of 
baseline CVC). However, when BIBP-3226 was combined with yohimbine, the reduction in 
CVC was only ~3% from baseline, an almost absent constrictor response. This demonstrates that 
neuropeptide Y is indispensable for full reflex cutaneous vasoconstriction. As there was no 
significant reduction in CVC following α-adrenergic receptor and neuropeptide Y blockade, it is 
unlikely that other co-transmitters are involved in autonomic cutaneous vasoconstriction. 
However, as Tsk was only reduced to a mild degree in the experiments described (Stephens et al. 
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2001; Stephens et al. 2004), it may not reflect the processes involved during more severe cold 
stress. This view is supported by evidence from our group that even a mild cold (20ºC) 
environment reduces Tsk to ~27ºC after 120 minutes of exposure. Because a Tsk of 30ºC is 
unlikely to elicit full vasoconstriction, it is possible that other factors are involved in this 
pathway. This was confirmed by evidence that inhibition of the Rho-A/Rho kinase (ROCK) 
signaling pathway blocked the vasoconstrictor response to skin cooling (Tsk = 26ºC) by 90% 
compared with saline in healthy participants. Interestingly, ROCK dependent vasoconstriction 
was more pronounced in hypertensive individuals, suggesting that ROCK antagonism could be 
beneficial in the treatment cardiovascular disease (Smith et al. 2013). 
2.3.7 Shivering thermogenesis   
Shivering thermogenesis is the largest contributor to heat production in an unacclimatised, cold 
exposed adult human (Blondin et al. 2014b). The biochemical mechanisms of shivering are 
homogenous with that of voluntary skeletal muscle contraction, which has been described in 
great-detail elsewhere (Allen et al. 2008; Baylor and Hollingworth 2012). Given that skeletal 
muscle makes up ~40% total body mass in the average middle aged human and ~25% basal 
metabolic rate (Rolfe and Brown 1997), it is not surprising that this mode of thermogenesis is 
employed early in response to a reduced Tsk. Surface electromyography (sEMG) is the most 
commonly used technique to quantify the intensity of shivering muscle in humans, where 
shivering intensity is expressed as a percentage of maximal voluntary contraction (% MVC). 
Several authors have used this method in humans (Bell et al. 1992; Blondin et al. 2010; Gagnon 
et al. 2014; Gosselin and Haman 2013; Haman et al. 2004a; Haman et al. 2004b; Haman et al. 
2016; Israel and Pozos 1989; Sessler et al. 1988; Tikuisis et al. 1991) because it is relatively 
simple to apply and is non-invasive compared to intramuscular EMG. Electrode fibres for 
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intramuscular EMG can be inserted into the muscle of the anesthetised animal because they do 
not show any movement besides shivering during cold stress (Nakamura and Morrison 2011). 
Prediction equations are also available for peak shivering intensity (shivpeak) based on body 
composition, oxygen consumption and metabolic rate (Eyolfson et al. 2001). However, use of 
this equation is now limited since brown adipose tissue also contributes to the increase in resting 
metabolic rate during cold exposure (Virtue and Vidal-Puig 2013).  
The timing for shivering onset in various muscle groups was examined by Tikuisis et al. (1991). 
The researchers passively exposed 13 young males [7 lean (< 12% body fat), 7 normal (< 23% 
body fat)] to cold air (10ºC, 42% relative humidity) and analysed sEMG patterns in the muscle 
groups within the trunk and legs (pectoralis major, rectus abdominis, bicep femoris, rectus 
femoris), and outer limbs (brachioradialis, gastrocnemius). In the lean subjects, shivering in the 
trunk muscles began in under 10 minutes, whereas there was no EMG signal from the outer 
limbs until ~40 minutes. In the subjects with higher body fat, shivering onset was similar in the 
pectoralis major (~3 minutes), but was delayed by ~40 minutes in the bicep femoris, ~15 minutes 
in the rectus abdominis, and ~20 minutes for the rectus femoris, and there was no EMG signal 
detected in the limbs in 5 of the 7 subjects with higher body fat. This work demonstrates that 
body fat % is a critical predictor of shivering onset during cold exposure i.e. less body fat 
insulation results in a faster shivering onset. Additionally, it shows that the pectoralis major is 
recruited for shivering thermogenesis early into acute cold exposure. In a subsequent paper using 
identical exposures, the researcher group investigated the relative shivering intensity from each 
muscle, which was expressed as % MVC (Bell et al. 1992). The authors demonstrated a 
differential shivering intensity between the ‘lean’ and ‘norm’ subjects. For example, the 
pectoralis major reached a shivering intensity of ~16% MVC in the ‘lean’ subjects, whereas this 
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was only ~4% MVC in the ‘norm’ group. This effect was not seen in any other muscle group. 
Differences in Tsk between the groups may have accounted for the differences between groups, 
but this was not reported. 
Reductions in mean Tsk can serve as a strong predictor of shivering intensity during cold 
exposure. However, it cannot be used in isolation since BAT thermogenesis may also contribute 
to thermogenesis during skin cooling (section 2.3.8). Using a liquid perfused suit, Haman et al. 
(2005) compared the thermogenic responses in subjects exposed to 5ºC (n = 8) and 10ºC (n = 6) 
water, where after 90 minutes, mean Tsk decreased by 8.4 and 6.8ºC in the 5 and 10ºC perfusions, 
respectively. Incorporating a prediction equation for shivpeak (Eyolfson et al. 2001), the authors 
demonstrated that relative shivering intensity was ~42% shivpeak in the 10ºC condition, and over 
57% shivpeak in the 5ºC condition. The impact of cold acclimation on the contribution of 
shivering during acute cold exposure was examined by Blondin et al. (2014a). Using a water 
perfused suit, 6 non-acclimatised males were exposed to 10°C for 2-hours daily for 4-weeks, 
with any change in brown adipose tissue volume, oxidative capacity, and shivering measured 
pre-and post-acclimation. Although brown adipose tissue volume and oxidative capacity 
increased by 45 and 119%, respectively, there was no change in the shivering response to cold 
stress following acclimation. Thus, a longer period of cold acclimation or a more stressful cold 
stimulus may be required for brown adipose tissue to be fully recruited in place of shivering, 
although it is possible that cold acclimation may have reduced shivering activity in deeper 
muscles not measured by sEMG.  
There appear to be two distinct patterns of shivering in response to skin cooling, both of which 
can be identified by EMG patterns (2-5% and 7-15% of MVC) and unit frequency (8-10 Hz vs 
0.1-0.2 Hz), each mediated by oxidative type I and glycolytic type II fibres, respectively (Meigal 
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et al. 1993). Studies in the 1990’s demonstrated this in the pigeon (Hohtola et al. 1998) and red-
winged blackbird (Olson 1994), where the gastrocnemius produced short high intensity bursts 
compared to the pectorals, which produce sustained low intensity bursts. Two studies in the 
1980’s support this by demonstrating that glycogen content of the deltoid (type I, oxidative) and 
vastus lateralis (type II, glycolytic) was reduced equally by ~100 mmol·kg-1 after 60-minutes 
immersion in 18°C water (Martineau and Jacobs 1988, 1989). This suggests that there is a 
dynamic pattern of sustained shivering and high intensity bursts during prolonged exposure to 
cold. If shivering reduces muscle glycogen content, can it be sustained in this state through 
utilisation of lipids or proteins? If lipids and proteins substitute glucose to fuel heat production, 
then nutritional status is unlikely to impact Tc maintenance during acute cold exposure. This 
question was answered through manipulation of glycogen reserves prior to mild (Haman et al. 
2004a) and moderate (Martineau and Jacobs 1989) cold exposure, eliciting an RMR increase of 
2.5 and 3.5 fold, respectively.   
Haman and colleagues (2004a) exposed 10 males to cold (5°C water perfusion for 90 minutes) in 
a glycogen loaded (high carbohydrate diet of 494 g/day for 7 days without exercise) and 
glycogen depleted (low carbohydrate diet of 68 g/day for 7 days and prior exercise) state. They 
showed that the total shivering intensity of 8 muscles and unit frequency did not change with 
glycogen depletion or loading, an effect compensated for by a large shift in substrate utilisation. 
The changes in fuel utilisation required to sustain shivering thermogenesis for 90 minutes in a 
glycogen loaded and depleted state are shown in Table 2.2. This finding supports the view that 
resting nutritional status does not influence shivering parameters during exposure to cold, at least 
for 90 minutes. However, nutritional status can still confound total heat production during acute 
cold stress due to the potential influence of diet-induced thermogenesis (Ishii et al. 2016).  
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The substrate utilisation patterns to fuel thermogenesis were recently analysed during a cold 
survival simulation (Haman et al. 2016). Prior to this work, substrates for fuelling thermogenesis 
was only reported for much shorter durations (< 3 hours), however, subjects (n = 8) were 
exposed to 7.5°C for 12-24 hours in the survival simulation. 
Table 2.3. Relative contribution of carbohydrates, lipids, and proteins for ATP production during 
shivering thermogenesis. Data taken from Blondin et al. (2014b).  
  Glycogen loaded Glycogen depleted 
Carbohydrates ~65% ~28% 
Lipids ~23% ~53% 
Proteins ~12 % ~19% 
 
Participants were lightly clothed (~0.61 Clo) and were fed a 1,641kcal survival ration bar every 
6-hours, and shivering thermogenesis from the pectoralis major, trapezius, rectus abdominis and 
rectus femoris was analysed for one hour at 6, 12, and 24 hours. The average total shivering 
activity of the four muscles was 4.5% (6 hours), 7.2 (12 hours) and 5% (24 hours) MVC, 
however there was a striking modification in fuel utilisation as time progressed. Carbohydrates 
were the preferred fuel in the period 0-6 hours, however lipids accounted for over 80% of total 
heat production between 12-24 hours, with protein accounting for less than 20% in all time 
periods. This is reflected by a near complete depletion of muscle glycogen content at 12 hours. 
These data demonstrates the remarkable capacity of the human body to mobilise lipid stores to 
maintain shivering thermogenesis, and aid survival during prolonged extreme cold exposure. 
This proffers that pharmacological activation of thermogenesis may play an important role as an 
anti-obesity treatment, a notion which has recently gained popularity (Xiao et al. 2015). 
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In summary, if there are sufficient stores of lipids or glycogen, shivering thermogenesis is a 
significant contributor to heat production regardless of nutritional status. In humans, the most 
effective method to analyse shivering thermogenesis is the use of sEMG because it is non-
invasive and can be applied to multiple muscle groups [researchers should refer to Haman et al. 
(2004a) for an in depth methodological overview of this technique for the analysis of shivering 
activity]. In the next section, attention is given to the contribution of non-shivering 
thermogenesis to total heat production during acute and chronic cold exposure. Although brown 
adipose tissue and skeletal muscle contribute to non-shivering thermogenesis, there is a greater 
focus on brown adipose tissue in this section due to the vast amount of literature in this area. 
However, attention is still paid to that of non-shivering thermogenesis from skeletal muscle 
tissue.  
2.3.8 Non-shivering thermogenesis 
Brown Adipose Tissue: What is it and how is it measured?  
There are two distinct forms of adipose tissue in the human body; white and brown, where the 
primary functions of each are to store and dissipate nutrient energy, respectively. Brown adipose 
tissue is found in all mammals (albeit in different volumes and activities), and it can be argued 
that the development of this organ gave our animal group a distinct advantage from an 
evolutionary perspective. For example, it supports Tc stability during periods of hibernation, 
allows neonates to survive the cold stress of birth, and protects against excessive storage of lipids 
through clearance of fatty acid to fuel thermogenesis. A long-held belief surrounding brown 
adipose tissue was that it was only found in infants, and was of no physiological significance in 
the few years following birth i.e. its volume of activity regresses with age. However, this view 
changed since the use of positron emission tomography (PET), which has allowed researchers to 
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image brown adipose tissue and identify the anatomical regions of its deposits. It has been 
demonstrated that, in adults, brown adipose tissue was present in physiologically significant 
volumes (Cypess et al. 2009). In that study, the authors analysed 3640 PET-CT scans from 1972 
patients and consistently found substantial depots of brown adipose in the neck, supraclavicular 
and paravertebral regions. Additionally, the likelihood of brown adipose tissue detection was 
reduced with increasing age, outdoor temperature, and beta blocker use. In the same year, it was 
also shown (using the PET-CT method) that brown adipose tissue could be induced by acute cold 
exposure (van Marken Lichtenbelt et al. 2009) and norepinephrine administration (Hwang et al. 
2015). These studies are described in more detail below.  
Brown adipocytes form during embryonic development and are entirely distinct from white 
adipocytes. To generate heat, brown adipose tissue uses endogenous lipids as fuel source for the 
generation of NADH and FADH2 in the citric acid cycle. In the mitochondria of non-brown 
adipocytes, these electrons carriers are used in the respiratory chain for the generation of 
adenosine triphosphate (ATP). However, there is a protein unique to brown adipocytes that 
uncouples the respiratory chain, such that the protons in the intermembrane space permeate 
readily back into the mitochondrial matrix, decreasing the gradient between these two spaces. 
The first law of thermodynamics states that energy cannot be created or destroyed, only 
converted from one form to another. Thus, the energy which would normally fuel ATP 
production is simply converted to a different form, heat. The protein in question is often referred 
to as thermogenin or uncoupling protein 1 (UCP-1); the nomenclature UCP-1 will be used in this 
thesis.  
Heat production from brown adipose tissue is initiated in line with activation of lipolysis. More 
specifically, the increased concentration of intracellular free fatty acids is the fuel for UCP-1 
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mediated thermogenesis. The signalling cascade for lipolytic or glycolytic enzyme activation 
originates in the CNS. Disinhibited pre-motor neurons in the DMH and rMR send sympathetic 
efferent projections to brown adipose tissue via the ventral horn. 
 
Figure 2.1. Norepinephrine induces lipolysis in brown adipocytes through the cAMP pathway. 
Free fatty acids diffuse into the mitochondrial membrane and are subject to beta-oxidation, 
generating acetyl co-A.  UCP-1 mediates thermogenesis in a brown adipocyte by uncoupling the 
respiratory chain. This uncoupling creates a futile cycle in which cellular metabolism remains 
high due to the constant exchange of H+ ions in and out of the inner mitochondrial membrane.  
 
As depicted in Figure 2.1, lipolysis in the brown adipocyte is mediated by norepinephrine 
binding to β3-adrenergic receptors, a process that switches on the cAMP signalling pathway via 
excitatory G protein-coupled receptors. This pathway phosphorylates enzymes required for 
breakdown of fats into free fatty acids, which are then utilised in the inner mitochondrial 
membrane for UCP-1 mediated heat generation. 
Because brown adipose tissue dissipates nutrient energy as heat, it is heavily involved in 
adaptive thermogenesis during cold acclimation, and also acute cold exposure in acclimated 
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individuals (Blondin et al. 2014b). The first conclusive evidence that cold exposure stimulates 
brown adipose tissue activity was provided by van Marken Lichtenbelt et al. (2009), who 
scanned 24 males (PET-CT) on two occasions; in ambient air temperatures of 22 (thermoneutral) 
and 16°C (mild cold). They found that cold exposure increased the activity of brown adipose 
tissue in all but one participant, and body fat percentage was a significant negative predictor (p < 
0.05) of overall activity (i.e. less fat equals increased activity). In accordance, the lone subject 
with no detectable 18FDG uptake in brown adipose tissue had the highest percentage of body fat 
(41.7 %). The mean brown adipose tissue activity [expressed in kiloBequerels (kBq)] in the 
obese subjects was 102 ± 93 kBq, but 428 ± 394 kBq in the lean subjects. It is also striking that 
one participant had virtually zero brown adipose tissue activity in thermoneutral conditions (0 
kBq), but this increased to 856.6 kBq during cold exposure. More recently, Ouellet (2012) 
reduced the global Tsk of 6 male participants (BMI range, 23.7 to 31 kg·m2) by 3.8 ± 0.4°C and 
monitored brown adipose tissue activity using 18FDG (glucose tracer), and 18F-fluoro-
thiaheptadecanoic acid [18FTHA (fatty acid tracer)]. There were substantial increases in brown 
adipose tissue metabolism, as marked by fatty acid [474 ± 66 vs 644 ± 73 µmol·min-1) and 
glucose (not detectable vs 1,493 ± 460 µmol·min-1) turnover in this tissue. Although these data 
confirms that acute cold exposure induces brown adipose tissue metabolism, the acclimation 
status of the participants was not accounted for; prior cold acclimation may explain the minimal 
contribution of shivering thermogenesis and variable glucose uptake patterns between subjects in 
prior work (Au-Yong et al. 2009; Cypess et al. 2009; van Marken Lichtenbelt et al. 2009). This 
notion is supported by many studies showing significantly greater basal brown adipose tissue 
activity in winter months compared with summer (Au-Yong et al. 2009; Ouellet et al. 2011; 
Persichetti et al. 2013). Interestingly, a review of studies which used PET-CT to quantify brown 
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adipose tissue activity revealed that there was a 1% decrease in total activity for every 5°C 
increase in ambient temperature at the time the experiment took place (Huang et al. 2012). 
Whether or not brown adipose tissue activity is a product of cold acclimation/acclimatisation was 
later addressed by Blondin et al. (2014a). In that study, 6 non-acclimated healthy males were 
passively exposed to 10°C for 2 hours for 4 weeks (5 d·wk-1) using a water perfused suit, and 
underwent PET-CT scanning at pre-and post-acclimation. The 4-week acclimation period 
significantly increased brown adipose tissue 18FDG uptake by 45% (66 mL vs 95 mL). The net 
tissue glucose uptake was also significantly greater in brown adipose tissue compared with a 
selection of skeletal muscles involved in shivering thermogenesis. The oxidative capacity of 
brown adipose tissue was analysed using a tracer [11C-acetate (11C)] which is rapidly converted 
to acetyl-coA (Grassi et al. 2012). The area under the curve for 11C radioactivity increased in 
brown adipose tissue and the longus colli muscle only. However, the authors demonstrated that 
the longus colli retained 11C for non-oxidative metabolism, while it was utilised rapidly in brown 
adipose tissue for oxidative metabolism.  
Beige/brite adipocytes: are they functionally thermogenic?  
Besides classical white and brown adipocytes, there is a third fat cell that resides within white 
adipose tissue depots, yet displays molecular characteristics akin to brown adipocytes i.e. they 
are dense in mitochondria and express common genes (i.e. Ucp-1, Cidea and Pgc1a). These cells 
have been named brite (Rosenwald et al. 2013) or beige (Lee et al. 2014); the beige 
nomenclature will be used in this literature review. The high concentration of mitochondria 
within beige cells allow them to be easily characterised within white adipose tissue biopsies 
through microscopy.  
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Beige cells differ from brown adipocytes in several ways; i) they derive from different 
embryonic precursors (Sanchez-Gurmaches et al. 2012) ii) they do not express entirely the same 
genes, despite many commonalities (Harms and Seale 2013) and iii) beige cells do not show a 
basal expression of Ucp-1, rather, it is induced through activation of β-adrenergic receptors 
(Madsen et al. 2010). In contrast, classical brown fat cells have a very high basal expression of 
Ucp-1 without the need for prior β-adrenergic receptor activation. Unlike classical brown 
adipocytes, beige cells do not appear to form during embryogenesis. Instead, they arise through 
activation of precursor cells residing in white fat depots, or transdifferentiation of white fat cells 
into beige cells during cold exposure or norepinephrine treatment. Whether beige fat cells arise 
through precursor cells or white fat cell transdifferentiation may depend on the anatomical 
location of white fat tissue (Harms and Seale 2013). For example, Wang et al. (2013) labelled 
mature white fat cells with the LacZ gene to determine if beige cells (induced by cold exposure) 
were derived from pre-existing white fat cells or precursor cells in subcutaneous fat depots. 
Because newly formed beige cells did not express the LacZ gene, it can be concluded that these 
cells derive from de-novo adipogenesis. It is striking that cold-induced beige cells return to 
classical white adipocytes after only 5-weeks of exposure to a warm environment (Rosenwald et 
al. 2013). Madsen et al (2010) showed in mice that blocking UCP-1 induction in beige cells 
during short-term cold exposure (5°C) reduced Tc by up to 2°C after 12 hours. Unfortunately, Tc 
was only measured at pre, 12, and 24 hours into the exposure, so it is unclear if the beige cell 
also contributed to thermoregulation in a more acute manner (i.e. in the first few hours). 
Interestingly, the authors showed that COX activity was indispensable for cold stress mediated 
UCP-1 induction in this cell type, since this process was inhibited by indomethacin (a non-
selective COX inhibitor). This will be expanded upon in section 2.5.3. 
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The physiological mechanisms regulating thermogenesis have been described thus far, with 
special attention paid to cutaneous thermosensation, the central nervous system, and the 
involuntary responses activated by a reduced Tsk. In the next section, attention is given to the 
cyclooxygenase (COX) enzyme, covering its biology, roles in lipopolysaccharide induced fever, 
and its potential role in cold-induced thermogenesis.  
2.4 Cyclooxygenase 
2.4.1 Biology and mechanism of action   
COX is an enzyme required for production of prostanoids. It uses arachidonic acid as a substrate 
for the generation of prostaglandin H2 (PGH2), a stable intermediate which can then be converted 
to prostaglandin E2, I2, D2, or thromboxane (TXA2) by cell specific isomerases and synthases. 
There are two COX isoforms, known most commonly as COX-1 and COX-2 (the nomenclature 
PGHS and PTGS are also used). COX-1 and COX-2 have a structural homology of ~60% but 
differ in their tissue distribution and regulation of expression (Zidar et al. 2009). Classic 
literature suggests that COX-1 is constitutively produced while COX-2 is only induced by 
cytokines, growth factors, and sheer stress. More specifically, COX-1 is commonly considered a 
‘housekeeping’ enzyme which exhibits a basal production of prostaglandins for normal 
homeostatic functions. Conversely, COX-2 has long been considered an ‘immediate early’ 
enzyme because it only produced prostaglandins when stimulated by mediators such as 
cytokines, growth factors and sheer stress. However, this approach is simplistic since it suggests 
that there are no meaningful upstream regulators of COX-1 gene transcription, and that COX-2 
has no constitutive homeostatic function in any cell type. The reaction which allows COX to 
oxidise arachidonic acid occurs in two steps catalysed by two distinct active sites on the COX 
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enzyme (Dubois et al. 1998). COX enzymes contain two sites of metabolism, coined 
cyclooxygenase and peroxidase sites. Arachidonic acid conversion to PGH2 is mediated through 
events in both active sites, whereby a tyrosine 385 amino acid be oxidised to form a radical 
[(Tyr·) (van der Donk et al. 2002)]. This is initiated in the peroxidase site by reduction of 
peroxides, yielding a heme ferryl proporphyrin radical [Fe(IV)PP·+]. The Fe(IV)PP·+ radical can 
then be transferred to the tyrosine 385 in the cyclooxygenase active site, resulting in Tyr· and a 
reduced form of The Fe(IV)PP·+ [Fe(IV)], which is further reduced by 1 electron to regenerate 
the resting heme [Fe(III)]. This heme reduction can be initiated by many reducing co-substrates 
within cells, and is essential for starting a new peroxidase cycle (Aronoff et al. 2006; Boutaud et 
al. 2002). The Tyr· initiates the oxygenation of arachidonic acid through proton abstraction, 
generating a radical species that is further oxidised by 2 molecules of oxygen (Wu and Tsai 
2016). This step yields a PGG2 radical that is then reduced to PGG2, regenerating the Tyr· in the 
process, and once PGH2 is produced, it is used as a substrate by cell specific isomerases which 
then generate PGE2, PGD2, PGI2, PGF2α, or TXA2 (Mitchell et al. 1993).  
In 2002, Chandrasekharan and colleagues cloned a third isoform that is derived from the COX-1 
gene but retains intron 1. This novel COX isoform, termed COX-1b, is abundantly expressed in 
canine cerebral cortex and to a lesser extent in human cerebral cortex and aorta 
(Chandrasekharan et al. 2002). Although this protein appeared to be the site of analgesic drugs 
acetaminophen, antipyrene and aminopyrene (Ayoub et al. 2004; Botting and Ayoub 2005) a 
COX-1 cDNA cloning experiment would later demonstrate that intron 1 is out of frame in 
humans (Dinchuk et al. 2003), and thus would require downstream editing (i.e. ribosomal frame 
shifting) to yield a functional protein. Interestingly, even when the frame shift is corrected by 
site-specific mutagenesis, human COX-1b was active but not inhibited by acetaminophen (Shen 
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et al. 2015). Since then, there has been very few studies investigating the biology and bioactivity 
of human COX-1b, likely due to a lack of therapeutic potential arising from its selective 
inhibition.  
Each isoform displays a myriad of unique and diverse functions. For example, products derived 
from COX-1 are crucial for gastrointestinal motility (Josephs et al. 1999), platelet aggregation 
(Huang et al. 2016), and parturition (Olson 2003). Selective COX-1 inhibitors such as aspirin are 
thus considered protective against ischemic events such as heart attack and stroke due to their 
anti-thromboxane (and thus, anti-clotting) activities (Calonge et al. 2009). However, regular use 
of aspirin and other non-selective COX inhibitors (i.e. ibuprofen) are also implicated in the 
development of stomach ulcers and other gastrointestinal complications. In contrast, the COX-2 
gene is upregulated in response to inflammatory stimuli (Chang et al. 2006), growth factors 
(Harding et al. 2006) and sheer stress (Inoue et al. 2002) The COX-2 gene holds binding sites for 
many transcription factors such as nuclear factor κB, activator protein 1, and cAMP response 
elements (Appleby et al. 1994). Thus, COX-2 is involved in pain (Gangadharan and Kuner 2013) 
inflammation (Seibert and Masferrer 1994) fever production (Ootsuka et al. 2008; Romanovsky 
et al. 1997), and neonatal development (Smith et al. 2012). However, more recent evidence has 
demonstrated that COX-2 is also constitutively expressed in the gastrointestinal tract, brain, 
thymus, and kidneys (Kirkby et al. 2013), and it is also involved in protection against the 
development of atherosclerotic lesions independently of COX-1 derived PGI2 (Kirkby et al. 
2014). Despite putative roles for COX-2 in gastro-intestinal homeostasis, selective COX-2 
inhibitors have established efficacy in the treatment of pain and inflammation, while exhibiting 
no gastrointestinal side effects as shown with non-selective COX inhibitors.  
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2.4.2 Role of COX in the febrile response to lipopolysaccharide  
Fever is a complex physiological response to infection or inflammation, the key feature of which 
is an increased Tc. This increase in Tc is a fundamental characteristic of fever as it activates and 
utilises elements of the heat shock response pathway to modify gene expression, cellular 
signalling and immune cell mobilisation to sites of infection or inflammation (Singh and Hasday 
2013). COX-2 is a principal mediator of this febrile response (Engblom et al. 2003; Fabricio et 
al. 2006; Ushikubi et al. 1998), such that antipyretic (anti-fever) drugs work by inhibition of 
COX-2 metabolism. After systemic administration of a potent fever inducing compound 
[lipopolysaccharide (5-100 µg·kg-1)], the COX-2 gene is upregulated in the brain (endothelial 
cells), and in liver and lung macrophages (Romanovsky et al. 1996). Experimental, 
lipopolysaccharide induced fever embodies two distinct phases [i.e. Tc peaks (Romanovsky et al. 
1997)]. The early phase of fever (peaking  ~1 h after lipopolysaccharide injection) involves PGE2 
release from lung and liver macrophages to the systemic circulation, which rapidly binds to 
albumin, and is subsequently delivered to the blood brain barrier (Romanovsky et al. 1996). At 
the blood brain barrier PGE2 dissociates from albumin and is transported to the pre-optic area, 
where it exerts potent febrile (thermogenic) effects. In the late phase of fever (peaking ~1 to 6 
hours after lipopolysaccharide injection), inflammatory cytokines produced by circulating 
polymorphonuclear leukocytes (Beeson 1948) act on endothelial cells within the brain 
vasculature to trigger the production of PGE2 synthesising enzymes in these cells (Matsumura et 
al. 1998). In addition, PGE2 may also be released from perivascular microglia and meningeal 
macrophages throughout various brain regions (Elmquist et al. 1997).  
Importantly, whether PGE2 is synthesised in the brain or peripheral organs (a process dependent 
on which phase of fever is present), thermogenic effects are exerted by PGE2 acting on EP1 and 
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EP3 receptor expressing neuronal populations in the pre-optic area. These neuronal populations 
were described in detail earlier in this thesis (section 2.4.4) Activation of the EP3 receptor (by the 
binding of PGE2) in the pre-optic blunts the activity of GABAergic projection neurons 
descending from the pre-optic area to the DMH or to the rMR (Yoshida et al. 2003). This 
PGE2/EP3 receptor interaction inhibits GABAergic neuron drive by reducing intracellular cAMP 
levels (Steiner et al. 2002), an effect mediated by the protein kinase C pathway (Akundi et al. 
2005). The resulting disinhibition of GABAergic neurons in the DMH and sympathetic premotor 
neurons in the rMR activates spinal motor output mechanisms which switch on shivering, brown 
adipose tissue, and cutaneous vasoconstriction (Nakamura 2011). Taken together, these 
mechanisms are capable of raising human in-vivo Tc to > 40°C without increases in 
environmental temperature, an immune response that may be crucial in the defence of infection 
[due to activation of the heat shock response described previously (Roth and Blatteis 2014)].  
2.4.3 Role of COX in non-febrile thermoregulation  
Despite the accepted roles of the COX enzyme in febrile thermoregulation (described above), its 
role in non-febrile thermoregulation is a relatively new concept. Given that many over-the-
counter and prescription drugs work by blocking the function of COX, it is important to learn if 
this has a downstream effect on normal thermogenesis. Consequently, ingestion of a COX 
inhibitor during cold exposure could disrupt thermogenesis and contribute to hypothermia. The 
evidence concerning COX in non-febrile thermoregulation is discussed below.   
Cold exposure or injection of PGE2 into the pre-optic area stimulates neurons in the rMR and 
DMH (Nakamura et al. 2002; Nakamura 2011; Nakamura and Morrison 2011; Yoshida et al. 
2003). This neuronal activation drives the physiological responses necessary during fever (to 
raise Tc) or cold stress (to maintain Tc). Given that EP3 receptor expressing neurons and cold 
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sensitive neurons innervate the same premotor neurons (i.e. DMH and rMR), it is possible that 
EP3 receptor activation (through binding of PGE2) within these areas might aid in, or even drive 
the thermoregulatory response to cold stress in non-febrile humans. The efficiency in which 
PGE2 initiates thermogenesis during fever would make this a useful mechanism for humans to 
defend their Tc in cold environments. Theoretically, hypothalamic PGE2 production may increase 
in response to depolarisation of cold sensitive neurons, although this has not been directly tested. 
This theory is supported by evidence in animal models (Ayoub et al. 2011; Ayoub et al. 2004; 
Bizzi et al. 1965; Satinoff 1972), and humans (den Hertog et al. 2009; Kasner et al. 2002; 
Mauger et al. 2014; Rollstin and Seifert 2013), whereby COX inhibitors (and thus reduced PGE2 
synthesis) have been shown to cause dose dependent Tc reductions in the absence of fever or 
immune response (non-febrile). In the following sections, non-febrile animal and human studies 
that have used COX/PGE2 inhibitors during cold stress, and its effect on Tc regulation, will be 
discussed. In Table 2.4, several cases of hypothermia induced by COX inhibitors are displayed. 
Evidence in animal models 
The COX inhibitor salicylate reduced the capability of experimental rats to defend their Tc in 
cold (2 to 5°C) ambient conditions (Bizzi et al. 1965; Satinoff 1972). As COX is an enzyme 
required for the conversion of arachidonic acid to PGH2 (Dubois et al. 1998), these data (Bizzi et 
al. 1965; Satinoff 1972) suggests COX may participate in cold defence, as blockade of PGE2 via 
salicylate significantly decreased Tc compared with control. However, it should be acknowledged 
that the experimental effect observed (Bizzi et al. 1965; Satinoff 1972) may be 
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Table 2.4. Acetaminophen, ibuprofen, and hypothermia      
Reference Species Subject(s) Drug  Study type 
Basal core  
Temperature Environment Outcomes 
Kasner et al. 
(2002) Human 
Non-febrile 
stroke patients 
(n = 20) 
APAP (650 mg 
every 4 hours) 
Original 
research 36.96 ± 0.64°C N/A 
0.22°C mean reduction over 
24 hours compared with the 
placebo (95% CI = -0.08 to 
0.51°C, p = 0.14) 
Visnjevac et al. 
(2014)  Human 
 Total Hip 
Arthroplasty 
patients (n = 
74).  
APAP (1 g 
intravenous) + 
general anaesthesia 
Original 
research N/A N/A 
APAP + general anaesthesia 
did not reduce Tc more than 
general anaesthesia alone. 
Reduction ~0.3 in both 
groups.  
Rollstin et al. 
(2013) Human 
37-year-old 
female 
APAP (50 g oral) + 
2.5 g 
diphenhydramine 
Case 
report N/A  
Patient found 
unconscious 
outdoors. 
Ambient 
temperature 
unknown.  
Patient had a Tc of 17°C upon 
admission. Drug ingestion 
occurred ~17 h prior to being 
found. Diphenhydramine 
effects on thermoregulation 
unknown.   
Ritter et al. (1998) Human 16-year-old male.  IBU (570 mg·kg
-1) Case report N/A N/A 
Tc on admission was 33.8°C. 
No other temperature data 
reported. The skin was cool 
and dry during initial physical 
examination.  
Desai et al. (2003) Human 7-year-old female.  IBU (6 mg·kg
-1) Case report 39.7°C N/A 
Tc fell to 32°C 4 h after IBU 
administration. Despite active 
warming Tc did not return to 
37°C for 4 days.  
Donati et al. 
(2016) Human 
Children aged 
0-17 years old. 
(analysis of 
events from 
1985-2015, n = 
12) 
IBU (60-270 mg) Database analysis  
N/A but IBU 
used to treat 
infection in all 
cases.  
N/A 
Tc fell to 34.3 ± 0.6°C in 12 
reported cases. Hypothermia 
developed in < 24 h in all 
cases.  
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Ayoub et al. 
(2004) 
C57/BL6 
Mouse 
Male (20 ± 2 g, 
n = 3 in each 
group)  
APAP (100, 200, 
or 300 mg·kg-1) 
Original 
research 37.6 ± 0.7°C 22 ± 1°C 
Dose dependent hypothermia. 
0.4, 0.8, and 2°C reduction in 
basal Tc following a 100, 200, 
and 300 mg·kg-1 dose, 
respectively.  
Ayoub et al. 
(2011) 
C57/BL6 
Mouse 
Male (20 ± 2 g, 
n = 5) 
APAP (200 mg·kg-
1) 
Original 
research 
~ 37.5°C 
(determined 
from figure 7. 
Not stated in 
results) 
22 ± 1°C 
~2.3°C Tc reduction at 1 h 
(figure 7). Tc returned to 
baseline at 2 h.  
Li et al. (2008) C57/BL6 Mouse 
Male (25-30 g, 
n = 6) 
APAP (160 mg·kg-
1) 
Original 
research 37 ± 0.2°C  23 ± 1°C 
2-3°C reduction in Tc at 1 h. 
Tc maintained hypothermic for 
the following 3 h.  
 
  
61 
 
due to salicylate induced decreases in plasma free fatty acid; reduced free fatty acids can limit 
substrates available for metabolic heat production (Bizzi et al. 1965), especially in brown 
adipose tissue (section 2.4.8). Therefore, studies using salicylate may not reliably support the 
hypothesis that PGE2 contributes to heat production during cold exposure. In contrast, studies 
using the COX inhibitor acetaminophen do not carry this confounding mechanism [i.e. decreases 
in plasma free fatty acid (Bizzi et al. 1965)]. When acetaminophen was administered 
intravenously (160 to 300 mg·kg-1) in non-febrile mice housed at 22°C, which is beneath their 
thermal neutral zone, Tc was reduced by ~3°C (Ayoub et al. 2011; Ayoub et al. 2004; Li et al. 
2008). Interestingly, it was shown via ELISA that when the maximum Tc reduction was reached 
(following a 300 mg·kg-1 dose), this coincided with a 96% decrease in whole brain PGE2 
concentrations (Ayoub et al. 2004). These findings support the notion that PGE2 located in the 
brain may play a crucial role in the regulation of non-febrile Tc, at least when mice are housed 
beneath their thermal neutral zone of 30°C (Ayoub et al. 2004; Karp 2012). However, it is 
important to note that in mice, the hypothermic action of acetaminophen may be independent of 
COX-2 inhibition, as COX-2 knockout mice showed an identical hypothermic response 
compared to their wild-type counterparts (Ayoub et al. 2004). Rather, the hypothermic effects of 
acetaminophen in mice may be due to inhibitory actions on the constitutive PGE2 synthesising 
enzymes (COX-1). This experiment was later replicated (Li et al. 2008) using a lower dose (160 
mg·kg-1), but with the same mouse strain (C57BL/6) and an identical PGE2 extraction (Powell 
1980) and quantification protocol (identical ELISA method). In that work (Li et al. 2008), the 
basal brain PGE2 concentrations were ~400% greater (1500 pg·100 µl vs 300 pg·100 µl) than 
shown previously by Ayoub et al. (2004). This suggests that measurement error may have 
occurred in one of these experiments, however it is not possible to identify in which experiment 
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this error occurred, as PGE2 concentrations have not otherwise been measured using whole brain 
samples within rodents. Interestingly, plasma PGE2 was reduced by intravenous acetaminophen 
[160 mg·kg (Li et al. 2008)], although this did not reach statistical significance (inferential 
statistics not reported). This suggests that a reduced systemic PGE2 might play a role in the 
hypothermic action of acetaminophen, and thus, systemic PGE2 might play a role in non-febrile 
thermoregulation. 
Evidence investigating a role for PGE2 in cats failed to show a statistically significant role for 
PGE2 as a cold-defensive molecule (Cranston et al. 1975). However, although the results from 
that study do not show a significant effect of acetaminophen on Tc during cold exposure (5 to 
9°C), there is clearly a trend toward a reduced Tc in response to intravenous acetaminophen 
administration (50 mg·kg). More specifically, the mean Tc in cats treated with the acetaminophen 
was 0.3°C lower after 60 minutes of cold exposure (Cranston et al. 1975). To our knowledge, 
only one study (subsequently described) has previously investigated this notion (Murray et al. 
2011b) within humans. Humans are unique among other species as we have primarily adapted in 
favour of efficiently losing body heat, which resulted in a substantial loss of body hair (Marino 
2008b). Consequently, humans lack well insulating fur coats, which is a feature used in cold 
defence by the mammals [cats and mice (Terrien et al. 2011)] previously studied to investigate 
the relationship between PGE2 and cold exposure (Aronoff and Romanovsky 2007). Thus, any 
data found in animal models (particularly mammals with fur coats) should be interpreted with 
care in the context of human translation (see section 2.3). The consensus opinion that PGE2 does 
not contribute to heat production in humans during cold exposure (Aronoff and Romanovsky 
2007) should not be ruled out as the reviewed data were primarily obtained from hosts that are 
devoid of the same cold defence mechanisms as humans. 
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Observational evidence in non-febrile humans 
The possibility that PGE2 might be involved in human afebrile thermoregulation is supported by 
several lines of research. In the Vigibase adverse drug reaction reporting database (Lindquist 
2008), there have been 185 reports of hypothermia associated with ibuprofen (a non-selective 
COX inhibitor) and 247 with acetaminophen use (Lindquist 2008). Specific case examinations 
detail Tc reductions of over 10°C following acetaminophen overdose (Rollstin and Seifert 2013; 
Van Tittelboom and Govaerts-Lepicard 1989). Here, the doses ingested were so large (30 to 50 
g) that they would cause complete blockade of PGE2 production, and thus any heat production 
associated with its activity. In stroke patients, it has been shown that intravenous administration 
of acetaminophen (6 g·d-1 i.e. 2 g every 4 hours) lowered Tc in stroke patients that were non-
febrile by ~0.4°C (Dippel et al. 2001; Dippel et al. 2003a). Although these findings support the 
routine use of acetaminophen in the management of Tc during acute ischemic stroke, it is 
difficult to speculate if blocked PGE2 production caused the Tc reductions because the ambient 
temperature was not reported. Based on the evidence presented in the current work, it is possible 
that acetaminophen mediated PGE2 blockade rendered the patient incapable of normal 
thermoregulation, an effect which may have been exacerbated if the patient collapsed in an 
environment beneath the thermal neutral zone. Thus, it may be speculated that blocking the 
production of PGE2 (mediated by acetaminophen) inhibits the activation of spinal motor outputs, 
which would normally mediate heat generation (through shivering, brown adipose tissue 
activation, cutaneous vasoconstriction or tachycardia) in conditions set beneath the thermal 
neutral zone (Nakamura 2011). The evidence for an involvement of COX or PGE2 in non-febrile 
thermogenesis is not limited to observational evidence in mammals. Table 2.3 details cases 
where COX inhibitors acetaminophen and ibuprofen have had a hypothermic side-effect. The 
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data presented in the next section details direct links between COX and specific thermogenic 
effectors.  
UCP-1 induction and recruitment of beige adipocytes  
There is no evidence for an involvement of COX in classical brown adipocyte formation or 
function. However, COX does appear to be required for beige cell proliferation and Ucp-1 
induction induced by cold stress or norepinephrine. Vegiopoulos et al. (2010) treated mice with 
the β3-adrenergic receptor agonist CL316243 (CL), and quantified the fold-change in COX-1 
and COX-2 genes in intra-abdominal white adipose tissue, along with plasma PGE2. Three hours 
after treatment with CL (which simulates acute cold stress), there was a significant increase in 
plasma PGE2 released from cultured intra-abdominal white adipose tissue (50 vs 120 pg·mg-1 
white adipose tissue) and a 3-fold increase in COX-2 mRNA. When released by white adipose 
tissue, PGE2 acts as a signalling molecule for proliferation of progenitor cells into beige 
adipocytes. Because PGE2 is a potent thermogenic activator, it is possible that its release from 
white adipocytes (and thus, presence in plasma) causes an unintended thermogenic side effect. 
Indeed, injection of low dose PGE2 (~0.08 µg) caused Tc to increase by 0.3°C (Ootsuka et al. 
2008). Assuming a PGE2 release rate from white adipose tissue of 120 pg·mg-1 in response to 
cold stress, the absolute plasma PGE2 concentrations could exceed 0.2 µg. This represents a 
150% increase in plasma PGE2 compared to a concentration that already activates 
thermogenesis. Future studies should determine the relationship between fat % and total PGE2 
release during acute cold exposure. 
Supporting work from Madsen et al. (2010) demonstrated that COX-2 deficient mice had a 
significantly lower Tc after 1 day cold exposure [4°C (36.5 vs 35.5°C)]. These data supports a 
role for COX-2 in the adaptive response to cold, but there were no early effects of COX-2 gene 
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deficiency on Tc maintenance. If COX-2 was directly involved in thermogenesis, then one may 
expect a more immediate difference in Tc between wild type and COX-2-/- mice, but there are 
caveats to this argument. Firstly, if a gene (in this case COX-2) is not expressed throughout the 
mouse’s lifespan, it is possible that compensatory mechanisms develop to ensure mice maintain a 
constant Tc, especially if housed beneath their thermal neutral zone. Secondly, the acute 
hypothermic effect of acetaminophen is not inhibited in COX-2-/- mice, but is reduced by ~50% 
in COX-1-/- mice (Ayoub et al. 2004). This demonstrates that COX-1 is primarily involved in 
acute responses to cold, whereas COX-2 is involved in adaptive thermogenic responses.   
Shivering  
The role of COX in non-febrile shivering has not been extensively explored in humans. Recently, 
the effect of intravenous parecoxib (a selective COX-2 inhibitor) has been explored for its 
inhibitory effect on post-operative shivering (Li et al. 2014; Shen et al. 2015). Shivering is a 
common side-effect of general anaesthetics because they lower the Tc threshold required for 
metabolic heat production (Campbell et al. 2015). In a double-blind clinical trial, Li et al. (2014) 
separated 120 patients into three groups, in which they were administered parecoxib, tramadol, 
or a placebo. The total number of patients who shivered in the placebo group was 28, while only 
7 and 6 patients shivered in the parecoxib and tramadol treated groups, respectively. These 
effects were replicated in a later study using similar methods, finding that shivering was 
observed in 55% of those treated with the placebo, but in only 22% of those of were 
administered parecoxib (Shen et al. 2015). Because parecoxib is a selective COX-2 inhibitor, this 
implies that the enzyme is required for non-febrile shivering. The criticism of these studies is 
their use of a subjective scale to assess shivering. While the pitfalls are obvious in quantifying 
shivering intensity, this method is likely acceptable for reliably stating whether shivering was 
66 
 
present in any form. Future studies should elucidate whether COX inhibitors reduce shivering in 
response to cold stress in humans, while incorporating sEMG for an accurate estimate of the 
relative intensity.  
Vasoconstriction 
Prostaglandins are well known for their conflicting roles in vasomotion, but whether they are 
involved in acute responses to thermal stress is not well understood. TXA2 is COX-1 derived and 
primarily secreted from platelets. It acts as an arterial smooth muscle constrictor through opening 
L-type Ca2+ and TRP channels (Grann et al. 2016). Because contraction of this tissue increases 
mean arterial pressure, hypertensive patients are often prescribed aspirin (a robust COX-1 
inhibitor) to reduce TXA2 synthesis, which may reduce the risk of cardiovascular events 
(Calonge et al. 2009; Hermida et al. 2005a; Hermida et al. 2005b; Smith et al. 1980). If TXA2 
was involved in the autonomic pathways regulating vasoconstrictor responses to skin cooling, 
inhibition of COX-1 may attenuate sympathetic cutaneous vasoconstriction, leading to greater 
potential heat transfer from the skin to the environment. Using a daily regimen of either low (81 
mg·day-1) or high dose (650 mg·day-1) aspirin for 7 days, Murray et al. (2011a) demonstrated 
that there was no effect on Tc control or heat production during a 120-minute passive exposure to 
cold (12°C) ambient air. However, it is unlikely that aspirin was present in the circulation during 
the cold exposure itself, since it was ingested many hours before each trial. Although aspirin 
acylates pre-existing COX-1, it would have no effect on COX-1 that is upregulated by cold 
exposure if it was not ingested immediately prior to the trial. Indeed, COX-1 is upregulated in 
response epinephrine in vivo (Suleyman et al. 2009), and epinephrine increased ~20 to 84% 
during acute cold exposure in humans (Radomski and Boutelier 1982; Wagner et al. 1987). 
Thus, it is possible that the cold induced increase in epinephrine elicits a rise in COX-1 gene 
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expression, and the subsequent synthesis of TXA2 could have a role in cold induced 
vasoconstriction.  
The RhoA/Rho-kinase (ROCK) pathway contributes to reflex vasoconstriction within vascular 
smooth muscle cells during cooling (Lang et al. 2009). Compared with young adults, aged skin 
does not show a diminished ability to constrict in the cold, but is more reliant on ROCK for this 
to take place (Thompson-Torgerson et al. 2007). Activated ROCK elicits vasoconstriction 
through mobilisation of alpha2C adrenoceptors from the golgi apparatus to the cell membrane 
(Bailey et al. 2004). There is evidence that COX-1 induced TXA2 receptors are involved in this 
pathway, upstream of ROCK activation. For example, human umbilical vein endothelial cells 
stimulated with a synthetic TXA2 shows increased activation of ROCK, and Y27632, a ROCK 
pathway inhibitor, diminishes the physiological effect of TXA2 in these cells (Song et al. 2009).  
Moreover, Grann et al. (2016) showed in isolated rat penile arteries that TXA2 induced 
vasoconstriction is critically dependent on the ROCK pathway. This suggests that COX-1 is 
involved in ROCK mediated smooth muscle contraction, such that pharmacological inhibition of 
COX-1 may reduce cutaneous vasoconstriction evoked by skin cooling.  Using microdialysis 
infusion of ketorolac, Medow et al. (2008) studied the effect of non-selective COX inhibition on 
cutaneous vascular conductance (CVC) in a thermoneutral environment. An interesting finding 
from that study was that ketorolac infusion (10 mM) increased resting CVC to ~32% maximal 
vasodilation, whereas CVC was ~16% max at the untreated site, providing strong evidence that 
COX vasoconstrictor products (likely TXA2) are required for vasomotor tone even in 
thermoneutral conditions. 
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Vasodilation 
During heat stress, acetylcholine is released from cholinergic nerve terminals to induce 
vasodilation (Holowatz et al. 2005). However, the function of acetylcholine is dependent on the 
activity of co-transmitters, namely nitric oxide and prostanoids. Kellogg et al. (2005) used 
microdialysis at different human forearm skin sites to infuse acetylcholine in conjunction with 
the non-selective COX inhibitor ketorolac. Acetylcholine infusion increased CVC to ~79% of 
maximum vasodilation. However, the addition of ketorolac with acetylcholine caused CVC to 
reach only 55% of max, and this decreased to only ~31% with ketorolac + L-NAME (a nitric 
oxide synthase inhibitor). This study demonstrates that COX activity is indispensable for 
acetylcholine induced vasodilation, but it was still unclear if ketorolac influenced skin blood 
flow in response to heat stress. Holowatz et al. (2009) examined the contribution of COX to 
vasodilation during normothermia and hyperthermia. In that study, the cutaneous vasculature of 
13 middle aged males (53 ± 2 years) was treated with ketorolac with and without a Tc increase of 
1°C. During normothermia (baseline Tc), ketorolac increased CVC by ~10% compared with the 
saline control (~18 vs 10% CVC max), but compared with saline, it had no effect on CVC in 
response to heat stress. In the L-NAME treated site, the rise in CVC evoked by heat stress was 
reduced by 30%, suggesting that nitric oxide is the primary contributor to vasodilation in 
response to a rise in Tc. On the other hand, it does appear that COX vasoconstrictor products 
(probably TXA2) are involved in vasomotor tone in thermal neutral conditions.  
Fujii et al. (2014b) examined the contribution of human nitric oxide and COX products in the 
forearm sweating and CVC response to exercise at a fixed moderate (400 Watts) and high (700 
Watts) heat load, using continuous microdialysis infusion of L-NAME and ketorolac, 
respectively. At a moderate heat load, compared with control solution, ketorolac reduced forearm 
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sweat output (p < 0.05) to a level comparable with L-NAME infusion (~64, 54, and 55 
mg·min−1·cm−1 with saline, ketorolac, and L-NAME, respectively). At a high heat load, there 
was no contribution of COX or nitric oxide to forearm sweating at a high heat load (p > 0.05). At 
both moderate and high heat loads, there was no influence of ketorolac on the CVC response at 
any time-point, whereas L-NAME reduced CVC by ~20% of max throughout the exercise trial. 
Given that ketorolac reduced sweat output without affecting skin blood flow (CVC), this 
suggests that COX may play a role within the sweat gland itself. Fujii et al. (2014a) examined 
the distinct role of COX and nitric oxide in the vasodilatory response to methacholine. 
Methacholine, an acetylcholine receptor agonist, was administered to 10 young adults (23 ± 4 
years) via intradermal microdialysis at 1, 10, 100, 1,000 and 2,000 mM doses, and in conjunction 
with ketorolac, L-NAME, or a combination of the two. Methacholine caused CVC to reach 
~100% max at doses of ≥ 100 Mm, but co-administration of ketorolac, L-NAME, or a 
combination had no influence on this response. As far as the sweating response, methacholine 
increased sweat output in line with the dose administered, yet ketorolac or L-NAME had no 
influence on sweat output compared with a saline control (p > 0.05).  
The contribution of COX to reflex vasodilation may be age dependent. For instance, Fujii et al. 
(2016) studied the sweating and CVC response to 9 young (25 ± 4 years) and 9 older (60 ± 6 
years) males in response to PGI2 at incremental doses of 0.04, 0.4, 4, 40 and 400 μm, each at 25 
minutes. PGI2 increased %CVC max to 20, 37, 53, and 70% at the 0.04, 0.4, 4, 40 and 400 μm 
dose, which was similar in both young and older subjects. Despite the increased skin blood flow, 
PGI2 administration did no induce sweating at any dose (p > 0.05). Interestingly, co-
administration of the nitric oxide inhibitor NG-nitro-L-Arginine (L-NAA) decreased 4, 40, and 
100 μm prostacyclin induced vasodilation by ~20% in the young adults, while it had no 
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inhibitory effect in the older subjects. This is suggestive of an age dependent crosstalk 
mechanism between PGI2 and nitric oxide.  
In summary, there are numerous pathways where COX may be involved in normal vasomotor 
tone, heat gain, and heat loss responses. Evidence for COX mediated vasodilation and sweating 
is equivocal, and is dependent on both age and the level of heat load placed upon subjects. PGI2 
is the primary vasodilatory COX product, and its effectiveness in this regard is highly dose 
dependent. Moreover, there is evidence that PGI2 does not act independently, but instead, there 
may be a crosstalk mechanism involving nitric oxide. In contrast, there are numerous pathways 
by which COX products (particularly PGE2) may be involved in non-febrile thermogenesis, but 
the tissue releasing PGE2 is more difficult to predict. While norepinephrine induced PGE2 release 
from white adipose tissue intriguing, studies have not yet reported plasma PGE2 responses to 
cold exposure in healthy humans. Finally, evidence that acetaminophen induced hypothermia is 
blunted in COX-1-/-  mouse strains suggest that COX-1 is involved in baseline Tc control, 
especially since brain PGE2 concentrations were highly correlated with Tc reduction evoked by 
acetaminophen. In the next section, the pharmacology of acetaminophen and ibuprofen will be 
introduced.  
2.5 Pharmacology of acetaminophen and ibuprofen  
2.5.1 Pharmacokinetics 
Acetaminophen 
Acetaminophen is an over-the-counter drug used for the treatment of mild to moderate pain and 
fever. It is sold as a single entity formulation or in combination with opioid analgesics such as 
codeine. Owing to a different molecular mechanism of action, it has very weak anti-
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inflammatory properties when compared with traditional NSAIDs such as ibuprofen and aspirin. 
This is discussed further in section 2.1.2. In adults, acetaminophen is normally prescribed in 1 g 
doses every 4 hours for the treatment of pain and fever (Bertolini et al. 2006). In laboratory 
settings, it is normally administered in doses corrected for body mass and lean mass to account 
for changes in the volume of distribution and volume of the liver (ethical constraint). Following 
oral ingestion, acetaminophen undergoes first-pass metabolism where ~15 to 25% is immediately 
metabolised in the liver. The majority (~90%) of acetaminophen is conjugated (bound) to 
glucuronide and sulphate to form non-toxic metabolites APAP-G and -S, respectively. A small 
amount is converted to N-acetyl-p-benzoquinoneimine (NAPQI) by the P450 family of enzymes 
in the liver (Zurlinden and Reisfeld 2016). This highly reactive metabolite is immediately 
conjugated with glutathione after therapeutic dose ingestion, but causes severe liver necrosis 
after toxic doses due to glutathione depletion (Hinson et al. 2010). Thus, it has been shown that 
glutathione administration following high dose acetaminophen is hepatoprotective, and P450 
enzyme induction causes further damage. Following glutathione conjugation, the NAPQI-G 
molecule is rapidly converted to cysteine which is then eliminated in the urine (Mitchell et al. 
1973). Oral acetaminophen reaches maximum plasma concentration (Tmax) ~60-120 minutes after 
ingestion at therapeutic doses. Using gas chromatography, Rawlins et al. (1977) demonstrated 
that acetaminophen Cmax was attained after ~60 minutes in healthy adult humans.  When Singla 
et al. (2012) examined this at higher doses, the mean Tmax increased to 100 ± x minutes, although 
no nutritional controls are outlined in that work which likely increase variability. When 
acetaminophen is ingested in a fed state, concentration max (Cmax) was reduced by nearly 50%, 
and the AUC was reduced from 43.5 to 34.6 µg·h-1·ml-1 (Moore et al. 2015). At therapeutic 
doses, the binding of acetaminophen to plasma proteins is extremely low (~1-5%) compared with 
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selective COX-2 inhibitors such as celecoxib. The half-life of acetaminophen is ~4 h after 
therapeutic doses, but is dependent on frailty, nutritional status, and dose. In a group of 55 older 
people (77 to 84 years old, 29 healthy vs 26 frail), frailty significantly increased the half-life of 
acetaminophen following a 1000 mg oral dose [2.7 ± 0.5 h in the fit older subjects vs. 3.4 ± 1.2 h 
in the frail older subjects (Ellmers et al. 1991)]. Acetaminophen has a volume of distribution of 
~1-2 litres·kg-1, passes through most tissue types via passive diffusion, and readily crosses the 
blood brain barrier, reaching peak cerebral spinal fluid concentrations ~4 hours after a 1.5 g dose 
(Singla et al. 2012).  
Ibuprofen 
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) available over-the-counter and on 
prescription. For over-the-counter use (800 to 1200 mg·day-1), it is recommended for the 
treatment of mild to moderate pain and inflammation, such as in headache, back pain, toothache, 
fever, and musculoskeletal ache (Bushra and Aslam 2010). On prescription, where doses are 
normally 1800 to 2400 mg·day-1, it is used for chronic conditions such as osteoarthritis, 
rheumatoid arthritis, ankylosing spondylitis, and other chronic conditions (Bushra and Aslam 
2010). It is also administered to paediatric patients for acute pain and fever at doses of 5 to 10 
mg·kg-1, where it is recommended above aspirin due to an increased safety profile, and is also 
preferred over acetaminophen due to enhanced analgesic and antipyretic effects (Rainsford 
2009). This may be due to alternative mechanisms of COX inhibition. Ibuprofen is administered 
as an equal (racemic) mixture of R and S enantiomers, where (S)-ibuprofen is considered 
responsible for much of its therapeutic effects, and (R)-ibuprofen is considered inactive (Rudy et 
al. 1991). When (R)-ibuprofen enters the liver via the portal circulation, 50-65% is converted to 
the S enantiomer by the α-methylacyl-coenzyme A racemase enzyme (Rudy et al. 1991). 
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Regarding prostanoid synthesis, (S)-ibuprofen inhibition of this pathway in vitro was 150 times 
more potent than (R)-ibuprofen (Evans 1992). Moreover, (S)-ibuprofen inhibited TXA2 
formation in the platelet with 10 times greater potency than a racemic mixture of ibuprofen (S + 
R), while (R)-ibuprofen was ~10-fold less potent than S and R combined (Villanueva et al. 1993). 
The pharmacodynamics of ibuprofen are described in detail in the next section. Ibuprofen is most 
commonly prepared in an oral formulation, although it is available via intravenous 
administration in the USA. Topical and rectal formulations are also available in most Western  
regions. After oral administration, ibuprofen reaches Cmax at 1 to 2 hours, but this depends on the 
coating of the capsules administered and whether it is ingested with or without food. For 
instance, Legg et al. (2014) compared the plasma concentration response to five oral 
formulations (Advil film-coated, Advil FastGel, Nurofen, Advil, and Nurofen Express) 
containing 400 mg ibuprofen in 71 participants in a fasted state. Advil film-coated, FastGel, and 
Nurofen express all reached Cmax within 40 minutes of oral administration, whereas standard 
Advil and standard Nurofen took between 80 and 120 minutes to reach Cmax. Ibuprofen has a low 
apparent volume of distribution (~0.1 to 0.2 l·kg-1) since it is highly bound to plasma proteins 
[~98% (Mazaleuskaya et al. 2015)], resulting in less transport into extravascular compartments 
compared with drugs with low plasma protein binding i.e. acetaminophen. Unbound ibuprofen 
readily crosses the blood-brain-barrier (BBB)  with considerable efficacy. Parepally et al. (2006) 
showed that rat brain uptake of ibuprofen was not inhibited by the addition of pyruvate, 
probenecid, digoxin, or valproate, showing that BBB transporters MCT1, OAT3 and MRP are not 
involed in the uptake of ibuprofen into the brain. Ibuprofen is extensivley bound to albumin in 
vivo, and replication of this binding (through the addition of albumin into the ibuprofen 
preparation) inhibited ibuprofen brain uptake in a dose dependent manner. In live humans, 
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measuring brain concentrations of any drug is not possible, so the cerebral spinal fluid (CSF) 
concentration is used as a surrogate for brain concentrations. Work from Kokki et al. (2007) 
showed that ibuprofen readily crosses the BBB in children during inguinal surgery (ages 3 
months to 12 years). In that study, the CSF tmax was 30 to 40 minutes post infusion of 10 mg·kg-1 
ibuprofen, and concentrations exceed the unbound plasma concentration in all subjects after 30 
minutes. In 46 adult patients undergoing lumbar puncture for nerve compression pain, oral 
administration of ibuprofen (800 mg) resulted in a plasma and CSF tmax of 1.5 and 3 hours, 
respectively (Bannwarth et al. 1995). In contrast to paediatric patients, it took ~90 minutes for 
the CSF concentration to exceed the unbound plasma concentration of ibuprofen. The half life of 
ibuprofen in the plasma and CSF was 2.5 and 7.5 hours, respectively.  
2.5.2 Pharmacodynamics 
Acetaminophen and ibuprofen reduces the synthesis of prostanoids through actions on different 
active sites of the COX homodimer. Acetaminophen acts on the peroxidase active site, whereas 
ibuprofen (and most NSAIDs) binds to COX on the cyclooxygenase active site. As a phenol, 
acetaminophen reduces the oxidative state of the enzyme, allowing the heme to return to its 
neutral resting state (Boutaud et al. 2002). Since acetaminophen acts as a reducing co-substrate, 
there is production of acetaminophen in a radical form, and this serves as evidence in favour of 
acetaminophen acting in this manner (Boyd and Eling 1981). In normal COX metabolism, 
hydroperoxides oxidise the heme within the peroxidase site, yielding a ferryl protoporphyrin IX 
radical cation. The radical from this form of the heme is donated to a neighbouring Tyr 385 
amino acid, generating the Tyr radical required for subsequent generation of PGG2 (Dubois et al. 
1998). Because of this mechanism, the potency by which acetaminophen inhibits prostanoid 
synthesis is dependent on the intracellular concentrations of hydroperoxides, also known as the 
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peroxide tone. This was confirmed by studies showing that the addition of glutathione peroxidase 
(a hydroperoxide scavenger) enhances the efficacy of acetaminophen in both COX-1 and COX-2 
(Hanel and Lands 1982; Ouellet and Percival 2001). Later experiments confirmed this hypothesis 
by treating cells with tert-butyl hydroperoxide and showing the inhibitory effect of 
acetaminophen on prostanoid synthesis was inversely proportional to the concentration of tert-
butyl hydroperoxide (Boutaud et al. 2002). Acetaminophen is a potent inhibitor of COX in the 
central nervous system, endothelial cells (Boutaud et al. 2002), neurons (von Bruchlausen and 
Baumann 1982), and circulating leukocytes (Hinz et al. 2008). In contrast, it has very little 
capacity to inhibit COX bioactivity in platelets or in any locally inflamed tissue (Lages and 
Weiss 1989). Again, this cell and tissue selectivity is due to differences in the peroxide tone of 
these cells.   
Ibuprofen’s primary mechanism of action is inhibition of the COX pathway. It is a non-selective 
COX inhibitor, since it is equipotent in its inhibition of COX-1 and COX-2 activity. Neupert et 
al. (1997) drew whole blood from adult humans which was i) allowed to clot for 1-hour (to 
induce COX-1 activity), or ii) stimulated with lipopolysaccharide (to induce COX-2 activity). 
Blood samples were treated with (R)-ibuprofen and (S)-ibuprofen to determine their effects on 
plasma TXB2 and PGE2, reflecting COX-1 and COX-2 metabolism, respectively. (S)-ibuprofen 
was equipotent for both COX isoforms, shown by IC50 values of 2.1 ± 1.3 µM for COX-1 and 
1.6 ± 0.8 µM for COX-2. In contrast, (R)-ibuprofen was a weak COX-1 inhibitor (IC50 = 34.9 ± 
13.2 µM) and showed negligible inhibition of COX-2 (IC50 = > 250 µM). To determine the 
mechanism of ibuprofen at the atomic level, crystallization of COX isoforms in complex 
ibuprofen were required, and this has now been achieved for both COX isoforms (Orlando et al. 
2015; Selinsky et al. 2001). These works demonstrated that ibuprofen forms a complex with 
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Arg-120 in the cyclooxygenase active site of the enzyme, competing with the arachidonic acid 
(AA) substrate which binds to the same residue. When this position on the cyclooxygenase active 
site is taken up by ibuprofen, the conversion of AA to PGH2 is ultimately decreased, resulting in 
a blunted prostanoid synthesis.  
2.5.3 Effect of acetaminophen and ibuprofen on normal body temperature 
The notion that acetaminophen and ibuprofen interact with non-febrile thermoregulation is a 
relatively new concept, especially in humans, but there is evidence from clinical studies dating 
back to the 1980’s. There are several case reports linking acetaminophen and ibuprofen 
administration and accidental hypothermia, at both therapeutic and high doses. Firstly Denes et 
al. (2002) report on four cases of acetaminophen induced hypothermia where patients with 
human immunodeficiency virus (HIV) presented to the emergency department with a Tc of 27 - 
33°C. It is unknown if the virus had any impact thermoregulatory responses to therapeutic 
acetaminophen ingestion, but given that metabolism of acetaminophen can change in HIV 
infected people, this could explain the increased susceptibility (O’Neil et al., 1999). That being 
said, there are many other reports of acetaminophen hypothermia in otherwise healthy 
individuals, suggesting that HIV is not a prerequisite for hypothermia to develop after 
administration. Van Tittelboom and Govaerts-Lepicard (1989) report on four cases where 
hypothermia developed in febrile children after therapeutic doses of acetaminophen. The 
development of hypothermia progressing after fever has been well documented since then, and 
the molecular pathways well described (Romanovsky et al., 2005; Song et al., 2016). It seems 
apparent from case reports, however, that fever is not required for acetaminophen induced 
hypothermia. Rollstin and Seifert (2013) document a case of a 37 year old female who reported 
to the emergency department with a Tre of 17°C. It was later determined that  the patient ingested 
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50 grams of acetaminophen 18 hours prior to presentation, and remarkable survived with 
treatment of N-acetylcysteine therapy.  
There are several case reports concerned with ibuprofen and accidental hypothermia. Therapeutic 
doses of ibuprofen and acetaminophen were used in combination to treat fever in a 15 month old 
child who presented to the hospital with a Tc of 39.2°C (Richardson and Sills, 2004). However, 
the child developed hypothermia after drug administration, marked by a Tc of 33.6°C which was 
sustained for 11 hours before returning to 37°C. Because hypothermia can develop as a by-
product of fever, it is difficult to determine if i) administration of acetaminophen and ibuprofen 
were just coincidental, or ii) the drugs invoked a hypothermic. reaction. A case report from 2003 
describes a similar scenario as above but with ibuprofen exclusively. A 7-year old girl reported 
to hospital with a high fever (and a Tc of 39.3°C), but after a single dose of ibuprofen her Tc 
decreased to 34.9°C in a 4 hour period (Desai and Sriskandan, 2003). Despite persistent efforts 
to raise the Tc back to normal with warming blankets, the patient’s Tc remained hypothermic for 
a further four days. Finally, Ritter and Eskin (1998) report on a 16 year old male who consumed 
approximately 40 grams ibuprofen orally, and presented to the emergency department with a Tc 
of 33.8°C. The pathophysiology of hypothermia in this case is probably linked to the very large 
dose causing central nervous system depression and a reduction in normal metabolism (Auriel et 
al., 2014). 
Reports of hypothermia following administration of acetaminophen and ibuprofen are extremely 
rare. At therapeutic doses, the cause of hypothermia after administration of either drug is largely 
unknown, and appear to be linked with a hypothermic response to fever. Overdose of 
acetaminophen and ibuprofen can cause profound hypothermia in the absence of prior fever. The 
probable cause is drug-induced toxicity within the central nervous system which disrupts  normal 
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metabolism (a constant source of heat production) or thermoregulatory mechanisms in the 
hypothalamus (Auriel et al., 2014; Smolinske et al.). Clinical trials It is general accepted that 
neurological outcome after acute ischemic stroke is partly determined by the Tc in the first 24 
hours after stroke onset (den Hertog et al., 2011). Thus, the “paracetamol (acetaminophen) in 
stroke (PAIS)” trial used information from case reports and animal work to determine if 
acetaminophen could be used as a strategy to reduce Tc in acute ischemic stroke victims (Dippel 
et al., 2003). Kasner et al. (2002) demonstrated that acetaminophen reduced average Tc across a 
24 hour period by ~0.3°C in non-febrile acute ischemic stroke patients. Because neurological 
outcome after stroke is inversely related to Tc on admission, this warranted a larger scale trial 
directly assessing if acetaminophen induced hypothermia improved neurological outcome after 
stroke. The work eventually progressed to a phase III trial which involved 1400 patients 
receiving acetaminophen (6 grams daily) or a placebo (den Hertog et al., 2009). There was a 
small benefit of acetaminophen administration on neurological outcome, but no adjustments 
were made between febrile and non-febrile patients. Thus, acetaminophen may have improved 
outcome in febrile stroke patients through its normal, well established antipyretic mechanism 
(Anderson, 2008).  
2.6 Aims and hypotheses  
Following completion of this literature review, the general methodologies employed in this thesis 
will be outlined in the proceeding Chapter. Subsequently, four experimental studies will be 
presented. Prior to reading the following sections, the aims and hypotheses of this thesis are 
presented below: 
Aims 
79 
 
1. To validate whether acetaminophen administered at therapeutic doses has a hypothermic 
action in healthy humans. This will be achieved through the completion of Study 1 
(Chapter 4). 
2. To investigate if acetaminophen administration influences thermoregulatory responses to 
dry and humid passive heat stress. This will be achieved through the completion of Study 
2 (Chapter 5). 
3. To use the information gained from Study 1 and 2 and elucidate the therapeutic or 
pathological potential of acetaminophen during extreme heat or cold stress. This will be 
achieved through Study 3 (Chapter 6). 
4. To investigate the pharmacodynamics behind the responses shown in Study 1, 2 and 3 
using a non-selective cyclooxygenase inhibitor. This will be achieved through the 
completion of Study 4 (Chapter 7).  
Null (H0) and Alternative (HA) Hypotheses 
     H01: There will be no difference in the Tre response between orally administered 
 acetaminophen and a placebo during a 2-hour exposure to 20°C. 
     HA1:  Acetaminophen will independently reduce Tre during a 2-hour exposure to 20°C  
 compared with a placebo.  
     H02: There will be no difference in the Tre rate of rise between acetaminophen and a placebo 
 during compensable and uncompensable passive heat stress.   
     HA2: Acetaminophen will independently reduce the Tre rate of rise during compensable heat 
 stress compared with a placebo.  
     H03: Acetaminophen induced hypothermia in humans will not be exacerbated by skin cooling.  
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    HA3: Skin cooling will exacerbate the hypothermic action of acetaminophen.   
    H04: Administration of a non-selective COX inhibitor (Ibuprofen) will not impact 
 thermoregulatory responses to a 2-hour passive exposure to 10°C.  
    HA4: Administration of a non-selective COX inhibitor will reduce Tre, shivering, and 
 metabolic rate during a 2-hour passive exposure to 10°C.     
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CHAPTER 3: GENERAL METHODOLOGY  
This section describes the general procedures that were performed in each experimental chapter. 
Details of study specific methodologies are present in their respective experimental chapters.  
3.1.1 Ethical approval and location of experiments 
Ethical approval for Study 1 to 3 was obtained from the Institute of Sport and Physical Activity 
Research (ISPAR). Study 4 was approved by ISPAR and the University of Bedfordshire 
Research Ethics Committee (UREC).  Ethical approval codes are stated in the “ethical approval” 
sections of each experimental chapter.  
3.1.2 Participants 
Each study required male participants aged between 18 and 35 years. Females were not included 
as participants for logistical reasons associated with i) the menstrual cycle and its potential 
impact on thermoregulatory responses to thermal stress, and ii) the potential interaction with 
experimental drugs and those used for contraception. Also, a maximum age of 35 was chosen 
based on prior work showing no differences in the cardiovascular responses to cold exposure in 
those aged between 18 – 35 (Hess et al., 2009). Participants were deemed healthy prior to 
participation. For this conclusion to be made, participants completed a physical activity readiness 
questionnaire (PAR-Q), blood screening questionnaire, alcohol use identification test, and an 
acetaminophen (Study 1, 2, and 3) or ibuprofen (Study 4) risk assessment questionnaire. 
Smokers were not permitted to take part in the study due to the impact smoking has on 
cardiovascular function (Michalak et al. 2012). Participants carrying a musculoskeletal injury, an 
acute or chronic illness, or those regularly taking any other medications were not permitted to 
take part in the study. Participants were informed of all the potential risks of taking part in the 
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experiments, and subsequently all provided verbal and written consent. Each volunteer was 
medically screened prior to participation (see “general experimental controls” in each 
experimental chapter).  
3.1.3 Anthropometry data 
Participant’s height (cm), body mass (kg), and body composition (body fat %) were measured 
using a stadiometer (Harpenden, HAR-98.602, Pembrokeshire, United Kingdom), digital scales 
(Tanita, BWB0800, Hoogoorddreef 56E 1101 BE Amsterdam, Netherlands), and air 
displacement plethysmography (Cosmed, Bod Pod, 2000A, Middlesex, United Kingdom), 
respectively. The reliability of the bod-pod was not measured by the researcher but an 
independent study showed that the equipment shows acceptable reliability, but may over-
estimate body fat in comparison to under water weighing (Tseh et al., 2010).  
3.1.4 Control measures and standardisations  
The following control measures were used in each experimental protocol to reduce the likelihood 
of confounding variables impacting experimental dependent variables. The following 
confounding variables were controlled in all experimental trials: 
Prior exercise  
Participants were required not to exercise at least 48 hours prior to participation due to the 
impact this may have had on thermoregulation and cardiovascular responses to cold stress. There 
was a minimum 30-minutes rest period prior to entry into the environmental chamber to allow Tc 
to stabilise.  
Diurnal variations and circadian rhythms  
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Experimental trials were completed at the same time of day to account for diurnal variations and 
circadian rhythms in Tc (Waterhouse et al. 2005). There was between subject variation Study 2 
due to time constraints for study completion, but no within subject variation for time of arrival. 
There was no between or within subject variation for time of arrival in any other experiment 
conducted within this thesis. 
Clothing  
During Study 1a, 1b, and 2, subjects donned underwear and shorts, equating to a Clo insulation 
value of ~0.2. In Study 3 and 4, subjects were also permitted to wear socks to minimise the risk 
of non-freezing cold injury. Additional clothing will likely affect participants Tsk and perceptual 
responses to cold stress. All participants adhered to this control measure.  
Acute and chronic alcohol ingestion  
Participants were asked not to ingest any alcohol 48 hours prior to participation. On test days, 
participant’s alcohol intake was monitored via breathalyser (AlcoSense, AlcoSense ONE, 
Maidenhead, United Kingdom). As chronic alcoholism can increase the potential for 
acetaminophen and ibuprofen hepatoxicity (Prescott 2001), participants were also required to 
complete a self-assessment alcohol use identification test (AUDIT) questionnaire. If scores on 
the AUDIT exceeded 8, participants were excluded from the study.  
Supplementation and nutritional intake 
Participants were restricted from ingesting caffeine 24 hours prior to testing due to the impact 
this may have had on thermogenesis (Gosselin and Haman 2013). Participants were not 
permitted to take part in the experiment if they were currently using any non-prescription or 
prescription medications. This was because it may have impacted thermoregulation, and to avoid 
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drug interactions with acetaminophen or ibuprofen. Participants were asked to arrive at the 
laboratory having fasted overnight or for at least 12 hours.  
In Study 1, 2, and 3, participants consumed a standardised meal 30 minutes after arrival, having 
fasted overnight. The meal consisted of 50 g cornflakes, 250 ml semi skimmed milk, and 500 ml 
water. In total, the meal 303 kcal. In Study 4, participants arrived fasted overnight and did not 
consume any food prior to cold exposure.  
Prior acclimatisation and acclimation  
All participants confirmed that they had not visited a hot or cold climate for one week, for at 
least 3 weeks prior to participation in experimental trials because this may have affected heart 
rate, Tc and Tsk, and thermal sensation during cold exposure (Poirier et al. 2015; Saat et al. 2005).  
Contraindications to acetaminophen or ibuprofen administration  
Nutritional restrictions are outlined in sections 3.4.4 and 3.4.5. In addition to these controls, 
participants were required to complete an acetaminophen risk assessment questionnaire for Study 
1 to 3, and an ibuprofen risk assessment questionnaire for Study 4. If participants answered “yes” 
to any questions they were not permitted to take part in the experiments.  
3.1.5 Physiological measurements and apparatus 
Measurement of Tc  
Rectal temperature was used as an index of Tc throughout this thesis. Rectal temperature 
measurement has been shown to be the gold standard method of measuring Tc (Huggins et al. 
2012) due to its accuracy (± 0.1°C) and practicality. Tc was measured using a rectal probe (YSI, 
400H/4491H, Hertfordshire, United Kingdom) inserted by participants 10 cm beyond the anal 
sphincter. Measurement of Tc was continuously displayed on a temperature monitor (Libra 
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Medical, ET402, Birmingham, United Kingdom). Participant’s inserted the rectal thermistor 
upon arrival to the laboratory to ensure resting Tc levels could be measured and were within the 
normal resting values (i.e. non-febrile if < 38°C).  
Measurement of Tsk 
In Study 1, 2 and 3, copper based thermocouples (Grant, EUS-U-VS5-0, Dorset, UK) connected 
to a wireless data logger (Grant, Squirrel Series, Dorset, UK) recorded Tsk at four sites; calf, 
thigh, chest, and triceps. Thermocouples were securely attached to the belly of each muscle by 
hypafix surgical adhesive tape (BSN medical, D-22771, Hamburg, Germany) on the participant’s 
right side of the body. The weighted Tsk of four sites was subsequently calculated using the 
Ramanathan (1964) equation below: 
Mean Tsk = 0.3*(Tarm + Tchest)+0.2*(Tcalf + Tthigh)  
The 4-point equation was used because it shows strong agreement with more complex equations 
requiring more contact points (Ramanathan, 1964). However, it was determined that more 
temperature sites were required to investigate if any effects on skin blood flow and thus, heat 
loss. To improve the mean Tsk prediction in Study 4, a twelve-point system was used. In this 
study, thermocouples were placed on the belly of the gastrocnemius, rectus femoris, triceps 
brachii, pectoralis major, trapezius, erector spinae, bicep femoris, and soleus. Because 
electromyography probes were placed on the participant’s dominant side, thermocouples were 
placed on the participant’s right side of the body. The Hardy and DuBois (1938) 12-point 
equation was used to estimate mean Tsk: 
Mean Tsk = (Tforehead*0.07)+(Tchest*0.0875)+(Tabdomen*0.0875)+(Touter lower 
arm*0.14)+(Thand*0.05)+(Tquad*0.095)+(Tshin*0.065)+(Tinstep*0.07)+(Ttrapezius*0.0875)+(Tlower 
back*0.0875)+(Thamstring*0.095)+(Tcalf*0.065) 
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Measurement of heart rate, blood pressure and thermal sensation  
Heart rate was continuously measured via a telemetric heart rate monitor (Polar, FS1, 
Birmingham, United Kingdom) attached to the chest. Blood pressure (Study 3 and 4) was 
measured using an automated, portable monitoring device (Omron healthcare, M5-1, Milton 
Keynes, UK).  Data was expressed as beat per minute (i.e. b·min-1). Participants provided 
thermal sensation scores verbally at rest and every 10 minutes during experimental protocols.  
Measurement of hydration via urine osmolality 
Prior to each experimental protocol, participants provided a small urine sample to ensure they 
were in a euhydrated state. A small sample of urine (~1 ml) was pipetted into a handheld digital 
refractometer (Atago Vitech, Pocket PAL-OSMO, Warwickshire, United Kingdom) to measure 
urine osmolality. If scores fell under 600, subjects were considered adequately hydrated. If 
scores exceeded 600, participants were required to drink a safe volume of water until euhydrated 
(< 600 mOsm∙kg-1).  
Calibration of equipment 
The Tsk probes (Grant, EUS-U-VS5-0, Dorset, UK) were checked for accuracy against ambient 
air temperature measurements. The Tsk probes were required to be within 0.1°C of i) each other 
and ii) the air calibration thermometer. Alternative probes were used if the error was over 0.1°C. 
The Servomex (Servomex, Servomex mini HF 5200, Sussex, UK) was calibrated on each 
morning of the trial by laboratory technicians as per manufacturer recommendations. 
3.1.6 Experimental design  
All experiments (excluding Study 1 a) were double blinded, randomised, and had a crossover 
design. Randomised treatment allocation was conducted with IBM Statistics Package for Social 
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Sciences (SPSS) version 21.0 (SPSS Inc, Chicago, IL, USA) by using the ‘random sample of 
cases’ function. Each trial was separated by at least 7 days to ensure full clearance of 
acetaminophen or ibuprofen.   
Preparation and administration of acetaminophen, ibuprofen and placebo  
All drugs were administered orally in the present study with ~ 150 ml of tap water. Each drug 
was housed in an opaque silicone coated capsule. Dextrose was used as a placebo in 
experimental trials 2, 3 and 4 and the mass was matched with experimental drugs administered. 
Acetaminophen [Paracetamol, Aspar Pharmaceuticals, London, UK (Study 1, 2 and 3)] was 
administered at 20 mg·kg of lean body mass-1 and weighed using an electronic analytical 
balancer. Acetaminophen was administered at a dose relative to lean body mass to reduce any 
toxic effects on the liver, as advised by a consultant anaesthetist (Dr David Conn, Exeter 
Hospital). Because lean body mass is better correlated to liver volume than total body mass 
(Kwo et al. 1998), the dose provided using this system ensures high doses are not given due to a 
large body fat %. Ibuprofen [Banner Pharmacaps Europe, Tillburg, Netherlands (Study 4)] was 
administered at a fixed dose of 400 mg, in line with the doses recommended by the food and 
drug administration (FDA) for acute pain.   
3.1.7 Blood collection  
Venous blood collection and storage 
Venous blood was obtained from the superficial vein in the antecubital fossa of the forearm via 
venepuncture or cannulation (study dependent). Time points of blood collection are displayed in 
relevant experimental chapters. Blood was drawn into a 6 ml tubes (Grenier Bio-One, 
Kremsmunster, Austria) containing either ethylenediaminetetraacetic acid (EDTA) or heparin 
88 
 
before being centrifuged (Heraus Multifuge X3R, Thermo Scientific, Waltham, USA) at 1500 g 
for 5 minutes, at 4°C. Once the plasma component was separated, 1 ml was pipetted (Finnpipette 
F2, Thermo Scientific, Waltham, USA) and stored in 1.5 ml microcentrifuge tubes (Eppendorf, 
Grenier Bio-One, Kremsmunster, Austria) in a -80°C freezer until further analysis.  
Plasma volume  
Blood samples were pipetted and drawn in duplicate into microhaematocrit capillary tubes 
(Hawksley, Lancing, Sussex, UK) before being centrifuged in a Hawksley HaematoSpin 1400 
(Hawksley, Lancing, Sussex, UK) for 3 minutes at 14,000 g. Subsequently, capillary tubes were 
placed on a Hawksley microhaematocrit tube reader (Hawksley, Lancing, Sussex, UK) and the 
haematocrit (%) read accordingly. For haemoglobin determination, 10 μl of blood was collected 
onto a HemoCue® Hb 201 microcuvette (HemoCue® Ltd., Dronfield, Derbyshire, UK) and 
placed into a HemoCue® Hb 201+ (HemoCue® Ltd., Dronfield, Derbyshire, UK) in accordance 
with manufacturer’s instructions. Haemoglobin and haematocrit concentrations were used to 
measure changes in plasma volume per the Dill and Costill method (Dill and Costill, 1974) using 
the following equation: 
((100*Hbpre/Hb post))*((1-(Hct post – 100))/(1-(Hct pre – 100)))-100 
Plasma biomarkers were adjusted accordingly to account for any change in plasma volume. The 
percentage change in plasma volume was either added or subtracted from the absolute 
concentration of the biomarker in question. 
3.1.8 Enzyme linked immunosorbent assays  
In Study 1, acetaminophen plasma concentrations were measured using a Neogen ELISA 
development kit (Neogen, Auchincruive, Aryshire, UK). In Study 4, PGE2 plasma concentrations 
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were measured using an Enzo Life Sciences high sensitivity ELISA development kit (Enzo Life 
Sciences, Exeter, Devon, UK). All assays were conducted in accordance with the manufacturers 
recommendations and analysed in duplicate.  
3.1.9 Statistical analysis  
All statistical analyses were completed using R software version 3.3.2 (R Core Development 
Team), a language and environment for statistical computing. Normality assumptions were 
checked using quantile-quantile (QQ) plots. Where data was normally distributed, central 
tendency and dispersion are reported as mean ± standard deviation (SD). Data was reported as 
median (range) if it did not follow a normal distribution. Linear mixed models were used to 
analyse the change in dependent variables over time of exposure, and the fixed and random 
components of each model are displayed in each experimental chapter. The Akaike information 
criterion (AIC) was used to determine the fit of the full model compared with the null model, and 
subsequently to compare models with different correlation structures. The model with the lowest 
AIC value was chosen based on this procedure (Akaike 1973). A cumulative link mixed model 
(also known as an ordinal regression model) was used to analyse thermal sensation data, which is 
presented as an odds ratio (OR) relative to a placebo trial. The alpha level of significance testing 
was set as p ≤ 0.05, and 95% confidence intervals (CI) are used to denote the imprecision in the 
point estimate.  
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CHAPTER 4. EXPERIMENT 1: EVIDENCE OF ACETAMINOPHEN INDUCED 
HYPOTHERMIA IN NORMOTHERIC, NON-FEBRILE HUMANS.  
4.1 Introduction 
Acetaminophen is a widely used analgesic antipyretic drug that is branded as Tylenol in the USA 
and as paracetamol in the UK. It is available over-the-counter in various single-entity 
formulations and is commonly prescribed in combination with various opioids to manage 
moderate pain symptoms. Despite its well-established validity as an analgesic and antipyretic via 
inhibition of COX (Aronoff et al. 2006; Li et al. 2008), a growing body of evidence also 
demonstrates a third, hypothermic action of acetaminophen i.e. Tc reduction in the absence of 
fever. This side effect may be beneficial for inducing therapeutic hypothermia, but may also 
increase rates of accidental hypothermia, via exacerbated Tc reductions in environments beneath 
the thermal neutrality. The hypothermic effects of intravenous acetaminophen have been 
reported in rodents, with up to a 4°C reduction in Tre (Ayoub et al. 2011; Gentry et al. 2015; Li et 
al. 2008). The hypothermic effects of intravenous acetaminophen have not been confirmed in 
non-febrile human beings in a controlled laboratory setting.  
Confirming if acetaminophen exhibits a hypothermic action in humans is pertinent for several 
reasons. Firstly, due to the inverse relationship between Tc and neurological outcome after stroke 
or traumatic brain injury (Reith et al. 1996), acetaminophen could be used as a cheap, safe, and 
easily administered pharmacological method to reduce Tc when more invasive and logistically 
challenging methods are not available or appropriate (den Hertog et al. 2009). Indeed, 
acetaminophen has been shown to reduce mean Tc in non-febrile stroke patients (Kasner et al. 
2002), however the acetaminophen dose used was small (650 mg), Tc was only averaged across a 
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24-hour period, and there were no obvious environmental or nutritional controls in place. 
Secondly, if acetaminophen reduces the resting Tc of healthy humans, it may be involved in the 
pathology of accidental hypothermia. For example, if acetaminophen reduces Tc via increasing 
heat loss or decreasing heat production, this places individuals who consume acetaminophen at 
greater risk of developing hypothermia, especially in winter months. This is of particular concern 
to thermoregulatory vulnerable individuals i.e. the very young (aged 0-4 years) or the elderly 
(age ≥65 years), who together contributed ≥85% of UK hospital admissions in 2014 where 
hypothermia was the primary or secondary diagnosis (HSCIC 2015). As acetaminophen is the 
most frequently administered over-the-counter medication worldwide (Blieden et al. 2014), any 
hypothermic action could have deleterious implications for a significant number of people as 
outlined above. In this preliminary trial, young adults were used as participants to first establish 
any cause and effect due to ethical considerations. 
4.1.1 Experimental aims and hypothesis  
The first aim was to determine the peak plasma concentration of acetaminophen following an 
oral dose of 20 mg·kg of lean body mass-1 (part a). The second aim of the present study was to 
determine whether acute, oral acetaminophen ingestion alters thermoregulatory control during 
passive exposure to a sub neutral environment of 20°C (part b). The final aim was to assess the 
reliability of rectal temperature, Tsk, heart rate, and thermal sensation responses within subjects. 
Based on prior experiments in mice, it was hypothesised that acetaminophen would significantly 
decrease Tre across the 120-minutes study period, compared with a placebo.  
4.2 Methods 
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For clarity, this methodology is separated into two parts (part a and part b). In part a, the methods 
involved in determining the plasma concentrations of acetaminophen after an oral dose of 20 
mg·kg lean body mass-1 is described. In part b, the methods used to determine the effect of 
acetaminophen on thermoregulation is described. Eight participants from part a went on to 
participate in part b (see Figure 4.1 for study design). 
4.2.1 Ethical approval 
All experimental procedures were approved by the University of Bedfordshire’s Institute for 
Sport and Physical Activity Research Ethics committee (approval code 2012ASEP021), and they 
conformed to the standards set by the World Association Declaration of Helsinki ‘Ethical 
Principles for Research Involving Human Subjects’. 
4.2.2 Power analysis 
Power analyses were conducted with GPower software version 3.1 (Heinrich University, 
Düsseldorf, Germany). Using Tre data from a previous experiment where acetaminophen was 
tested as a hypothermic agent in non-febrile stroke patients (Dippel et al., 2003a), it was 
determined that a total of nine participants were required to achieve a statistical power of 80%. 
4.2.3 Participants 
Ten Caucasian males [Age (23 ± 2 years), Height (181 ± 8 cm), Mass (80 ± 8 kg), body fat (16 ± 
4%)] participated in part a. Thirteen Caucasian males [Age (23 ± 1 years), Height (174 ± 3 cm), 
Mass (73.6 ± 8 kg), body fat (15.5 ± 4.8%)] participated in part b. Eight participants from part a 
went on to participate in part b, with two discontinuing their participation for part b (see 
Figure 4.1 for trial profile). Participants were provided with written information regarding all 
experimental procedures, with supporting oral explanations from the principal investigator. 
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Participants then subsequently provided written informed consent. The participants were non-
smokers, non-febrile (resting Tre 36.5 – 37.5°C), and were free from musculoskeletal injury. 
 
 
Figure 4.1. Study Design.  
4.2.4 Inclusion/exclusion criteria 
Prior to each laboratory visit, participants completed an informed consent sheet, alcohol use 
disorder identification test [AUDIT; (Saunders et al. 1993)] a breathalyser test (AlcoSense, One, 
Berkshire, UK), and an acetaminophen risk assessment questionnaire. To avoid the risk of liver 
damage inflicted by acetaminophen, participants were not able to participate in the research if 
they scored above ten on the AUDIT questionnaire or alcohol was present in their bloodstream. 
No participants presented with any pre-existing medical conditions that may have put them at an 
increased risk of acetaminophen toxicity. Further details are provided in section 2.14.4 and 
2.14.7, respectively. Due to potential thermoregulatory adaptions (Poirier et al. 2015), 
individuals were not permitted to take part in any experimental procedures if they were heat 
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acclimated or acclimatized. Thus, those who had travelled to a hot climate or participated in a 
laboratory based heat acclimation protocol less than three weeks prior to the experiment were not 
permitted to take part (Saat et al. 2005). All participants presented with a stable Tre (36.5–
37.5°C).  
4.3 Part a methodology 
4.3.1 Part a design 
To identify when the peak plasma concentration of acetaminophen arises after oral ingestion (20 
mg⋅kg lean body mass-1), ten Caucasian males visited the laboratory on one occasion. 
Participants adhered to all experimental controls listed in the “general experimental controls” 
section. 
4.3.2 Part a controls 
On the trial day, acetaminophen (Paracetamol, Aspar Pharmaceuticals, London, UK) was 
administered at a dose equal to 20 mg⋅kg of lean body mass-1. Each capsule contained a 
maximum of 500 mg of acetaminophen. The dosing range of acetaminophen in the present work 
was 1019 to 1420 mg (mean ± SD = 1293 ± 163 mg). This dosing was advised by a leading 
clinician and consultant anaesthetist, and has been used previously (Mauger et al. 2014). All 
participants arrived at the laboratory having fasted overnight for 12 hours. To control the gastric 
emptying rate of acetaminophen, participants ingested a standardized meal [cornflakes (50 g), 
milk (250 ml) and 1 litre of water] 1 hour prior to acetaminophen or placebo ingestion. 
Experimental trials took place within a custom built environmental chamber (Custom build, 
T.I.S.S, Hampshire, UK) which simulated the desired environmental condition of 20°C and 40% 
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relative humidity. The participants’ clothing was standardized across all trials, in which they 
were barefoot, topless, and wore knee length shorts. 
4.3.3 Part a protocol 
Participants arrived at the laboratory at 08:30. Upon arrival, participant’s lean body mass was 
calculated via air displacement plethysmography (Bod Pod, 2000A, Birmingham, UK). At 08:45 
participants consumed a standardised meal (see “part a Controls”). At 09:20, participants 
remained seated and a 20G cannula (Introcan® Safety Winged, B Braun Medical, Sheffield, UK) 
was placed in a prominent vein within the antecubital fossa. At 09:30, participants entered the 
environmental chamber (20°C, 40% r.h.). Fifteen minutes after entry, participants orally ingested 
acetaminophen (Paracetamol, Aspar Pharmaceuticals, London, UK). Blood samples were drawn 
into a heparin coated EDTA tube (Vacuette®, Greiner Bio-One, Stroudwater, UK) immediately 
prior to acetaminophen ingestion, and subsequently at 20, 40, 60, 80, 100, and 120-minutes post 
ingestion. Peak plasma levels of acetaminophen were quantified using a commercially available 
ELISA kit (Microplate EIA kit, Alere toxicology, Abingdon, UK) read in duplicate at a dual 
wavelength of 450 and 650 nm (Sunrise, Tecan, Seestrasse, Männedorf). The average inter-plate 
CV was 5% (intra-plate CV not applicable due to assay layout). Venous hemoglobin (Hb 201+, 
Hemocue, Staines, UK) and haematocrit (Haematospin 1300, Hawksley, Sussex, UK) 
concentrations were taken in duplicate and averaged at each point of blood sampling. This data 
was used to calculate changes in plasma volume according to the Dill and Costill method (1974), 
and acetaminophen concentrations were subsequently adjusted in accordance with any changes 
in plasma volume. 
4.4 Part b methodology 
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4.4.1 Power calculation 
Power analyses were conducted with GPower software version 3.1 (Heinrich University, 
Düsseldorf, Germany). Utilising Tre data from a previous experiment where acetaminophen was 
tested as a hypothermic agent (Dippel et al. 2003a), it was determined that a total of 13 
participants were required to achieve a statistical power of 90%. 
4.4.2 Part b design 
To determine the hypothermic effect of acetaminophen, 13 participants visited the laboratory at 
the same time of day on three occasions (acetaminophen, placebo, and control), each separated 
by at least seven days. The data from the acetaminophen and placebo trials were used for the 
determination of acetaminophen’s hypothermic action. The data from the placebo and control 
trials were used to generate reliability statistics. All visits were randomized, and the 
acetaminophen and placebo trials were double blinded. The trials took place within an 
environmental chamber (20°C, 40% r.h.) set beneath the thermoneutral zone [i.e., 
subneutral; (Kingma et al. 2012; Kingma et al. 2014)] for 120 minutes. A sub-neutral 
environment was chosen for two reasons, (i) to ensure that heat loss mechanisms would not 
become activated during the protocol and (ii) to help replicate the sub-neutral conditions in 
previous animal work concerning acetaminophen induced hypothermia (Ayoub et al. 2011; 
Ayoub et al. 2004)]. On each trial day, acetaminophen (Paracetamol, Aspar Pharmaceuticals, 
London, UK) or a placebo (dextrose, MYPROTEIN, Cheshire, UK) was administered at a dose 
equal to 20 mg⋅kg of lean body mass-1. Each capsule contained a maximum of 500 mg of 
acetaminophen. The dosing range of acetaminophen in the present work was 1019–1420 mg 
(mean ± SD = 1226 ± 135 mg). Controls for gastric content, nutritional intake, environmental 
conditions, and clothing were identical to that of part a (see “part a controls”). 
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4.4.3 Part b protocol 
Participants arrived at the laboratory at 7am or at 10am, where each participant’s time of arrival 
was consistent through all experimental trials to account for any circadian rhythm or diurnal 
variations in Tre (Waterhouse et al. 2005). Upon arrival, participants were instrumented for the 
measurement of Tre, Tsk, and heart rate (see “Instrumentation and Equations” for details). Thirty 
minutes after arrival, participants consumed the standardised breakfast. Sixty minutes after the 
meal was consumed, participants ingested acetaminophen, a placebo (dextrose), or nothing 
(control). Participants remained rested in an upright-seated position between meal consumption 
and acetaminophen or placebo ingestion, and for the duration of data collection to ensure resting 
physiological status was attained and maintained throughout the data collection. Data collection 
began immediately after ingestion of acetaminophen or placebo, i.e., 60 minutes after meal 
consumption. Resting measurements of Tre, Tsk, heart rate, and thermal sensation were taken 5 
minutes prior to chamber entry, and subsequently every 10 minutes for 120-minutes post entry. 
4.4.4 Part b instrumentation and equations 
Equipment details and equations for Tre, Tsk, heart rate, and thermal sensation are described 
within the General Methodology (section 3.1.5).  
4.4.5 Statistical analysis 
All statistical analyses for were performed using the ‘psych’, ‘nlme’, ‘ordinal’, ‘ez’, and ‘stats’ 
packages in R version 3.3.2 (R Core Development Team 2014). Normality assumptions were 
checked using quantile-quantile plots (Grafen and Hails 2002) and were plausible in all 
instances. Central tendency and dispersion are reported as means ± standard deviation (SD). 
Reliability of all variables from consecutive pairs of trials were assessed using data from the 
98 
 
control and placebo trial. The following reliability measures [change in mean (CIM), coefficient 
of variation (CV), intraclass correlation coefficient (ICC), and typical error (TE) were all 
reported. The Akaike information criterion (AIC) was used to determine model fit against the 
null model (Akaike 1973). The correlation structure with the lowest AIC was chosen based on 
this procedure. A linear mixed model with fixed (‘drug’, ‘time’) and random (‘subject i.d’) 
effects was fitted with an autoregressive correlation structure (to account for autocorrelation) to 
examine the effect of acetaminophen on Tre, Tsk, and heart rate [Time (13 levels): pre, 10, 20, 30, 
40, 50, 60, 70, 80, 90, 100, 110, 120 minutes × Drug (2 levels): placebo, acetaminophen]. A 
cumulative link mixed model with fixed (‘drug’, ‘time’) and random effects (‘subject i.d.’) was 
used to compare thermal sensation scores between placebo and acetaminophen. The thermal 
sensation analysis is presented as an odds ratio, and the output example is explained in the text. 
The two-tailed alpha level of significance testing was set as p ≤ 0.05. 95% confidence intervals 
(CI) are presented to denote the imprecision of the point estimate. 
4.5 Results: Part a 
The peak plasma concentration of acetaminophen during the 120-minutes experiment was 14 ± 4 
μg/ml (range, 8-19 μg/ml). The time for acetaminophen to reach maximal concentrations was 96 
± 13 minutes (range, 80-100 minutes). Figure 4.2 displays the plasma concentration response of 
acetaminophen, every 20 min for 2 hours. 
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Figure 4.2. Mean ± standard deviation values for plasma acetaminophen concentration response 
to oral intake of 20 mg⋅kg lean body mass-1 acetaminophen during a resting 120-minutes period. 
n=10. 
4.6 Results: Part b 
4.6.1 Reliability  
Reproducibility statistics (i.e. control vs placebo) demonstrated that there was no systemic bias 
for any of the variables tested. Results are presented in Table 4.1.   
4.6.2 Tre 
Main effects were found for condition (F1,1 = 28.68, p < 0.001), and time (F1,12 = 17.23, p < 
0.001) between acetaminophen (36.73 ± 0.1°C; 95% CI = 36.67 to 36.8°C) and placebo (36.83 ± 
0.1°C; 95% CI = 36.77 to 36.89°C). A significant interaction effect was also found (F1,12 = 
51.68, p < 0.001), revealing that mean Tre was significantly lower in the acetaminophen group 
from 30 minutes to the cessation of the trial. The peak Tre reduction from baseline arose 110 
minutes (6 subjects) or 120 minutes (7 subjects) after ingestion, and the drop ranged from 0.10 to 
0.39°C (mean = 0.19 ± 0.09°C). The mean Tre response to acetaminophen ingestion is displayed 
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in Figure 4.3. The individual responses to dextrose and acetaminophen are displayed in Figure 
4.4.  
 
Figure 4.3. Mean ± standard deviation values for Tre in both the acetaminophen and placebo 
conditions. ∗Significant main effect for condition. #Significant main effect for time. †Significant 
interaction effect. n=13. 
 
4.6.3 Tsk 
There were no significant main effects for condition (F1,1 = 0.01, p > 0.05) between 
acetaminophen (26.8 ± 1.3°C; 95% CI = 26 to 27.6°C) and placebo (26.9 ± 0.8°C; 95% CI = 
26.41 to 27.3°C), but there was a main effect for time (F1,12 = 30.46, p < 0.001). No interaction 
effects were found (F1,12 = 0.39, p > 0.05) 
4.6.4 Thermal sensation 
TS did not change with acetaminophen administration (p > 0.05). Compared with time-point 0, 
TS was reduced from time-point 20 to 120 (p < 0.05). The odds ratios are displayed in Table 4.2. 
The average thermal sensation in both trials was 3.5 ± 2 (4 = “comfortable”). 
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4.6.5 Heart rate  
There were no significant main effects for condition (F1,1 = 0.76, p > 0.05) between 
acetaminophen (62 ± 8 b·min-1; 95% CI = 58 to 66 b·min-1) and placebo (63 ± 7 b·min-1; 95% CI 
= 60 to 66 b·min-1), but there was a main effect for time (F1,12 = 5.57, p < 0.001). No interaction 
effects were found (F1,12 = 0.24, p > 0.05). 
 
Figure 4.4. Individual Tre responses in the placebo (A) and acetaminophen condition (B). n=13. 
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Table 4.1. Reproducibility of dependent variables commonly used throughout this thesis.  
 
Change in mean (CIM), Effect size (ES), Intraclass correlation coefficient (ICC), Coefficient of variation (CV), Typical error (TE). 
95% confidence intervals are presented in parentheses where appropriate. 
 
 
 
Variable Placebo Control CIM p value ES ICC CV (%) TE (%) 
Tre 36.82 ± 0.10 36.82 ± 0.12 
0.03 
(-0.03 to 0.03) 0.89 0.05 
0.91 
(0.75 to 0.97) 
0.2 
(1.8 to 7) 
0.03 
(0.02 to 0.05) 
Tsk 31.45 ± 0.54 31.37 ± 0.79 
0.1 
(0.31 to 0.5) 0.6 0.09 
0.54 
(0.02 to 0.83) 
0.29 
(0.18 to 0.72) 
0.47 
(0.34 to 0.78) 
Heart rate 63 ± 4 63 ± 6 0 (-3.43 to 2.63) 0.77 0.06 
0.54 
(0.05 to 0.83) 
6 
(4.4 to 10.1) 
3.71 
(2.69 to 5.98) 
TS 3.99 ± 0.04 3.96 ± 0.15 0.03 (-0.06 to 0.12) 0.53 0.2 
0.49 
(0.42 to 0.9) 
3 
(2.2 to 4.9) 
0.11 
(0.08 to 0.18) 
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Table 4.2. Changes in TS as a product of time (duration of exposure) and time + drug 
(interaction effect). Significance codes: < 0.001***, < 0.01 ** 
 
 
OR  SE p 
Placebo vs APAP 
(Intercept) 0.989 2.435   
Time Only       
TIME10 0.288 2.536   
TIME20 0.052 2.994 ** 
TIME30 0.051 2.948 ** 
TIME40 0.051 2.948 ** 
TIME50 0.025 3.047 *** 
TIME60 0.025 3.024 *** 
TIME70 0.013 2.975 *** 
TIME80 0.005 2.925 *** 
TIME90 0.002 2.851 *** 
TIME100 0.001 2.854 *** 
TIME110 0.001 2.879 *** 
TIME120 0.000 3.211 *** 
Drug×Time Interaction       
TIME10:DRUGAPAP 1.024 3.712   
TIME20:DRUGAPAP 3.485 4.261   
TIME30:DRUGAPAP 1.991 4.338   
TIME40:DRUGAPAP 1.991 4.338   
TIME50:DRUGAPAP 2.054 4.498   
TIME60:DRUGAPAP 1.009 4.445   
TIME70:DRUGAPAP 0.573 4.039   
TIME80:DRUGAPAP 0.942 3.765   
TIME90:DRUGAPAP 0.984 3.542   
TIME100:DRUGAPAP 0.994 3.514   
TIME110:DRUGAPAP 0.667 3.557   
TIME120:DRUGAPAP 1.512 3.849   
The OR is a score of likelihood relative to 1. For example, for the “time only” model at time 
point 20, the likelihood of a score being higher than time point 0 is 0.052 out of 1 i.e. ~ 5%. In 
the same model, the likelihood of scoring higher at 100 minutes than 0 minutes is 0.001 i.e. ~ 
0.001%. The “drug×time” model displays the likelihood of a score in the acetaminophen group 
(APAP) being higher than the placebo at the same time point. For example, at time point 120, 
the likelihood of a score being higher in the acetaminophen group was 1.512 i.e. ~50%. 
However, this is not statistically significant due to the high standard error.    
  
104 
 
4.7 Discussion   
4.7.1 Overview of results  
The aim of this study was to investigate if oral acetaminophen ingestion exhibited a hypothermic 
action in non-febrile humans. On average, Tre was 0.14°C lower during the 120-minutes 
exposure to 20°C in the acetaminophen condition compared with a placebo. The maximum 
(peak) reduction in Tre in the acetaminophen condition was 0.19 ± 0.09°C (range = 0.10 to 
0.39°C), as shown in Figure 4.2. Having ingested acetaminophen, all participants displayed a 
gradual decrease in Tre, and in seven participants, this did not plateau in the 120-minutes study 
period (Figure 4.3 and 4.4). However, due to the relatively short experiment time, the notion that 
Tre began to recover before the end of the 120-minutes period in the remaining six participants is 
speculative. To our knowledge, this is the first study that accurately demonstrates that 
acetaminophen reduces non-febrile human Tre in sub neutral conditions (i.e. beneath thermal 
neutrality) within apparently healthy human participants (figure 4.3). 
4.7.2 Agreement with prior work in this area  
The effect of acetaminophen on non-febrile temperature regulation has been investigated 
previously in mice (Ayoub et al. 2011; Ayoub et al. 2004; Gentry et al. 2015; Li et al. 2008) and 
humans (den Hertog et al. 2009; Dippel et al. 2003b; Kasner et al. 2002). There are also reports 
of severe hypothermia (Tre = 28°C on hospital admission) following acute acetaminophen 
overdose (Rollstin and Seifert 2012). Prior to the present work, this potentially hazardous side-
effect had not been confirmed in passive, nutritionally controlled participants or conducted in a 
temperature controlled environmental chamber. Despite a significant interaction effect 
(condition*time) for Tre, the 120 minute trial period did not consistently allow for a plateau in Tre 
to be demonstrated i.e. the maximum Tre reduction in seven of the thirteen participants was not 
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seen prior to the final time point of 120 minutes (Figure 4.4). Although Tre seemed to plateau in 
six participants, a trial of longer duration is needed to reliably determine when Tre will begin to 
recover to normal values after administration of acetaminophen. However, given that the cellular 
target of acetaminophen for inducing hypothermia is not known in humans, it is difficult to 
predict if the peak reduction in Tre is in line with the peak plasma or cerebral spinal fluid (CSF) 
concentrations. 
4.7.3 Pharmacokinetic comparison with prior work 
Due to its worldwide use, the pharmacokinetics of acetaminophen has been investigated 
extensively. However, it was important to determine the short-term concentration response in the 
present experiment (Study 1) as this has not been analysed (i) following doses of 20 mg·kg of 
lean body mass-1 and (ii) following the implemented nutritional controls. The data presented here 
is; however, in line with previous work. Early work using gas chromatography demonstrated that 
in adult humans (fasted and apparently healthy), oral doses of 1000 and 2000 mg acetaminophen 
reach peak plasma concentrations in ∼60 and 120 minutes, respectively (Rawlins et al. 1977). 
An oral dose relative to lean body mass was used in the present experiment because the volume 
of distribution of hydrophilic drugs correlates more strongly with lean body mass compared with 
total body mass (Morgan and Bray 1994). Consequently, the doses administered here ranged 
from 1019 to 1415 mg (mean = 1226 ± 135 mg). Thus, modelling previous pharmacokinetic data 
(Rawlins et al. 1977) and that from part a, it can be predicted that during part b, peak plasma 
concentrations were reached within the study period of 120 minutes. However, given that Tre did 
not consistently recover in the 120 minutes study period (Figure 4.4), this raises the notion that 
the peak reduction in Tre is more likely to be in line with peak CSF concentrations of 
acetaminophen, which may take 4 hours to arise after an acute 1000 mg dose (Singla et al. 2012). 
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Future work should elucidate when Tre begins to recover after acute acetaminophen exposure, as 
this may have important implications if acetaminophen is to be used as a hypothermic agent 
following brain injury (Saxena et al. 2015). It would also be beneficial to ascertain if the 
maximal Tre reductions are in line with peak CSF concentrations, as this would help identify if 
acetaminophen induced hypothermia is mediated within the central nervous system. 
4.7.4 Implications for accidental hypothermia 
In the United Kingdom, cold-related mortality presently accounts for at least one order of 
magnitude more deaths than heat-related mortality i.e. around 61 and 3 deaths per 100,000 
population per year, respectively (Vardoulakis et al. 2014). Consequently, in 2014 there were 
over 16,000 hospital admissions in the UK whereby hypothermia was the primary or secondary 
cause (HSCIC 2015). Exposure to environments beneath thermo-neutrality clearly present a 
major health risk, particularly in thermoregulatory vulnerable populations such as the very young 
and the elderly, who account for more than 85% of these admissions. The primary deleterious 
effects of cold on the human body arise when Tc falls below 35°C, although the autonomic 
physiological responses required to maintain Tc (tachycardia and shivering) can increase 
cardiovascular strain and can lead to secondary events particularly in elderly individuals (Parsons 
2014). The data obtained in this experiment demonstrates that Tre is not as efficiently defended 
when participants ingest acetaminophen in a subneutral environment. This is particularly 
concerning as the average thermal sensation in both groups (acetaminophen and placebo) was 3.4 
± 2 (4 = “comfortable”), and no participants reported feeling “cold” on the thermal sensation 
scale. If acetaminophen inhibited normal thermogenic mechanisms in these conditions, it is 
likely that these Tre reductions will be exacerbated in colder environments. More work is needed 
in this area to confirm when the peak reduction in Tre arises, and the variability in this response. 
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Moreover, it is unclear if acetaminophen induced hypothermia is exacerbated in cold conditions 
(where there is a greater reliance on thermogenesis). These findings could have implications for 
public health recommendations.  
4.7.5 Possible physiological underpinnings  
The observed hypothermic effect of acetaminophen may be due to a decrease in heat production 
or an increased heat loss. During exposure to cold environments, veno and vasoconstriction 
occur rapidly and the magnitude depends on the gradient between the Tsk and the air temperature 
(Castellani and Tipton, 2015). Thereafter, metabolic heat production through shivering and BAT 
activation increases in an effort to maintain Tc close to 37°C. If we assume that the Tsk reduction 
(i.e. 27°C) reflects the level of cold stress in this study, it is likely that a change in vasomotor 
tone was the dominant factor for preserving Tre (Blondin et al., 2014). If this were true, Tsk would 
increase in vasodilatory sites (i.e. glabrous skin), reflecting an increase in skin blood flow. An 
elevated Tsk in these sites would be detrimental for Tc preservation due to the increased gradient 
between Tsk and air temperature, resulting in increased convective heat loss from the skin 
(Parsons, 2003).  
That being said, the reductions in Tsk have been shown to initiate a shivering response (Gosselin 
and Haman, 2013). The possible inhibition of this response with acetaminophen is described in 
more detail below.  
4.7.6 Possible molecular underpinnings 
The molecular target for acetaminophen induced hypothermia in humans is not well established, 
but is likely due to inhibition of the COX enzyme. When administered orally (1000 mg), 
acetaminophen is a potent inhibitor of COX-2 in intact cells, but may also inhibit COX-1 (Hinz 
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et al. 2008). Given that participants in this study were exposed to sub-neutral environmental 
temperatures, it is possible that COX may have been prevented from activating thermogenic 
responses to this environment. Although the role of COX in non-febrile thermogenesis remains a 
topic of debate (Aronoff and Romanovsky 2007), recent evidence supports a role for COX in this 
capacity. For example, it has been demonstrated that COX-2 is essential for UCP-1 induction in 
beige/brite adipocytes during cold exposure, such that Tre was not efficiently defended during 
acute cold exposure in COX-2 gene deficient mice compared with their wild-type counterparts 
(Madsen et al. 2010). More recently, intravenous parecoxib (COX-2 selective inhibitor) 
administration significantly reduced post-operative shivering in non-febrile patients. Thus, it is 
possible that during sub neutral conditions, a reduction in autonomic shivering responses 
(mediated by acetaminophen induced COX-2 inhibition) could contribute to the decline in Tre 
witnessed in the present work. Indeed, the magnitude of reductions in Tsk seen in this study have 
been shown to initiate shivering in prior research (Gosselin et al. 2013). 
4.7.7 Delimitations  
This experiment contains several delimitations which should be considered in future 
experiments. In part a, the concentrations of acetaminophen in the plasma were quantified 
through an ELISA assay. The use of an ELISA in this context is not common in pharmacokinetic 
research due to the increased specificity and performance of liquid chromatography/mass 
spectrometry (LC/MS). Despite this, the results in the present study (part a) were in line with 
prior research in this area (Rawlins et al. 1977; Singla et al. 2012). The second limitation of this 
experiment was the anatomical position of the participants (i.e. seated upright). Positioning 
participants in this way promotes activation of the trunk (anti-gravitational) muscles (abdominal 
muscles, erector spinae, obliques), which may have interfered with resting metabolic rates and 
109 
 
therefore heat production (Rubini et al. 2012). The seated upright position was used in this study 
to best replicate the behaviours of thermoregulatory vulnerable individuals in their home during 
winter months. The third limitation of this study is the requirement that participants ingest food 
(~ 300 kcal) one hour prior to the 20°C exposure. In thermogenesis research, it is advisable that 
participants enter a cold environment in a fasted state to avoid any potential confounding effects 
of diet induced thermogenesis (Westerterp 2004). A 300 calorie meal (as used in this study) 
would be expected to cause a Δ increase in energy expenditure of ~0.2 kcal·minutes-1 (Ishii et al. 
2016). This nutritional intake was used in the present study to reduce heterogeneity of 
acetaminophen absorption rates (Divoll et al. 1982b). A final limitation of this study was the use 
of doses adjusted for lean body mass. The use of a fixed dose (i.e. 500, 1000, and1500 mg) 
would have allowed a potential dose response to be identified, an important factor for future 
public health recommendations. For example, a 500-mg dose of acetaminophen may have no 
effect on Tre stability, and thus be a suitable dose for those at risk of hypothermia in winter 
months. The absolute doses administered in the present study ranged from 1019 to 1420 mg, 
with no relationship between dose quantity and Tre reduction being apparent.  
4.7.8 Conclusions 
In conclusion, it has been demonstrated that acute acetaminophen ingestion at a dose of 20 
mg·kg lean body mass reduces non-febrile Tre during a 120-minute passive exposure to 20°C, 
40% r.h (figures 4.3 and 4.4). Future research should seek to determine if acetaminophen reduces 
the capacity of the thermoregulatory system to maintain Tre during cold exposure. If 
acetaminophen reduces metabolic heat production during exposure to sub neutral environments, 
an amplified effect on Tre may occur when the ambient temperature is markedly reduced. 
Moreover, it should be determined if the peak reductions in Tre are in line with peak CSF 
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concentrations. Such findings would determine if acetaminophen induced hypothermia may be 
involved in the pathology of accidental hypothermia, especially during overdose.  
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CHAPTER 5. EXPERIMENT 2: NO EFFECT OF ACETAMINOPHEN ON CORE 
TEMPERATURE DURING PASSIVE HEAT EXPOSURE 
5.1 Introduction 
Heat stress is a topic that receives considerable attention in the context of human health and 
performance. An individual is under heat stress when active heat loss mechanisms are required to 
keep Tc stable, marked by an elevation of skin blood flow and secretion of sweat upon the skin 
surface. As humans, we live most of our lives in a state of heat balance (i.e. S is ~0), and this is 
primarily mediated through behavioural adaptations. Here, afferent neurons synapse with 
neurons in the thalamus which project to the primary somatosensory cortex, allowing conscious 
derivation of the state of the external environment (Craig 2002). Changing clothing, adjusting the 
thermostat, and seeking the shade on a hot sunny day are all examples of behavioural 
thermoregulation. If the Tsk continues to rise despite these behavioural responses, autonomic heat 
loss effector pathways are activated. Here, heat sensitive cutaneous nerves project to the anterior 
hypothalamus, activating cholinergic nerves which serve to increase skin blood flow and 
sweating (Nakamura and Morrison 2010). However, the Tc will rise if active heat loss 
mechanisms are insufficient, inducing cardiovascular strain, dehydration, and a reduced 
cognitive and physical function. This may progress into heat stroke if Tc reaches levels required 
for protein denaturation, or is raised for a very prolonged period which may activate innate 
immune responses (Lim and Mackinnon 2006).  
In an occupational setting, a reduced ability to maintain cognitive or physical function can have 
adverse effects on health and safety. Studies demonstrate an increased risk of occupational injury 
while working in a hot environment (Tawatsupa et al. 2013), and there is also a strong negative 
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correlation between the environmental temperature and labour productivity (Hübler et al. 2008; 
Zander et al. 2015), each caused by feelings of discomfort and distraction (Taylor et al. 2015). 
These productivity losses are estimated to incur an annual loss of ~$6.2 billion in Australia 
(Zander et al. 2015) and ~$771 million in Germany (Hübler et al. 2008). Although these 
projections are based on exceptionally hot periods, the climate is consistently warming, and even 
if Europe achieves their goal of reducing CO2 emissions to 20% below the level shown in 1990 
by 2020, the effects of climate change will persist for at least a further 50 years (Nybo 2016). To 
offset these health perturbations and productivity losses, knowledge on contributing factors, or 
methods that may off-set internal heat strain are of interest since they may be used 
therapeutically to curtail Tc elevations.  
In Study 1, it was demonstrated that acetaminophen holds a hypothermic action in healthy males, 
decreasing Tre by ~0.2°C at 120-minutes exposure to mild cold (20°C). That preliminary study 
warrants future work which will elucidate if the risk of acetaminophen induced hypothermia 
increases as the ambient temperature declines. However, given that acetaminophen is one of the 
most commonly administered drugs in the world, any beneficial or adverse effects on heat stress 
responses should be reported. It is currently unclear how acetaminophen might alter the Tc 
responses to passive heat stress as there is evidence for conflicting effects on cutaneous 
vasodilation. For example, acetaminophen is a potent COX inhibitor, an enzyme which is 
required for vasodilatory responses when young adult humans are subjected to a moderate (400 
Watts) heat load (Fujii et al. 2014b). The evidence pertaining to this is discussed in section 2.5.8. 
Thus, it is possible that acetaminophen mediated inhibition of COX could curtail heat transfer 
from the skin to the environment by inhibiting full reflex vasodilation. A conflicting argument is 
that acetaminophen administration potentiates heat loss through an action of one of its active 
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metabolites, N-acetylbenzoquinoneimine (NAPQI). NAPQI is a potent agonist of the TRPA1 ion 
channel which is present on heat sensitive thermosensory neurons (Nassini et al. 2010). When 
these neurons are activated by NAPQI in vivo, there is a profound hypothermic effect in mice, 
which is highly dose dependent (Gentry et al. 2015). Therefore, acetaminophen (or NAPQI) 
could decrease the rate of heat storage by driving heat loss effector responses, providing a 
protective effect on Tc during heat stress. Research supporting an effect of acetaminophen during 
heat stress is varied. During fixed intensity cycling exercise in the heat (70% VO2max), 
acetaminophen reduced Tre prior to and throughout the exercise trial by ~0.15°C (Mauger et al. 
2014). Additionally, a recent case report showed that acetaminophen was effective in the 
management of mild heat illness, although its effectiveness was anecdotal and not supported by 
consistent Tc monitoring before and after its administration (Valente et al. 2017). Conflicting 
evidence shows that acetaminophen had no influence on Tre or sweating during exercise at a 
fixed rate of heat production (8 W∙kg-1 body mass), but this effect may be dose dependent since 
there was a trend towards an increased Tsk and decreased Tre towards the end of the 60-minute 
cycling trial (Coombs et al. 2015). None-the-less, no study has investigated the effects of 
acetaminophen on Tre during passive heat stress i.e. without the confounding effect of exercise.    
5.1.1 Experimental aims and hypothesis  
Thus, the aim of the present study was to document the thermoregulatory responses to passive 
heat stress with and without acetaminophen administration. As the hypothermic effect of 
acetaminophen may be mediated through increasing heat loss (Gentry et al. 2015), it was 
hypothesised that the Tre rise would be reduced in the acetaminophen condition compared with a 
placebo.    
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5.2 Methods 
5.2.1 Ethical approval 
All experimental procedures were approved by the University of Bedfordshire’s Institute for 
Sport and Physical Activity Research Ethics committee (approval code 2012ASEP021), and they 
conformed to the standards set by the World Association Declaration of Helsinki ‘Ethical 
Principles for Research Involving Human Subjects’.  
5.2.2 Participants  
The 13 Caucasian males who participated in Study 1 part a also volunteered for this experiment. 
Participants were randomly divided into two groups which involved dry heat exposure [dry, 120 
minutes at 45°C, 30% r.h. and humid heat exposure (humid, 45 minutes at 45°C, 70% r.h.). 
Subject characteristics are displayed in table 5.1.   
 
Table 5.1. Participant anthropometrical characteristics in the hot dry and hot humid conditions. 
Data is presented as mean ± standard deviation with the range in square brackets.  
 
Exposure Age (years) Height (cm) Mass (kg) Body Fat (%) 
Lean Mass 
(kg) 
DRY (n = 6) 23 ± 2 
[21 to 26] 
175 ± 7 
[167 to 187] 
71 ± 8 
[61 to 81]  
15 ± 5 
[12 to 21] 
60 ± 6 
[51 to 68] 
HUMID (n = 
7) 
23 ± 1 
[21 to 24] 
174 ± 8 
[169 to 188] 
74 ± 8 
[67 to 86] 
17 ± 4 
[15 to 24] 
61 ± 8 
[51 to 71] 
 
5.2.3 General design  
Participants were exposed to heat stress (45°C) having ingested acetaminophen (20 mg∙kg-1 lean 
body mass) or a sugar placebo (dextrose) 100 minutes prior to environmental chamber entry. 
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Based on the data from Study 1 part a (Chapter 4), this allowed time for the peak plasma 
concentration of acetaminophen to arise, ensuring that a therapeutic concentration was present in 
the circulation during heat stress. The two exposures to DRY (30% r.h.) or HUMID (70% r.h.) 
heat stress was separated by at least 7 days. Based on pilot work, the total exposure times in each 
trial was sufficient to induce a significant change in Tre over time. Drugs (acetaminophen or 
placebo) were administered in a double blind, randomised manner. 
5.2.4 Inclusion/exclusion criteria 
The general inclusion and exclusion criteria are outlined in Chapter 4 (section 4.2.3). 
5.2.5 Heat stress protocol 
Participants arrived at the laboratory at 07:00 or 10:00 in a fasted state, where each participant’s 
time of arrival was consistent through all experimental trials to account for any circadian rhythm 
or diurnal variations in Tre (Waterhouse et al. 2005). Upon arrival, participants were 
instrumented for the measurement of Tre, Tsk, and heart rate (see section 3.1.5 for details). Thirty 
minutes after arrival, participants consumed the standardised meal (see section 3.1.4). One hour 
after the meal was consumed, participants were administered acetaminophen or a placebo by a 
laboratory technician. Participants entered the environmental chamber 100 minutes after drug 
ingestion, for peak plasma concentrations to be reached, as informed by Study 1 part a. Between 
drug administration and chamber entry, participants were rested in temperate environment. Five 
minutes prior to entering the chamber, resting measures of Tre and Tsk, heart rate, and thermal 
sensation were collected. Participants entered the environmental chamber 3 hours after initial 
arrival at the lab, in which they remained in a seated upright position for the duration of the heat 
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exposure. Due to differences in trial length (i.e. 45 and 120 minutes)Tre, Tsk, heart rate, and 
thermal sensation were measured every 5 and 10 minutes in the dry and humid trial, respectively.  
5.2.6 Instrumentation and equations  
Equipment details and equations for Tre, Tsk, heart rate, and thermal sensation are described 
within the General Methodology (section 3.1.5). The rate of Tre increase was calculated as 
follows:  
Rate of change = (T1-T2)/exposure time               (3) 
Where T1 is the final Tre reached, T2 is the pre/baseline Tre attained 5 minutes prior to heat 
exposure, and exposure time is the duration of heat exposure expressed in minutes. This value 
was 120 and 45 minutes in the dry and humid trials, respectively. This equation yields a value for 
the change in Tre per minute (Tre∙min-1). 
5.2.7 Statistical analysis  
All statistical analyses were performed using the ‘nlme’, ‘ordinal’, ‘ez’, ‘sjPlot’ and ‘stats’ 
packages in R version 3.3.2 (R Core Development Team 2014). Normality assumptions were 
checked using quantile-quantile plots (Grafen and Hails 2002) and were plausible in all 
instances. Central tendency and dispersion are reported as means ± standard deviation (SD). The 
Akaike information criteria (AIC) was used to determine model fit (Akaike 1973). The 
correlation structure with the lowest AIC was chosen based on this procedure. The rate of Tre 
change (Tre∙min-1) was analysed with a paired t-test. A linear mixed model with fixed (‘drug’, 
‘time’) and random (‘subject i.d’) effects was fitted with an autoregressive correlation structure 
(to account for autocorrelation) to examine the effect of acetaminophen on Tre, Tsk, and heart rate 
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in dry [Time (13 levels): pre, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120 minutes × Drug (2 
levels): placebo, acetaminophen] and humid [Time (10 levels): pre, 5, 10, 15, 20, 25, 30, 35, 40, 
45 minutes × Drug (2 levels): placebo, acetaminophen]. A cumulative link model was used to 
compare thermal sensation scores between placebo and acetaminophen in the thermoneutral and 
cold conditions. The two-tailed alpha level of significance testing was set as p ≤ 0.05, and 95% 
confidence intervals (CI) are presented to denote the imprecision of the point estimate. 
5.3 Results  
Figure 5.1 displays the Tre, Tsk, and TS responses to passive heat stress in the dry and humid 
condition.  
5.3.1 Tre  
Dry 
The rate of Tre change (°C∙min-1) was not different between the acetaminophen and placebo trials 
(t = 0.43, p = 0.65). Throughout the trial, Tre increased at a rate of 0.005 and 0.006°C∙min-1 in the 
acetaminophen and placebo trials, respectively.  
There was a main effect for drug (F1,2 = 181.24, p < 0.001) and time (F1,9 = 34.19, p < 0.001), but 
there was no interaction effect (drug × time) for the Tre response (F1,9 = 0.16, p = 0.99) in the 
placebo (37.15 ± 0.11°C, 95% CI = 37.06 to 37.32) and acetaminophen (37.14 ± 0.13°C, 95% CI 
= 37.04 to 37.24) trial. Compared with the baseline (0) value, Tre was increased from 15 minutes 
to the end of the trial (p < 0.05).  
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Humid 
The rate of Tre change (°C∙min-1) was not different between the acetaminophen and placebo trials 
(t = 0.59, p = 0.57). Throughout the trial, Tre increased at a rate of 0.023 and 0.021 °C∙min-1 in 
the acetaminophen and placebo trials, respectively.  
There was a main effect for drug (F1,2 = 181.24, p < 0.001) and time (F1,12 = 34.19, p < 0.001), 
but there was no interaction effect (F1,12 = 0.16, p = 0.997) for the Tre response between the 
placebo (37.21 ± 0.32°C, 95% CI = 36.95 to 37.47) and acetaminophen (37.19 ± 0.29°C, 95% CI 
= 36.96 to 37.42) group.   
5.3.2 Tsk 
Dry 
There was a main effect for drug (F1,2 = 215.45, p < 0.001) and time (F1,12 = 77.32, p < 0.001), 
but there was no interaction effect (F1,12 = 0.19, p = 0.991) for the Tsk response between the 
placebo (35.9 ± 1.1°C, 95% CI = 35.02 to 36.8) and acetaminophen (35.9 ± 0.9°C, 95% CI = 
35.2 to 36.6) group.   
Humid 
There was a main effect for drug (F1,2 = 351.41, p < 0.001) and time (F1,12 = 50.39, p < 0.001), 
but there was no interaction effect (F1,12 = 0.32, p = 0.96) for the Tsk response between the 
placebo (37.5 ± 1.5°C, 95% CI = 36.3 to 38.7) and acetaminophen (37.1 ± 2.2°C, 95% CI = 35.3 
to 38.9) group.   
5.3.3 Heart rate 
Dry 
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There was a main effect for drug (F1,2 = 52.31, p < 0.001) and time (F1,12 = 14.51, p < 0.001), but 
there was no interaction effect (F1,12 = 0.41, p = 0.965) for the Tsk response between the placebo 
(82 ± 6 b·min-1, 95% CI = 77 to 87) and acetaminophen (83 ± 13 b·min-1, 95% CI = 73 to 93) 
group.   
Humid 
There was a main effect for drug (F1,2 = 5.34, p = 0.02) and time (F1,12 = 73.89, p < 0.001), but 
there was no interaction effect (F1,12 = 0.32, p = 0.97) for the heart rate response between the 
placebo (94 ± 4 b·min-1, 95% CI = 91 to 97) and acetaminophen (93 ± 9 b·min-1, 95% CI = 86 to 
100) group. 
5.3.4 Thermal sensation 
Dry 
TS did not change with acetaminophen administration (p > 0.05). Compared with timepoint 0, 
TS was increased from timepoint 10 to 120 (p < 0.05). The odds ratios are displayed in Table 
4.2.   
Humid 
TS did not change with acetaminophen administration (p > 0.05). Compared with timepoint 0, 
TS was increased from timepoint 10 to 120 (p < 0.05). The odds ratios are displayed in Table 
4.3. 
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Figure 5.1. Tre, Tsk, and TS responses to passive dry (A) and humid (B) heat stress. The triangles 
represent the placebo condition, and the squares represent the acetaminophen condition. DRY 
n=6, HUMID n = 7. 
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Table 5.2. Changes in TS as a product of time (duration of exposure) and time + drug 
(interaction effect) during DRY heat stress. Significance codes: < 0.001***, < 0.01 ** 
  OR  SE P 
Placebo vs APAP 
(Intercept) -0.764 1.427   
Time Only       
TIME20 4.615E+03 4.555 *** 
TIME40 1.102E+04 4.873 *** 
TIME60 2.274E+04 5.152 *** 
TIME80 2.460E+04 5.160 *** 
TIME100 3.673E+04 5.399 *** 
TIME120 3.673E+04 5.399 *** 
Drug×Time Interaction       
TIME20:DRUGAPAP 3.281 5.810   
TIME40:DRUGAPAP 3.786 6.117   
TIME60:DRUGAPAP 5.006 5.932   
TIME80:DRUGAPAP 11.488 6.042   
TIME100:DRUGAPAP 7.232 6.024   
TIME120:DRUGAPAP 24.146 6.268   
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Table 5.3. Changes in TS as a product of time (duration of exposure) and time + drug 
(interaction effect) during HUMID heat stress. Significance codes: < 0.001*** 
 
  OR  SE P 
Placebo vs APAP 
(Intercept) 0.894 3.600   
Time Only       
TIME5 1.387E+05 5.426 *** 
TIME10 8.274E+06 7.665 *** 
TIME15 4.233E+09 12.746 *** 
TIME20 3.561E+10 15.912 *** 
TIME25 8.616E+11 20.538 *** 
TIME30 6.748E+12 25.729 *** 
TIME35 4.299E+13 29.415 *** 
TIME40 6.459E+14 39.997 *** 
TIME45 3.914E+15 46.016 *** 
Drug×Time Interaction       
TIME5:DRUGAPAP 0.624 5.677   
TIME10:DRUGAPAP 0.517 5.856   
TIME15:DRUGAPAP 0.048 6.006   
TIME20:DRUGAPAP 0.277 5.790   
TIME25:DRUGAPAP 0.586 5.714   
TIME30:DRUGAPAP 0.143 5.753   
TIME35:DRUGAPAP 0.0903 5.716   
TIME40:DRUGAPAP 0.040 5.781   
TIME45:DRUGAPAP 0.0522 6.126   
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5.4 Discussion  
5.4.1 Overview of results  
It was hypothesised that acetaminophen would reduce the rate of Tre rise during passive heat 
stress. The experimental hypothesis was not accepted in this experiment, as there was no 
difference in Tre during dry and humid heat stress elicited by acetaminophen. The findings from 
this study do not support a role for acetaminophen use during heat stress, as there was no 
improvement in Tre maintenance compared with a placebo. Due to its inhibitory effect on COX, 
it was possible that acetaminophen could reduce heat loss during passive heat stress, but this was 
not supported in the present study (Figure 5.1). This experiment supports previous work, 
showing a lack of effect of acetaminophen on the physiological responses to exercise heat stress 
(Coombs et al. 2015).  
5.4.2 Comparisons with previous research 
Although this is the first study to investigate the effect of acetaminophen on thermoregulatory 
responses to passive heat stress, its thermoregulatory effects have been reported with exercise in 
hot ambient conditions (Coombs et al. 2015; Mauger et al. 2014). When acetaminophen was 
orally ingested 45 minutes prior to a cycling time to exhaustion trial in the heat (30°C, 50% r.h.), 
the participant’s Tre was lower compared with the placebo condition (-0.15°C). Moreover, Tre 
remained ~0.15°C lower throughout the exercise trial, which the authors suggest could contribute 
to the increased time to volitional exhaustion. Although there was a paradoxical decrease in Tsk 
(~0.7°C) which occurred from 30% of trial through to 100% (i.e. volitional exhaustion), the 
effect was not large enough to override the acetaminophen mediated reduction in baseline Tre. 
Thus, it appears that acetaminophen inhibits full vasodilation during moderate to high heat load 
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(increasing heat gain), but induces heat loss in normal ambient conditions, but ambient 
temperatures outside of the chamber were not reported in that study. It is important to consider 
that comparing Tre responses over a percentage of completion time leads to different absolute 
time intervals, which is not favourable from a thermoregulatory perspective. To address this 
issue, Coombs et al. (2015) explored if acetaminophen changed the thermoregulatory responses 
to 60-minute cycle exercise in the heat (34.5°C, 52% r.h.) at a fixed rate of metabolic heat 
production (8 W·kg-1). Using absolute time intervals, they showed that acetaminophen (20 
mg·kg-1 body mass) had no effect on Tre, Tsk, or sweating responses (arm and back) compared 
with the placebo condition. Thus, it appears that the changes in Tre evoked by acetaminophen in 
prior work (Mauger et al. 2014) may be due to changes in the baseline Tre, an effect which could 
depend on the ambient conditions outside of the environmental chamber.  
5.4.3 Implications  
Some pharmaceutical agents increase the risk of heat illness during exposure to hot weather. For 
example, it was shown that use of ACE inhibitors, diuretics, beta blockers and NSAIDs 
increased the risk of hospital admissions for heat illness in older people by 2.96 (95% CI = 1.53 
to 4.43), 1.95 (95% CI = 1.58 to 2.11), 1.56 (95% CI = 1.30 to 1.84) and 1.51 (95% CI = 1.22 to 
1.83) in the period January 2001 and June 2013 (Kalisch Ellett et al. 2016). The increase risk of 
heat illness from NSAID use is likely due to inhibition of COX bioactivity, and thus a reduced 
synthesis of PGE2 and PGI2. These molecules play important roles in kidney function and blood 
pressure regulation due to their vasodilatory actions. For instance, acetaminophen and ibuprofen 
depress renal blood flow and glomerular filtration rate due to their inhibitory actions on COX 
(Colletti et al. 1999), an effect which may contribute to excess hospital admission rates under 
heat stress conditions. Furthermore, there is evidence that COX contributes to vasodilation 
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(Holowatz and Kenney 2009; Kellogg et al. 2005; Medow et al. 2008; Noon et al. 1998) and 
sweating (Fujii et al. 2014b) responses during heat stress. Although acetaminophen had no effect 
on thermoregulatory capacity in our participants, this may not be mirrored with other COX 
inhibitors (NSAIDs) because acetaminophen has additional actions that promote heat loss 
responses. There is no evidence that NSAIDs induce heat loss responses, so a blunted heat loss 
response is more likely in drugs such as Ibuprofen, Aspirin, and COX-2 selective inhibitors 
(compared with acetaminophen). That-being-said, the use of acetaminophen may still be a hazard 
during heat waves since it can cause renal dysfunction (Satirapoj et al. 2007), which is 
concerning as renal disease/failure increases as a product of heat stress (Hansen et al. 2008).  
Acetaminophen has been shown to improve repeated sprint and endurance exercise performance 
(Foster et al. 2014; Mauger et al. 2010), an effect which the authors attribute to a reduced pain 
perception. Given the recent finding that cycling time to exhaustion is also improved during heat 
stress (Mauger et al. 2014), and that there is at least no negative impact on thermoregulation, 
athletes may begin increase self-administration of acetaminophen for ergogenic purposes. It is 
important to note that such activity is not recommended, since chronic acetaminophen use can 
lead to liver toxicity and cardiovascular dysfunction, even at therapeutic doses (Hinz and Brune 
2012). Moreover, pain relief during exercise is a potential hazard since nociception may serve 
provide information to the brain of actual or impending tissue damage (Foster et al. 2014; 
Mauger et al. 2010). Blocking these signals with acetaminophen could lead to a greater risk of 
injury, especially in highly motivated athletes.      
5.4.4 Delimitations 
There are several delimitations to this work which the reader should consider. Firstly, the 
administration time of acetaminophen was 100 minutes prior to entering the environmental 
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chamber. This was chosen based on prior pharmacokinetic work (Singla et al. 2012), and that of 
Study One, where the peak plasma concentration of acetaminophen arose at 100-minutes post-
ingestion. acetaminophen could not be administered at the onset of heat stress since the humid 
trial was only 45 minutes in duration, which was not enough time for acetaminophen to reach 
therapeutic plasma concentrations. The benefit of this design is that acetaminophen would have 
been present in the circulation at the time of entry into the chamber, however, as systemic 
acetaminophen was not measured in this study, the actual concentration (and its decay during 
heat stress) is not known. Because acetaminophen did not differentially alter Tre in the dry or 
humid trial, future research should examine the Tre responses to heat stress (120 minutes at 45°C, 
30% r.h.) with acetaminophen administered at the onset of the exposure. This would allow for 
examination of how the Tre response changes in line with the acetaminophen concentration, a 
model that was used effectively in study one. A second limitation is the use of a passive heat 
exposure and not an exercise model. The benefit of using a passive model is that it closely 
reflects the conditions where older people would be subjected to heat stress (i.e. in a heat wave), 
improving the link between acetaminophen use and potential thermoregulatory dysfunction. 
Because the metabolic heat load seems to determine the requirement of COX for vasodilation, a 
moderate (~45% VO2max) and high (~80% VO2max) heat load condition may have yielded 
differences in the Tre responses with acetaminophen administration (Fujii et al. 2014b). The final 
limitation to this study is the use of young adults as a model to determine the effect of 
acetaminophen on thermoregulation. During heat waves, it is the elderly who are considered 
most at risk, which is in part due to the presence of comorbidities such as diabetes, 
cardiovascular disease, respiratory disease, and renal impairments (Kenney et al. 2014). Also, 
the thermoregulatory responses are not homogenous between young adults and older people, 
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largely due to differences in nitric oxide bioavailability (Holowatz et al. 2003). Because young 
adults are generally more efficient at dissipating heat than older people, it is not certain that 
acetaminophen will have no effect on Tre in an aged individual. Indeed, aspirin ingestion resulted 
in an elevated Tre during exercise in the heat in middle aged (50 to 65 years) participants, an 
effect which occurred through increase in the Tre threshold required for cutaneous vasodilation 
(Bruning et al. 2013).  
5.4.5 Conclusions 
In conclusion, it has been demonstrated that acetaminophen (20 mg·kg-1 lean body mass) had no 
effect on the thermoregulatory response to passive heat stress in young adults. Although 
acetaminophen did not affect Tre during dry or humid heat stress, its potential impact on renal 
function do not make it a suitable alternative to NSAIDs during a heatwave. Future research 
should identify if Tre is maintained during passive heat stress, particularly in older people, while 
also assessing its acute effects on renal function.   
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CHAPTER 6. EXPERIMENT 3: ACETAMINOPHEN INDUCED HYPOTHERMIA IS 
POTENTIATED DURING ACUTE COLD STRESS.  
6.1 Introduction 
6.1.1 Background 
Accidental hypothermia is characterised by an unintended Tc reduction to 35°C or lower. Such a 
fall in Tc can induce ventricular fibrillation and ultimately cardiac arrest if Tc declines to < 28ºC 
(Brown et al. 2012; Filippi et al. 2014). In the United States, hypothermia was the cause or 
contributing cause of death in over 5500 cases between 2006 and 2010 (Berko 2016), but this is 
likely underestimated since Tc needs to be measured at or near the time of death. Nonetheless, 
data from United Kingdom hospital episode statistics indicate that hypothermia was the primary 
or secondary diagnosis in over 100,000 hospital admissions from 2005 to 2015 (HSCIC 2015). 
Although death from hypothermia is rare, it remains a significant health risk in elderly and very 
young individuals, particularly during winter months and unaccustomed cold spells (Brown et al. 
2012). Interestingly, there is a growing body of evidence demonstrating that acetaminophen 
could reduce Tc stability during cold exposure (discussed below), placing users at an increased 
risk of accidental hypothermia.  
Acetaminophen is an over-the-counter drug marketed as paracetamol in Europe and Tylenol in 
the United States. It is best known for its ability to decrease pain perception and reduce Tc during 
a fever; each of these actions are in part mediated through an inhibition of COX enzyme activity 
(Anderson 2008). However, there is evidence of a ‘hypothermic’ action of acetaminophen, which 
refers specifically to an acetaminophen-induced reduction in Tc independent of febrile status. In 
mice, high doses (150 to 300 mg·kg-1 body mass) administered intravenously reduced Tre by 2 to 
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4°C (Walker et al. 1981), an effect that was confirmed in subsequent experiments (Ayoub et al. 
2004; Ayoub et al. 2011; Li et al. 2008; Massey et al. 1982). In humans, there have been 246 
reports in Vigibase© (the WHO international database of adverse drug reactions) specific to 
acetaminophen-induced accidental hypothermia (Lindquist 2008). In addition, several case 
studies report profound hypothermia following therapeutic doses (Van Tittelboom and Govaerts-
Lepicard 1989) and high doses of acetaminophen when ingested orally (Block et al. 1992; 
Rollstin and Seifert 2012). Finally, oral acetaminophen administration (20 mg·kg lean body 
mass-1) reduced Tre in young adults by ~0.2°C (range, 0.10 to 0.39°C) during exposure to mild 
cold [(20°C) Study 1 b]. Although the Tre reductions were small, this hypothermic side-effect of 
acetaminophen occurred in all thirteen participants. Despite this data, additional criteria, such as 
the environmental temperature, are needed to accurately predict when acetaminophen poses the 
greatest risk for hypothermia development. Since the COX pathway could be involved in non-
febrile thermogenesis (Ayoub et al. 2006), inhibition of this enzyme by acetaminophen might 
cause Tre to fall during cold exposure, while exerting negligible effects on Tre while exposed to a 
warm environment.   
6.1.2 Experimental aims and hypothesis  
The aim of this pilot trial was to examine the thermoregulatory response to acetaminophen 
administration (20 mg·kg-1 of lean body mass) during a 120-minute exposure to a thermo-neutral 
and cold environment in healthy adult humans. Due to a potential role of COX in non-febrile 
thermogenesis (Ayoub et al. 2004), it was hypothesised that acetaminophen would reduce Tre in 
cold conditions, but have no effect on Tre in thermo-neutral conditions relative to a placebo. 
6.2 Methods 
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6.2.1 Ethical approval 
All experimental procedures were approved by the University of Bedfordshire’s Institute for 
Sport and Physical Activity Research Ethics committee (approval code 2014ISPAR011), and 
they conformed to the standards set by the World Association Declaration of Helsinki ‘Ethical 
Principles for Research Involving Human Subjects’. 
6.2.2 Power calculation  
Power analyses were conducted with GPower software version 3.1 (Heinrich University, 
Düsseldorf, Germany). Using Tre data from a previous experiment where acetaminophen was 
tested as a hypothermic agent in non-febrile stroke patients (Dippel et al., 2003a), it was 
determined that a total of nine participants were required to achieve a statistical power of 80%. 
6.2.3 Participants  
Nine Caucasian males [Age (22 ± 1 years), height (179 ± 5 cm), mass (80.7 ± 11.9 kg), body fat 
(20 ± 5 %)] volunteered to take part in the study. Participants were provided with written 
information regarding all experimental procedures, with supporting oral explanations from the 
principal investigator. Participants then subsequently provided written informed consent. The 
participants were non-smokers, non-febrile (resting Tre < 38°C), and were free from 
musculoskeletal injury. 
6.2.4 Inclusion/exclusion criteria 
Prior to each laboratory visit, participants completed an informed consent sheet, alcohol use 
disorder identification test [AUDIT; (Saunders et al., 1993)] a breathalyser test (AlcoSense, One, 
Berkshire, UK), and an acetaminophen risk assessment questionnaire. To avoid the risk of liver 
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damage inflicted by acetaminophen, participants were not able to participate in the research if 
they scored above ten on the AUDIT questionnaire or alcohol was present in their bloodstream 
(i.e. > 0% BAC). In addition, the acetaminophen dose was relative to lean body mass because it 
is a better indicator of liver volume than total body mass (Kwo et al. 1998). No participants 
presented with any pre-existing medical conditions that may have put them at an increased risk 
of acetaminophen toxicity. Due to potential thermoregulatory adaptions (Blondin et al., 2014a;  
Poirier et al., 2015), individuals were not permitted to take part in any experimental procedures if 
they were heat or cold acclimated or acclimatised. Thus, those who had travelled to a hot/cold 
climate or participated in a laboratory based heat/cold acclimation protocol less than three weeks 
prior to the experiment were not permitted to take part. All participants presented with a stable 
resting Tre (36.5-37.5°C). 
6.2.5 Experimental design  
To determine if acetaminophen reduces Tre stability during cold stress, nine participants visited 
the laboratory on 5 occasions, each separated by at least seven days. On visit 1, participants 
arrived fasted (overnight) and had their body fat assessed via air displacement plethysmography 
(Bod Pod, 2000A, Birmingham, UK). Visits 2-5 (experimental trials) were randomised (SPSS 
Inc., Chicago, USA), double blinded [drug ingestion only (i.e. “A” or “B”)], and followed a 
repeated measures design. On these visits, participants were exposed to either cold (10°C, 40% 
r.h.) or thermoneutral (25°C, 40% r.h.) environmental temperatures for 120 minutes, having been 
administered acetaminophen (20 mg⋅kg of lean body mass) or a placebo (dextrose). The dose of 
acetaminophen administered in the present work was 1287 ± 173 mg (range, 1082 to 1486 mg). 
6.2.6 Experimental protocol 
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All participants arrived at the laboratory at 1000. Upon arrival, participants were instrumented 
for the measurement of Tre, Tsk, and heart rate (see “Instrumentation and Equations” for details). 
Thirty minutes after arrival participants consumed a standardised breakfast (1030) and ingested 
acetaminophen or a placebo one hour after the meal was consumed (~1135). Participants 
remained rested in an upright seated position between meal consumption and acetaminophen or 
placebo ingestion to ensure resting physiological status was attained. Participants were wheeled 
into the environmental chamber immediately following drug administration. Resting 
measurements of Tre, Tsk, heart rate and thermal sensation were taken five minutes prior to 
acetaminophen or placebo ingestion (1120) and subsequently every 10 minutes for 120 minutes’ 
post-ingestion. Blood pressure was taken prior to chamber entry and every 30 minutes (pre, 30, 
60, 90, 120 minutes) until the end of the trial.  
6.2.7 Instrumentation and equations  
Tre and Tsk was measured via portable data loggers. The Tsk from 4 sites was used to estimate 
mean Tsk  (Ramanathan 1964). See section 3.1.5 for equipment details and the formula for 
calculating mean Tsk. Section 3.1.5 also details the measurement of heart rate and thermal 
sensation.  
Mean arterial pressure (MAP) was measured using a portable blood pressure monitor (Omron 
M5-1, Omron, Milton Keynes, UK). Measurements were taken at baseline (pre), and every 30 
minutes of the 120-minute exposure period (i.e. 30, 60, 90, and 120 minutes). MAP was later 
calculated as [(2 × DBP) + SBP]/3, in accordance with Yu et al. (2016). 
6.2.8 Statistical analysis  
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All statistical analyses were performed using the ‘nlme’, ‘ordinal’, ‘ez’, ‘sjPlot’ and ‘stats’ 
packages in R version 3.3.2 (R Core Development Team 2014). Normality assumptions were 
checked using quantile-quantile plots (Grafen and Hails 2002) and were plausible in all 
instances. Central tendency and dispersion are reported as means ± standard deviation (SD). The 
Akaike information criteria (AIC) was used to determine model fit (Akaike 1973). The 
correlation structure with the lowest AIC was chosen based on this procedure. A linear mixed 
model with fixed (‘drug’, ‘time’) and random (‘subject i.d’) effects was fitted with an 
autoregressive correlation structure (to account for autocorrelation) to examine the effect of 
acetaminophen on Tre, Tsk, and heart rate in thermo-neutral and cold conditions [Time (13 levels): 
pre, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120 minutes × Drug (2 levels): placebo, 
acetaminophen]. The same model with different levels of time [Time (5 levels): pre, 30, 60, 90, 
120 minutes) × Drug (2 levels): placebo, acetaminophen] was fitted to determine the effect of 
acetaminophen on MAP in thermo-neutral and cold conditions. A cumulative link model was 
used to compare thermal sensation scores between placebo and acetaminophen in the thermo-
neutral and cold conditions. The two-tailed alpha level of significance testing was set as p ≤ 0.05. 
95% confidence intervals (CI) are presented to denote the imprecision of the point estimate. 
6.3 Results  
Thermoneutral 
There was no main effect for drug or interaction effect (drug × time) for Tre, Tsk, heart rate, TSS, 
or MAP. A main effect for time was present in each of these variables apart from MAP, showing 
that Tre, Tsk, heart rate and TSS changed (p < 0.05) over time with no differences observed 
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between acetaminophen and placebo. Descriptive (mean ± SD) data for each 30-minute interval 
is shown in Table 6.1.  
Cold 
The Tre response during cold exposure differed between the acetaminophen and placebo 
conditions. An interaction effect (F1,12 = 2.25, p = 0.01), main effect for drug (F1,2 = 2.25, p < 
0.01), and main effect for time (F1,12 = 8.33, p < 0.01) was found between placebo (37.06 ± 
0.20°C; 95% CI = 36.99 to 37.12°C) and acetaminophen (36.90 ± 0.32°C; 95% CI = 36.79 to 
37.01°C). Specifically, Tre was 0.18, 0.19, 0.22, 0.27, 0.29 and 0.35°C lower in the 
acetaminophen trial at time points 70 to 120 minutes compared with the placebo. The peak Tre 
reduction in the nine participants (120 minute compared with baseline) was 0.16 to 0.57°C 
(mean = 0.40 ± 0.15°C). Mean and individual Tre responses over the 120-minute exposure period 
are displayed in Figures 6.1 and 6.2, respectively.  
There were no main effects for drug or interaction effects between drug and time for Tsk, heart 
rate, TSS, or MAP. A main effect for time was present in each of these variables excluding 
MAP. All descriptive data for each 30-minute interval is shown in Table 6.1. For Tre, Table 6.2 
displays the model’s fixed effects coefficients and random effect variances.  
6.3.1 Tsk 
Thermoneutral 
There was no significant interaction effect (F1,12 = 0.49, p > 0.05) or main effect for drug (F1,2 = 
0.13, p > 0.05) between placebo (30.7 ± 0.7°C, 95% CI = 30.7 to 30.9°C) and acetaminophen 
(30.7 ± 0.5°C, 95% CI = 30.6 to 30.8°C), but there was a main effect for time (F1,12 = 4.45, p < 
0.05).  
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Cold 
There was no significant interaction effect (F1,12 = 0.33, p > 0.05) or main effect for drug (F1,2 = 
0.06, p > 0.05) between placebo (26.1 ± 2.5°C, 95% CI = 25.2 to 26.9°C) and acetaminophen 
(26.4 ± 2.5°C, 95% CI = 25.5 to 27.2°C), but there was a main effect for time (F1,12 = 114.39, p 
< 0.05). Mean Tsk responses are displayed in Figure 6.1.  
6.3.2 Thermal sensation 
Thermoneutral 
TS did not change with acetaminophen administration and did not change as a product of time (p 
> 0.05). The odds ratios are displayed in Table 6.2.    
Cold 
TS did not change with acetaminophen administration (p > 0.05). Compared with timepoint 0, 
TS was increased from time-point 10 to 120 (p < 0.05). The odds ratios are displayed in Table 
6.2.   
6.3.3 Heart rate  
Thermoneutral  
There was no significant interaction effect (F1,12 = 0.81, p > 0.05) or main effect for drug (F1,2 = 
2.13, p > 0.05) between placebo (60 ± 9 b·min-1, 95% CI = 58 to 61 b·min-1) and acetaminophen 
(63 ± 9 b·min-1, 95% CI = 61 to 64 b·min-1), but there was a main effect for time (F1,12 = 2.00, p 
< 0.05).  
Cold 
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There was no significant interaction effect (F1,12 = 0.80, p > 0.05) or main effect for drug (F1,2 = 
1.57, p > 0.05) between placebo (63 ± 8 b·min-1, 95% CI = 60 to 65 b·min-1) and acetaminophen 
(60 ± 8 b·min-1, 95% CI = 58 to 63 b·min-1), but there was a main effect for time (F1,12 = 2.42, p 
< 0.05). 
 
Figure 6.1. (A & C) Tre in the acetaminophen and placebo conditions during the 25°C and 10°C 
exposure, respectively. (B & D) Tsk in the acetaminophen and placebo conditions during the 
25°C and 10°C exposure, respectively. ∗Significant main effect for condition. #Significant main 
effect for time. †Significant interaction effect. Values are mean ± standard deviation. n=9. 
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Figure 6.2. Delta (Δ) core temperature responses during cold exposure (10°C) in each 
participant following administration of a placebo (A) or acetaminophen (B). n=9. 
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Table 6.1. Beta coefficients (B), 95 % confidence intervals (CI), alpha values (p), and the Phi 
coefficient are reported for the fixed components (drug & time) during exposure to cold stress 
(10ºC). The standard deviation of the intercept and residual are reported for the random effect 
(subject ID).  
    Core Temperature (ºC) 
    B CI P 
Fixed Parts  
Intercept   36.95 36.71 to 37.13 <.001 
Drug×Time 
Interaction     
DRUGAPAP:TIME10   0.03 -0.11 to 0.17 .694 
DRUGAPAP:TIME20   -0.03 -0.17 to 0.11 .672 
DRUGAPAP:TIME30   -0.06 -0.20 to 0.09 .442 
DRUGAPAP:TIME40   -0.10 -0.24 to 0.04 .179 
DRUGAPAP:TIME50   -0.12 -0.26 to 0.02 .109 
DRUGAPAP:TIME60   -0.13 -0.28 to 0.01 .076 
DRUGAPAP:TIME70   -0.18 -0.32 to -0.03 .021 
DRUGAPAP:TIME80   -0.21 -0.36 to -0.07 .006 
DRUGAPAP:TIME90   -0.24 -0.38 to -0.10 .002 
DRUGAPAP:TIME100   -0.29 -0.43 to -0.15 <.001 
DRUGAPAP:TIME110   -0.31 -0.45 to -0.17 <.001 
DRUGAPAP:TIME120   -0.36 -0.50 to -0.22 <.001 
Phi Coefficient  
0.938 
Random Parts (Subject ID) 
  Standard Deviation 
Intercept   0.13 
Residual   0.16 
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Table 6.2. Changes in TS as a product of time (duration of exposure) and time + drug 
(interaction effect). Significance codes: < 0.001***, < 0.01** 
 10°C 25°C 
 
OR  SE p OR SE P 
Placebo vs APAP 
(Intercept) 0.575 2.540   0.989 2.435  
Time Only          
TIME10 2.55E-03 2.918 *** 0.773 2.459  
TIME20 2.57E-04 2.981 *** 1.302 2.529  
TIME30 2.57E-04 2.981 *** 1.352 2.524  
TIME40 7.53E-05 3.130 *** 2.013 2.533  
TIME50 3.41E-05 3.202 *** 2.992 2.532  
TIME60 1.59E-05 3.340 *** 2.013 2.533  
TIME70 1.11E-05 3.351 *** 2.992 2.532  
TIME80 3.49E-06 3.530 *** 4.031 2.596  
TIME90 1.46E-06 3.622 *** 4.031 2.596  
TIME100 1.10E-06 3.728 *** 4.031 2.596  
TIME110 1.46E-06 3.619 *** 4.219 2.624  
TIME120 6.74E-07 3.792 *** 4.219 2.624     
Drug×Time Interaction          
TIME10:DRUGAPAP 0.805 3.883   2.233 3.631  
TIME20:DRUGAPAP 1.736 3.831   1.952 3.725  
TIME30:DRUGAPAP 0.156 3.767   1.880 3.718  
TIME40:DRUGAPAP 0.576 3.724   1.899 3.720  
TIME50:DRUGAPAP 0.436 3.727   1.278 3.711  
TIME60:DRUGAPAP 0.940 3.754   1.899 3.720  
TIME70:DRUGAPAP 0.442 3.730   1.278 3.711  
TIME80:DRUGAPAP 0.815 3.789   1.423 3.781  
TIME90:DRUGAPAP 1.293 3.739   2.046 3.748  
TIME100:DRUGAPAP 1.307 3.733   4.080 3.747  
TIME110:DRUGAPAP 0.644 3.696   5.780 3.886  
TIME120:DRUGAPAP 1.143 3.780   8.252 3.973  
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Table 6.3. Descriptive data for each of the five response variables in the thermo-neutral condition (25°C). Descriptive data are the 
mean values (± standard deviation) during the 120-minute exposure period. The range is provided in parentheses. 
 Time-point (minutes) 
  Pre 30 60 90 120 
Tre (°C) 
Placebo 37.00 ± 0.13 (36.80 - 37.15) 
36.93 ± 0.15 
(36.72 - 37.13) 
36.95 ± 0.15 
(36.73 - 37.15) 
36.94 ± 0.14 
(36.75 - 37.15) 
36.94 ± 0.16 
(36.74 - 37.21) 
APAP 37.04 ± 0.20 (36.78 - 37.25) 
36.95 ± 0.22 
(36.78 - 37.14) 
36.93 ± 0.21 
(36.77 - 37.05) 
36.91 ± 0.23 
(36.68 - 37.10) 
36.89 ± 0.19 
(36.62 - 37.10) 
       
Tsk (°C) 
Placebo 30.6 ± 0.9 (28.7 - 31.8) 
30.9 ± 0.7 
(29.9 - 31.9) 
30.8 ± 0.7 
(29.8 - 31.7) 
30.7 ± 0.7 
(29.5 - 31.8) 
30.7 ± 0.7 
(29.3 - 31.7) 
APAP 30.3 ± 0.6 (29.0 - 31.1) 
30.8 ± 0.5 
(29.9 - 31.4) 
30.7 ± 0.4 
(29.9 - 31.2) 
30.7 ± 0.5 
(29.9 - 31.5) 
30.6 ± 0.6 
(29.6 - 31.6) 
       
HR (b.min-1) 
Placebo 65 ± 8 (53 - 79) 
59 ± 8 
(50 - 76) 
58 ± 10 
(46 - 79) 
58 ± 9 
(48 - 74) 
60 ± 10 
(49 - 86) 
APAP 68 ± 8 (53 - 81) 
62 ± 10 
(49 - 80) 
65 ± 10 
(50 - 84) 
59 ± 7 
(49 – 68) 
59 ± 10 
(42 - 71) 
       
TS (0 to 8 
scale) 
Placebo 4.0 ± 0.1 (4.0 - 4.5) 
4.1 ± 0.3 
(4.0 - 5.0) 
4.2 ± 0.4 
(4.0 - 5.0) 
4.3 ± 0.4 
(4.0 - 5.0) 
4.4 ± 0.6 
(4.0 - 5.5) 
APAP 4.0 ± 0.2 (3.5 - 4.5) 
4.2 ± 0.3 
(4.0 - 5.0) 
4.3 ± 0.4 
(4.0 - 5.0) 
4.4 ± 0.4 
(4.0 - 5.0) 
4.6 ± 0.5 
(4.0 - 5.0) 
       
MAP 
Placebo 91 ± 7 (83 - 103) 
91 ± 9 
(73 - 101) 
91 ± 10 
(81 - 113) 
92 ± 4 
(88 -  99) 
90 ± 6 
(82 - 99) 
APAP 88 ± 6 (80 - 97) 
91 ± 6 
(82 - 100) 
88 ± 9 
(78 - 111) 
88 ± 5 
(83 - 97) 
91 ± 6 
(85 - 104) 
Acetaminophen (APAP), Core temperature (Tre), Skin temperature (Tsk), Heart rate (HR), Thermal sensation (TS), Mean arterial 
pressure (MAP). Values are means ± standard deviation 
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Table 6.4. Descriptive data for each of the five response variables in the cold condition (10°C). Descriptive data are the mean values 
(± standard deviation) during the 120-minute exposure period. The range is provided in parentheses. 
 
 Time-point (minutes) 
  Pre 30 60 90 120 
Tre (°C) 
Placebo 36.98 ± 0.20 (36.70 - 37.13) 
37.09 ± 0.19 
(36.79 - 37.38) 
37.03 ± 0.22 
(36.72 - 37.34) 
36.97 ± 0.23 
(36.71 - 37.29) 
36.96 ± 0.25 
(36.64 - 37.19) 
APAP 36.97 ± 0.21 (36.61 - 37.36) 
37.05 ± 0.26 
(36.59 - 37.49) 
36.94 ± 0.31 
(36.52 - 37.45) 
36.76 ± 0.30* 
(36.33 - 37.29) 
36.58 ± 0.23* 
(36.11 - 36.87) 
       
Tsk (°C) 
Placebo 30.5 ± 0.5 (29.6 - 31.3) 
25.8 ± 1.0 
(24.7 - 27.6) 
24.9 ± 1.0 
(23.8 - 26.9) 
24.4 ± 1.0 
(23.2 - 26.5) 
24.2 ± 1.0 
(22.8 - 26.6) 
APAP 30.7 ± 0.7 (29.6 - 31.8) 
26.1 ± 1.0 
(24.7 - 28.2) 
25.1 ± 1.0 
(23.7 - 26.6) 
24.5 ± 1.2 
(23.0 - 26.3) 
24.3 ± 1.3 
(22.4 - 26.5) 
       
HR (b.min-
1) 
Placebo 68 ± 7 (54 - 79) 
62 ± 9 
(48 - 74) 
61 ± 4 
(55 - 67) 
57 ± 8 
(48 - 68) 
60 ± 9 
(51 - 75) 
APAP 66 ± 11 (50 - 79) 
59 ± 9 
(41 - 70) 
58 ± 10 
(39 - 73) 
54 ± 7 
(42 - 64) 
57 ± 9 
(41 - 70) 
       
TS (0 to 8 
scale) 
Placebo 4.1 ± 0.2 (4.0 - 4.5) 
2.8 ± 0.4 
(2.0 - 3.0) 
2.3 ± 0.5 
(1.5 - 3.0) 
1.9 ± 0.2 
(1.5 - 2.0) 
1.8 ± 0.4 
(1.0 - 2.0) 
APAP 3.9 ± 0.2 (3.5 - 4.0) 
2.3 ± 0.4 
(2.0 - 3.0) 
2.2 ± 0.4 
(1.5 - 3.0) 
1.8 ± 0.6 
(1.0 - 3.0) 
1.7 ± 0.5 
(1.0 - 2.5) 
       
MAP 
Placebo 92 ± 10 (78 - 104) 
97 ± 9 
(86 - 112) 
99 ± 8 
(90 - 110) 
97 ± 7 
(88 - 111) 
105 ± 8 
(92 - 117) 
APAP 93 ± 6 (78 - 102) 
94 ± 9 
(74 - 102) 
103 ± 7 
(91 - 111) 
96 ± 6 
(88 - 104) 
99 ± 6 
(77 - 104) 
Acetaminophen (APAP), Core temperature (Tre), Skin temperature (Tsk), Heart rate (HR), Thermal sensation (TS), Mean arterial 
pressure (MAP). * denotes significant difference between the acetaminophen and placebo condition.  
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6.4 Discussion   
6.4.1 Overview of results  
It was hypothesised that acetaminophen would reduce Tre in cold conditions, but have no effect 
on Tre in thermo-neutral conditions relative to a placebo. The experimental hypothesis was 
accepted. The major finding of the present study was that, compared with a placebo, 
acetaminophen administration reduced Tre (0.16 to 0.57°C decrease after 120-minutes exposure) 
during an acute cold stress (10°C), while it appeared to have no effect on thermoregulation at a 
thermo-neutral ambient temperature (25°C). During cold exposure, acetaminophen caused Tre to 
fall by ~0.40°C compared with the baseline value at 120 minutes, while it did not decline in the 
placebo trial. The variability in the response may be due to between subject differences in the 
rate of acetaminophen absorption, but unfortunately this was not analysed in this pilot trial. The 
hypothermic response to acetaminophen ingestion observed in the current study corroborates our 
prior work in humans, in which acetaminophen reduced Tre by ~0.19°C in humans exposed to 
milder cold [20°C, Study 1b]. Furthermore, this is the first study to demonstrate that the ambient 
temperature can dictate the degree of hypothermia induced by acetaminophen. During cold 
exposure, this pilot trial shows that healthy young adults could not defend their Tre following 
acetaminophen administration (Figure 2). Given that elderly individuals already struggle to 
defend their Tre without prior drug ingestion (Collins et al. 1995), it is reasonable to suspect that 
acetaminophen would cause Tre to decline at a faster rate, increasing the risk of accidental 
hypothermia.    
6.4.2 Comparison with previous research 
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The notion that ambient and skin temperature dictates the magnitude of acetaminophen’s 
hypothermic action is in line with previous research. In a recent experiment, Coombs and 
colleagues (2015) demonstrated that acetaminophen had no effect on sweat output and Tre during 
1-hour exercise in hot conditions (34°C, 52% r.h.) at a fixed rate of heat production (8 W·kg-1). 
In that study, the mean skin temperature increased by 1°C during the trial (up to ~35°C), a 
condition in which no heat producing mechanisms will be active (Nakamura and Morrison 
2010). Because the mean skin temperature during cold stress was ~24°C at the end of the trial 
(Figure 2), cutaneous vasoconstriction and active thermogenesis were required for Tre to remain 
stable (Haman et al. 2004a; Haman et al. 2004b; Nakamura and Morrison 2011). The presence of 
thermogenesis and vasoconstriction indicates that acetaminophen may reduce Tre through 
inhibition of at least one of these mechanisms, but the precise mechanism needs to be confirmed 
in future work. Study 1 demonstrated that acetaminophen reduced Tre by 0.10 to 0.39°C (mean ± 
SD, 0.19 ± 0.09°C) at rest when the mean skin temperature was ~27°C. Similar reductions in 
skin temperature induce shivering thermogenesis (Gosselin and Haman 2013), which, if inhibited 
by acetaminophen, may explain the small reduction in Tre seen in Study 1.  
Studies in mice have shown Tc fell by 0.40, 0.80, and 2°C following 1-hour acetaminophen 
infusion of 100, 200, and 300 mg·kg-1 body mass respectively (Ayoub et al. 2006). Thus, 
acetaminophen-induced hypothermia is not only dependent on ambient temperature, but also on 
the dose administered. It is important to note here that mice are often housed in environments of 
18 to 20°C, which is 8 to 10°C beneath their normal thermo-neutral zone (Speakman and Keijer 
2013). These housing conditions are consistent in experiments concerning acetaminophen-
induced hypothermia in rodents (Ayoub et al. 2004; Li et al. 2008; Massey et al. 1982; Walker et 
al. 1981), such that these animals constantly produce heat to maintain their Tc. Inhibition of this 
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heat production through acetaminophen may explain its hypothermic action, a notion that should 
be confirmed through the administration of high dose acetaminophen in mice housed within and 
below their thermo-neutral zone (i.e. 30°C and 20°C, respectively).  
6.4.3 Possible physiological underpinnings 
The results from the present study raise an interesting question; does acetaminophen increase 
whole body heat loss, or decrease whole body heat production? Because either action would 
theoretically result in a decreased Tre in the present work, the Tre data collected does not provide 
clues as to which answer is in fact true. Coombs et al. (2015) documented that acetaminophen 
ingestion had no effect on regional sweat output (a marker of heat loss) during cycling at a fixed 
heat production. However, due to the high evaporative requirement for heat balance in that study, 
any effect of acetaminophen on heat loss would be difficult to detect due to an already high 
sweat rate. If the evaporative requirement for heat balance is reduced to zero i.e. resting in a cool 
environment, a small increase in heat loss by acetaminophen would likely result in a reduced Tc, 
as observed in the present study. An increased Tsk at vasodilatory sites (i.e. hands and feet) would 
provide evidence for heat loss activation, but a limitation of the 4-point Tsk equation used in this 
study is that temperature is measured on largely non-vasodilatory sites (Taylor et al., 2014). 
Thus, it remains possible that heat loss was elevated in the cold with acetaminophen, despite 
prior work finding a null effect during exercise in hot humid conditions.  
The fact that Tre rose in the first 30 minutes of cold stress has been shown in previous studies 
where humans were exposed to cold stress. For example, Murray et al.  exposed young adults to 
12°C air and found a 0.2°C Tre increase during the first 30 minutes of exposure. In that study, 
and in line with the present work, Tre returned to normal in the control conditions after this 
period i.e. from 30 to 120 minutes. Interestingly, this transient rise in Tre was not witnessed when 
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participants ingested acetaminophen. Although the lower Tre was not statistically significant until 
80 minutes, the depressed thermogenic response in the first third of the trial may be attributed to 
an altered “null zone”. The null zone is a narrow range of internal temperatures (approximately ± 
0.5°C) in which neither heat loss or heat gain responses are activated, and was first described in 
1983 using a method that clamped the Tsk during exercise and recovery (Mekjavić et al. 1991). 
The fact that in the acetaminophen trial, reductions in Tsk were not met with an increased Tre 
suggests that the “null zone” was shifted to the left i.e. thermogenic responses were activated for 
a lower drop in Tsk in the placebo condition. During fever, the null zone is shifted to the right i.e. 
shivering activated at a higher Tc (Nakamura, 2011). Acetaminophen depresses thermogenesis 
during fever by shifting the null zone back to normal values i.e. 36.5 – 37.5°C (Li et al., 2008). It 
is unknown if this explains the reduced thermoregulatory responses to cold with acetaminophen, 
but this could be directly investigated using similar methods to Mekjavić et al. (1991), and 
comparing the responses between a placebo/control and acetaminophen.    
6.4.4 Implications 
Given acetaminophen reduced Tc stability in healthy adult males its hypothermic effect is likely 
to be larger in populations already considered vulnerable in sub-neutral ambient temperatures 
(i.e. the very young and the elderly). Accidental hypothermia is a rising global health concern. In 
the USA, the Centre for Disease Control and Prevention report that hypothermia was the cause of 
nearly 17,000 deaths from 1999 to 2011 (Xu 2013). In the UK, hospital episode statistics show 
that there were over 108,000 admissions to NHS hospitals from 2005 to 2014, where 
hypothermia was the primary or secondary cause (HSCIC 2015). This database also shows that 
the very young (0-4 years; 43,868 admissions) and the elderly (≥ 65 years; 48,477 admissions) 
make up 85% of the total admissions. This is concerning for two reasons. Firstly, acetaminophen 
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is the most frequently administered analgesic among frail and pre-frail elderly individuals 
(Koponen et al. 2013), with no age-related delay in drug absorption (Divoll et al. 1982a). 
Secondly, acetaminophen is the analgesic of choice in neonates (Allegaert and van den Anker 
2016). In the perioperative setting, Tc monitoring after acetaminophen administration in these 
vulnerable groups is recommended. A 2011 study showed that intravenous acetaminophen (~20 
mg·kg-1 body mass) did not cause hypothermia in 93 neonates (Hopchet et al. 2011). However, 
the ambient temperature was not reported (presumably 23-25°C), and only the skin temperature 
was measured. This is problematic since our work showed a clear reduction in Tc without a 
change in skin temperature between acetaminophen and placebo (Study 1, Chapter 4). Moreover, 
neonates are exposed to cold stress when wet with amniotic fluid, during transportation, or 
during surgery. Based on our data, we propose that acetaminophen may increase the risk of 
neonatal hypothermia only when coupled with one of these cold stressors, and not in a thermo-
neutral environment.  
6.4.5 Proposed molecular mechanism 
As acetaminophen is a potent COX inhibitor in non-inflamed tissue (Aronoff et al. 2006; 
Boutaud et al. 2002; Hinz et al. 2008; Hinz and Brune 2012), it is likely that the hypothermic 
action of acetaminophen is also mediated through inhibition of this enzyme. There are two COX 
isoforms (COX-1 and -2), and their function is to convert arachidonic acid to PGH2 (Simmons et 
al. 2004), which cell specific isomerases and synthases then convert to prostanoids 
(prostaglandin E2, F2, D2, and I2) or thromboxane. The strongest evidence that acetaminophen 
induced hypothermia is mediated through COX inhibition was provided by Ayoub and 
colleagues (2004). They demonstrated that acetaminophen reduced Tre by 1.5°C in COX-1 
knockout mice, where it fell by nearly 4°C when administered to wild-type mice. In addition, 
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they showed a strong positive correlation between brain PGE2 concentrations and Tre. This data 
demonstrates that COX-1 may be required for normal Tre maintenance in mice housed in sub-
neutral ambient temperatures, and that PGE2 is the prostaglandin responsible for this 
phenomenon.  
PGE2 is indispensable for lipopolysaccharide induced fever (rise in Tre) because it dis-inhibits 
pre-optic area neurons that induce shivering and brown adipose tissue activation, such that 
nanoinjection of PGE2 into the pre-optic area of anaesthetised mice induces a sharp rise in 
thermogenesis, and consequently Tre (Nakamura and Morrison 2011). Production of PGE2 is a 
crucial component of the febrile response because the increased internal temperature creates a 
sub-optimal environment for bacterial growth and viral replication (Small et al. 1986). In section 
2.4.3, it was argued that PGE2 release is required for full thermogenesis during acute cold 
exposure, and suggested that pharmacological inhibition of COX metabolism (and thus, PGE2 
production) would reduce Tc stability in non-febrile cold exposed humans. Given that 
acetaminophen is a potent COX inhibitor in non-inflamed tissue, the present study provides 
compelling evidence that this enzyme is required for full thermogenesis in cold exposed humans. 
Confirmation of this theory may have major implications for acetaminophen users who are 
vulnerable to hypothermia (i.e. the elderly and the very young).   
6.4.6 Limitations  
One limitation of the present study is the use of young, healthy individuals as participants 
because this age demographic does not represent an at-risk group vulnerable to hypothermia. 
However, this age group was chosen because the body of evidence supporting the experimental 
hypothesis is too small to warrant investigation in a vulnerable age group (i.e. the elderly). Given 
that acetaminophen significantly reduce Tc in a group capable of strong metabolic responses to 
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cold stress, this warrants future research in elderly individuals. The second limitation to this 
study was the use of a cold stressor which does not reflect the minimum indoor temperatures 
witnessed during winter months, which is ~15°C. The reason for using severe cold stress was to 
clearly establish if a link existed between acetaminophen administration and cold-induced 
thermogenesis. The use of a higher ambient temperature may have resulted in an under-
estimation of the effect of acetaminophen on non-febrile thermoregulation. A final limitation of 
this study was the absence of plasma acetaminophen concentrations during the environmental 
exposures. A dose-concentration relationship was clearly defined in Study 1a. However, plasma 
acetaminophen concentrations in this study would have allowed the reader to establish whether 
the inter-subject variability was due to differential plasma acetaminophen concentrations.  
6.4.7 Conclusions 
In conclusion, this study demonstrates that acute acetaminophen ingestion (20 mg·kg lean body 
mass) reduces Tc maintenance during acute cold exposure. Future work should determine if these 
hypothermic effects are limited to acetaminophen, or are witnessed in other COX inhibitors such 
as Ibuprofen, Aspirin, and Coxibs. If all COX inhibitors reduce thermogenesis during cold 
exposure, the prescription of these medications should be carefully considered in winter months 
and in the perioperative environment, especially in those already vulnerable to hypothermia. 
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CHAPTER 7. EXPERIMENT 4: EFFECT OF IBUPROFEN, A NON-SELECTIVE 
CYCLOOXYGENASE INHIBITOR, ON THERMOGENESIS DURING ACUTE COLD 
EXPOSURE.  
7.1 Introduction 
In Study 3 (Chapter 6), it was demonstrated that acetaminophen induced hypothermia is 
exacerbated in line with reductions in ambient temperature and Tsk. In a thermoneutral 
environment (25°C), there was no hypothermic side-effect of acetaminophen since Tre was stable 
throughout the passive 120-minute exposure (Figure 6.1). However, when the ambient 
temperature decreased to 10°C (reducing Tsk to 24°C), acetaminophen reduced Tre by 0.4°C 
(range = 0.16 to 0.57°C) after 120-minutes (p < 0.001). The results from that work raise concerns 
regarding the safe use of acetaminophen in those vulnerable to accidental hypothermia. For 
instance, it was shown that older people may not maintain a constant Tre during acute cold stress, 
an effect attributable to a reduction in endogenous heat production and possibly a reduced 
thermal sensitivity. The added administration of a drug which has a hypothermic side effect 
(such as acetaminophen) may accelerate reductions in Tre, leading to a greater risk of accidental 
hypothermia.   
Information regarding acetaminophen’s hypothermic mechanism of action is absent in humans. 
In mice, this side-effect may be mediated through interaction with TRPA1 (Gentry et al. 2015), 
hypothalamic GABAA receptors (Ahangar et al. 2016), or inhibition of COX metabolism (Ayoub 
et al. 2006). COX deserves specific investigation because it is the drug target of alternative 
analgesic and antipyretic medications such as ibuprofen, aspirin, and Coxibs. If COX is required 
for non-febrile thermogenesis, administration of any COX inhibitor should be avoided during 
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uncompensable cold stress. There is growing evidence that COX is involved in thermogenesis 
induced by skin cooling. In COX-1-/- mice, the hypothermic effect of intravenous acetaminophen 
(300 mg·kg-1) was reduced by ~50% compared with wild-type mice. Moreover, the Tc reductions 
elicited by acetaminophen was strongly related to total brain PGE2 concentrations, showing that 
COX-1 derived PGE2 may play a role in normal Tc regulation. In section 2.5.3, evidence 
suggestive of a COX involvement in non-febrile vasomotion, shivering, and brown adipose 
tissue activation is discussed, as well as PGE2’s hyperthermic mechanism of action. Aside from 
the metabolic pathways that initiate thermogenesis, COX induced TXA2 may also be involved in 
the veno-vasoconstrictor response to cold stress.  
Although acetaminophen is a potent COX inhibitor in vivo (Hinz et al. 2008), its actions on 
TRPA1 and GABAA mean that is its hypothermic action could be independent of COX. 
Furthermore, actions on each of these sites combined may be responsible for the physiological 
change in Tc (during cold stress), which is a powerfully regulated variable in human biology. 
Thus, using acetaminophen as a model to investigate if COX is involved in non-febrile 
thermoregulation specifically is problematic. A preferred option may be to administer ibuprofen, 
as it is not known to have any additional mechanistic actions besides non-selective inhibition of 
COX-1 and COX-2. Additionally, ibuprofen blocks COX metabolism within the cyclooxygenase 
active site of the enzyme, whereas acetaminophen works on the peroxidase active site (Boutaud 
et al. 2002). This is an advantage since ibuprofen is effective in all tissue types regardless of the 
peroxide tone. Finally, ibuprofen crosses the blood brain barrier, resulting in non-selective COX 
inhibition in and outside of the central nervous system (Parepally et al. 2006). Taken together, 
administration of ibuprofen during acute cold stress is an effective tool to determine if COX is 
involved in thermogenesis.  
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7.1.1 Experimental aims and hypothesis  
The aim of this trial was to examine the thermoregulatory response to ibuprofen administration 
(400 mg) during a 120-minute exposure to a cold environment (10°C) in healthy adult humans. It 
was hypothesised that ibuprofen would have a hypothermic side-effect by reducing metabolic 
rate and shivering thermogenesis.  
7.2 Methods 
7.2.1 Ethical approval 
All experimental procedures were approved by the University of Bedfordshire’s Institute for 
Sport and Physical Activity Research Ethics committee and University Research Ethics 
Committee (UREC), and they conformed to the standards set by the World Association 
Declaration of Helsinki ‘Ethical Principles for Research Involving Human Subjects’. 
7.2.2 Power calculation  
Power analyses were conducted with GPower software version 3.1 (Heinrich University, 
Düsseldorf, Germany). Using Tre data from Study 3 (Chapter 6) it was determined that a total of 
six participants were required to achieve a statistical power of 90%. Specifically, the maximum 
reduction in Tre induced by acetaminophen (0.42°C) and the variability in the response (0.13°C) 
were parameters in the model.  
7.2.3 Participants  
Six Caucasian males [Age (20 ± 1 years), height (182 ± 6 cm), mass (82 ± 20 kg), body fat (16 ± 
7 %)] volunteered to take part in the study. Participants were provided with written information 
regarding all experimental procedures, with supporting oral explanations from the principal 
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investigator. Participants then subsequently provided written informed consent. The participants 
were non-smokers, non-febrile (resting Tre < 38°C), and were free from musculoskeletal injury. 
7.2.4 General experimental controls  
The general experimental controls are described within the General Methodology (section 3.1.4). 
In addition, participants were required to complete the American College of Sports Medicine 
cardiovascular screening questionnaire prior to participation in the experiment. On the morning 
of each trial, participants were required to detail any medicinal activity in the prior 48 hours. No 
participants reported any pharmaceutical use in this time-period.  
7.2.5 Experimental design  
To determine the hypothermic effect of ibuprofen, 6 participants visited the laboratory at the 
same time of day on two occasions (ibuprofen vs placebo), each separated by at least seven days. 
All visits were randomized, and the ibuprofen and placebo trials were double blind. The trials 
took place within an environmental chamber set at 10°C for 120 minutes. This temperature was 
chosen as it allowed for thermoregulatory comparisons with Study 3 (Chapter 6) and was 
sufficient to induce shivering early in the trial (based on pilot data). Ibuprofen (Ibuprofen 
Modified Release Capsules, Banner Life Sciences, North California, USA) was administered at a 
400-mg dose, and the placebo (dextrose, MYPROTEIN, Cheshire, UK) was presented in the 
same number of capsules to improve blinding.  
7.2.6 Experimental protocol  
All participants arrived at the laboratory at 0830. Upon arrival, participants were instrumented 
for the measurement of Tre, Tsk, and heart rate (see “Instrumentation and Equations” for details).  
On arrival, participants rested supine for 15 minutes, and subsequently a 5-minute resting sEMG 
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from the vastus medialis and a 2-minute expired air sample was taken (for energy expenditure). 
At ~0900, participants’ maximal voluntary contraction (MVC) was taken on an isokinetic 
dynamometer (details below). At ~0920, 20G cannula was inserted into the participants’ 
antecubital region and blood samples were taken 5-minutes prior to chamber entry, and 
subsequently at 60 and 120 minutes (inside the chamber). At ~0930, participants were 
instrumented for the measurement of Tre, Tsk, heart rate, and their body mass was taken (see 
section 3.1.5 for details). At this point, participants rested for 30 minutes in a supine position for 
resting physiological status to be attained. Ten-minutes prior to chamber entry, measurements for 
Tre, Tsk, heart rate, TS and MAP were taken. One-minute prior to entry into the cold chamber 
(10ºC, 40%), participants were administered 400 mg ibuprofen or a placebo in a double-blind 
manner (i.e. pills were made and administered by a laboratory technician). Participants laid 
supine in the chamber for 120-minutes with measurements for Tre, Tsk, heart rate, TS measured 
every ten-minutes. MAP was measured at 30, 60, 90, and 120 minutes, and a 2-minute expired 
air samples was taken at 40, 80, and 120 minutes. A 20-mL venous blood sample was drawn at 
60 and 120 minutes. Vastus medialis sEMG was recorded at 5-20, 25-40, 45-60, 65-80, 85-100, 
and 105-120 minutes, in line with Haman et al. (2004a).  
7.2.7 Instrumentation and equations  
Thermometry  
The Tsk from 12 sites was used to estimate mean Tsk (Hardy and DuBois, 1938). See section 3.1.5 
for equipment details (Tre and Tsk) and the formula for calculating mean Tsk. 
Metabolic rate  
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Changes in energy expenditure [EE (J∙kg∙min-1)] were quantified using indirect calorimetry 
(Servomex, Servomex mini HF 5200, Sussex, UK). Two-minute expired air samples were taken 
at time point 0, 40, 80, and 120 minutes. The expired gas samples were collected in Douglas 
bags. These samples were analysed for volume of gas expired (litres), O2 consumption, and CO2 
production.EE was calculated using the Weir equation (Weir 1949). 
Maximal voluntary contraction and shivering activity  
Shivering EMG was normalised and expressed as a percentage of the maximal voluntary 
contraction (%MVC). MVC measurements were performed on the morning of each experimental 
trial using an isokinetic dynamometer (Kin Com 125E Plus, Chattecx, Tennessee, USA). 
Subjects sat securely in an upright position and the load cell was attached slightly above the 
ankle. The load cell arm was placed at a 45° angle from its vertical position, and participants 
performed three maximal knee extensions pushing against the load cell. Each MVC was held for 
5 seconds and was separated by a 30 second rest. All six MVCs from the two trials were later 
analysed with MATLAB, and the MVC which yielded the greatest EMG signal was used to 
normalise the shivering EMG values from both trials. Shivering intensity was measured using 
surface EMG at the vastus medialis. This muscle was chosen since its activity is induced by skin 
cooling by as little as 27°C (Haman et al. 2004a; Haman et al. 2004b), whereas Tsk is expected to 
reach ~25°C in the present work (Based on Study 3). Raw EMG signals were analysed by an 
external collaborator (Dr Denis Blondin, Université de Sherbrooke) with the use of custom-
designed MATLAB algorithms (Mathworks). Dr Blondin was not aware which dataset 
corresponded to the placebo or ibuprofen trial at the time of analyzing this data. EMG signals 
were filtered to remove spectral components below 10 Hz and above 500 Hz, as well as 60 Hz 
contamination (and associated harmonics). Shivering intensity of the VM and its mean (EMGshiv) 
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was determined from root mean square values (RMS) rectified from EMG signals using a 50ms 
overlapping window (50 %). Baseline RMS values (RMSbaseline: 5 min RMS average measured 
before cold exposure) were subtracted from RMS shivering (RMSshiv) as well as RMSmvc values. 
EMGshiv was then normalized to RMSmvc by using the following equation: 
EMGshiv (%MVC) = RMSshiv - RMSbaseline 
× 100 
  
                           RMSmvc - RMSbaseline 
 
7.2.8 Statistical analysis  
All statistical analyses were performed using the ‘nlme’, ‘ordinal’, ‘ez’, and ‘stats’ packages in R 
version 3.3.2 (R Core Development Team 2014). Normality assumptions were checked using 
quantile-quantile plots (Grafen and Hails 2002) and were plausible in all instances. Central 
tendency and dispersion are reported as means ± standard deviation (SD). The Akaike 
information criterion (AIC) was used to determine model fit against the null model (Akaike 
1973). The correlation structure with the lowest AIC was chosen based on this procedure. A 
linear mixed model with fixed (‘drug’, ‘time’) and random (‘subject i.d’) effects was fitted with 
an autoregressive correlation structure (to account for autocorrelation) to examine the effect of 
ibuprofen on Tre, Tsk, EE, shivering, and heart rate [Time (13 levels): pre, 10, 20, 30, 40, 50, 60, 
70, 80, 90, 100, 110, 120 minutes × Drug (2 levels): placebo, ibuprofen]. A cumulative link 
mixed model with fixed (‘drug’, ‘time’) and random effects (‘subject i.d.’) was used to compare 
thermal sensation scores between placebo and ibuprofen.  The two-tailed alpha level of 
significance testing was set as p ≤ 0.05. 95% confidence intervals (CI) are presented to denote 
the imprecision of the point estimate. 
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7.3 Results  
7.3.1 Tre 
The Tre response to cold exposure was not different between groups. There was no main effect 
for drug (F1,2 = 0.91, p = 0.34), time (F1,12 = 1.69, p = 0.07), and there was no interaction effect 
(F1,12 = 0.38, p = 0.97). At 120 minutes, Tre was reduced by 0.04 ± 0.10°C and 0.08 ± 0.17°C in 
the placebo and ibuprofen group, respectively. The Tre response to cold stress in each group is 
displayed in Figure 7.1.   
7.3.2 Tsk 
The Tsk response to cold exposure was not different between groups. There was a main effect for 
drug (F1,2 = 45.83, p < 0.01) and time (F1,12 = 112.77, p < 0.001), but there was no interaction 
effect (F1,12 = 0.69, p = 0.76). At 120 minutes, mean Tsk fell by 4.3 ± 0.8°C and 4.7 ± 0.4°C in 
the placebo and ibuprofen trials, respectively. The Tsk response to cold stress in each group is 
displayed in Figure 7.1.   
7.3.3 Heart rate  
The heart rate response to cold exposure was not different between groups. There was no main 
effect for drug (F1,2 = 1.22, p = 0.27) and time (F1,12 = 0.05, p = 0.90), and there was no 
interaction effect (F1,12 = 0.50, p = 0.90).  
7.3.4 Energy expenditure (J∙kg-1∙min-1) 
EE did not change with ibuprofen administration. There was no main effect for drug (F1,2 = 1.22, 
p = 0.56) and no interaction effect (F1,12 = 1.51, p = 0.23), but EE did increase over time (F1,12 = 
59.63, p < 0.001). Compared with baseline, EE rose by 77 ± 22 kJ in the placebo condition and 
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by 61 ± 18 kJ in the ibuprofen condition, but this was not significantly different (p > 0.05). The 
EE response is displayed in Figure 7.2. 
7.3.5 Shivering thermogenesis 
The shivering responses of the vastus medialis was not different between groups. There was no 
main effect for drug (F1,2 = 1.25, p = 0.28) and no interaction effect (F1,12 = 1.10, p = 0.38), but 
shivering did increase over time (F1,12 = 52.84, p < 0.001). In the final 30 minutes of the trial, 
shivering activity reached 1.10 ± 0.20 and 1.26 ± 0.30 %MVC in the placebo and ibuprofen 
group, respectively. The shivering response is displayed in Figure 7.3.  
7.3.6 Thermal sensation 
The thermosensory responses to cold exposure were no different between the ibuprofen and 
placebo group. Table 7.1 demonstrates effects for time (p < 0.001), whereas there was no main 
effect for condition and no interactions between groups at any time point (p > 0.05).  
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Table 7.1. Changes in TS as a product of time (duration of exposure) and time + drug 
(interaction effect). Significance codes: < 0.001***, < 0.01** 
  OR SE P 
Placebo vs IBU (Intercept) 1.818 3.688   
Time Only       
TIME10 9.77E-04 4.197 *** 
TIME20 9.24E-04 3.834 *** 
TIME30 9.24E-04 3.834 *** 
TIME40 7.80E-04 3.940 *** 
TIME50 4.19E-04 3.860 *** 
TIME60 1.85E-04 3.981 *** 
TIME70 1.91E-04 4.058 *** 
TIME80 8.40E-05 4.244 *** 
TIME90 1.32E-04 4.238 *** 
TIME100 8.40E-05 4.244 *** 
TIME110 8.40E-05 4.244 *** 
TIME120 1.27E-04 4.083 *** 
Drug×Time Interaction       
TIME10:DRUGIBU 0.180 6.143   
TIME20:DRUGIBU 0.134 5.561   
TIME30:DRUGIBU 0.138 5.571   
TIME40:DRUGIBU 0.143 5.547   
TIME50:DRUGIBU 0.266 5.308   
TIME60:DRUGIBU 0.601 5.299   
TIME70:DRUGIBU 0.536 5.401   
TIME80:DRUGIBU 0.787 5.419   
TIME90:DRUGIBU 0.248 5.466   
TIME100:DRUGIBU 0.165 5.380   
TIME110:DRUGIBU 0.108 5.387   
TIME120:DRUGIBU 0.168 5.256   
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Figure 7.1. Mean ± standard deviation values for Tre (A), Tsk (B), and TS (C) in the placebo and 
ibuprofen conditions during a 120-minute exposure to 10°C. n=6. 
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Figure 7.2. Boxplots displaying the change in EE and MAP during the 120-minute exposure to 
10°C. The white boxes and shaded boxes denote the placebo and ibuprofen trials, respectively. 
n=6. 
 
 
Figure 7.3. Shivering intensity of the vastus medialis during the 120-minute cold exposure, 
expressed relative to an isometric MVC.  n=6. 
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7.4 Discussion   
7.4.1 Overview of results  
The experimental hypothesis was not accepted in this paper since neither thermogenic nor Tre 
responses to cold differed with ibuprofen administration (400 mg) compared to a placebo (p > 
0.05). As ibuprofen is a potent non-selective COX inhibitor, this suggests that neither COX 
isoform has a significant role in the acute thermogenic responses to skin cooling.  
This is the first study to compare thermoregulatory responses to cold stress with prior 
administration of ibuprofen (T minus 5 minutes). However, the effect of chronic aspirin 
administration on acute thermoregulatory responses to cold has been investigated previously 
(Murray et al. 2011a). Unlike other NSAIDs, aspirin inhibits COX-1 in a non-reversible manner, 
rendering aspirin an effective antithrombotic drug since it inhibits COX-1 for the life-span of the 
platelet (platelet COX-1 produces TXA2 which increases thrombus formation (Schror 1997)]. 
Although these anti-thrombotic effects had no influence on Tre, Tsk or heat production during 
acute cold exposure, it is uncertain whether aspirin was present in the blood stream at the onset 
of the trial. This limitation was described in more detail in section 2.5.8, but in brief, if COX 
activity was induced by cold stress it is unlikely that it was inhibited due to the administration 
timing on the trial day. This was addressed in the present work since prior pharmacokinetic 
analysis suggested that therapeutic concentrations would be maintained from 15 minutes through 
to the end of the 120-minutes trial (Legg et al. 2014), suggesting that ibuprofen was present in 
the circulation during the cold exposure trials. Although there was no measurable difference in 
thermoregulatory responses between the two trials, this does not conclusively demonstrate that 
COX is not involved in these processes. Although free ibuprofen readily crosses the blood-brain 
barrier, it is extensively bound to plasma proteins (99%) and cannot cross into the brain in this 
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form (Parepally et al. 2006). Thus, the concentration of ibuprofen within the brain may not have 
been sufficient for COX inhibition in the hypothalamus, so the reduction in Tre seen with 
acetaminophen in identical conditions (Study 3) may be because a greater concentration of the 
drug reached this brain region. However, this is speculative since mammalian hypothalamic 
concentrations have not been obtained with either drug following administration.     
The thermometric and metabolic responses to this level of cold stress are similar to that seen in 
previous studies. For example, Gosselin and Haman (2013) demonstrated that EE rose to ~125 
kJ·kg-1·min-1 after 120-minutes of 10ºC cold exposure, while Tre remained stable and Tsk fell to ~ 
26ºC. Indeed, there are many studies, including Study 3 (placebo trial), which show that Tre 
should remain stable with a 120-minute passive cold exposure to 10ºC (Blondin et al. 2010; 
Haman et al. 2004a; Haman et al. 2004b). While pilot work determined that a 2-minute sample 
provided a suitable volume of expired air for metabolic analysis, it is a relatively small sample 
for a 120 minute trial i.e. it reflects only 6 minutes of V̇O2 data. The use of an online gas analysis 
system in future studies can provide a more detailed analysis of metabolic heat production 
throughout the course of the exposure and for longer time-periods.  The shivering activity of the 
vastus medialis reached a peak of ~1.5% MVC in the current study, while it reached ~3% MVC 
in prior work where humans were exposed to 10ºC for 120-minutes, but this was achieved with a 
water perfused suit (Haman et al. 2004a). Such a garment would affect nearly 100% of the body 
surface area, whereas only ~50% of the body surface area was influenced by the cold air in the 
present study because the posterior side of the body was in contact with a hospital bed. A 
consequence of these methodological differences is that fewer skin cold thermoreceptors would 
have been activated during the cold exposure in the present study, perhaps contributing to the 
lower shivering activity observed. Another contributing factor is that participants in the work of 
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Haman et al. (2004a) had a lower and less variable body fat % (13 ± 1.9% vs 16 ± 7%), and a 
greater layer of body fat may have reduced the signal from the shivering muscle to the sEMG 
electrode.  
The specific possibility that COX products (prostanoids) are involved in Tc defence against the 
cold has been investigated in rodents. Solomonovich and Kaplanski (1985) administered 
indomethacin (a highly potent and non-selective COX inhibitor) intraperitoneally to rats which 
were subsequently exposed to an ambient temperature of 4 ± 1°C, 23 ± 2°C and 34 ± 2°C. In 
addition, the authors measured hypothalamic PGE2 concentrations following each exposure. In 
line with the present study, acute COX inhibition had no influence on the Tc of rodents, arguing 
against a COX mediated thermogenesis or vasoconstriction in response to cold. After 2 -hours 
cold exposure, hypothalamic PGE2 concentrations were reduced from 8 pg∙mg-1 to 0.7 pg∙mg-1. 
This shows that PGE2 is either constitutively expressed in this tissue or that COX is upregulated 
by cold exposure, but since baseline PGE2 concentrations were not made in another group of 
animals, it is not possible to know which is true in either case. Ayoub et al. (2004) studied the 
hypothermic response to high dose acetaminophen infusion (300 mg∙kg-1 body mass) in wild-
type, COX-1 and COX-2 genetic knockout mice housed at 20°C. They demonstrated that the 
hypothermic response to acetaminophen persisted in COX-2-/- mice, but was reduced by ~50% in 
the COX-1-/- strain. This suggests that COX-1 may participate in normal Tc regulation, at least in 
mice housed beneath thermo-neutrality. Later work confirmed this hypothermic side-effect in 
mice, but showed that neither plasma nor brain PGE2 concentrations were not influenced by 
acetaminophen in mice housed at 20°C (Li et al. 2008). This contradicts prior work in which 
there was a pronounced reduction in whole brain PGE2 concentrations following acetaminophen 
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infusion, but this may be due to the difference in the relative doses administered (160 vs 300 
mg∙kg-1 body mass).  
7.4.2 Conclusions 
In summary, the administration of ibuprofen, a non-selective COX inhibitor, had no effect on 
heat production (shivering and metabolic rate) or thermometric (Tre, Tsk) responses to cold stress. 
Despite evidence that acetaminophen reduces Tre during mild (Study 1) and extreme (Study 3) 
cold stress, this side-effect was not mirrored with ibuprofen, suggesting that acetaminophen 
induced hypothermia (Study 1b and 3) is independent of COX inhibition.  
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CHAPTER 8: SYNTHESIS OF EXPERIMENTAL FINDINGS AND GENERAL 
DISCUSSION  
8.1 General discussion  
The aim of this chapter is to provide a general overview of the experimental findings from 
studies 1 to 4. This chapter will revisit the aims and objectives of the thesis and reviewing if 
each, in turn, have been achieved. The aim of this chapter is to integrate the findings of all the 
studies completed in this thesis with brief conclusions from all chapters leading to an overall 
conclusion from the thesis.  
One of the main aims of this thesis was to determine if acetaminophen administration interacted 
with normal, non-febrile Tc regulation. During fever, Tc is raised through the actions of PGE2 
within the pre-optic anterior hypothalamus, and acetaminophen can reduce this hyperthermia 
through inhibition of PGE2 synthesis within the brain (Li et al. 2008). Walker et al. (1981) were 
the first to document that high dose acetaminophen infusion causes hypothermia in non-febrile 
mice, and they also showed that this side-effect occurred prior to any hepatotoxicity. Since then, 
there have been many other reports of acetaminophen induced hypothermia in mice (Ahangar et 
al. 2016; Ayoub et al. 2004; Briyal and Gulati 2010; Gentry et al. 2015; Li et al. 2008; Massey 
et al. 1982; Walker et al. 1981), and several studies have shown the absolute Tc reduction is dose 
dependent (Ayoub et al. 2004; Gentry et al. 2015; Walker et al. 1981). Evidence of a 
hypothermic side-effect of acetaminophen prompted clinical research trials to investigate 
whether acetaminophen administration improved neurological outcome in ischemic stroke 
patients by reducing Tc and brain temperature (de Ridder et al. 2013; den Hertog et al. 2009; 
Dippel et al. 2001; Dippel et al. 2003a; Kasner et al. 2002). Although preliminary trials showed 
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a slightly reduced Tc with acetaminophen over 24 hours (~0.2°C), this did not have a clinical 
benefit in larger trials [paracetamol (acetaminophen) in stroke trial (PAIS)] when neurological 
outcome was assessed. These trials did not support acetaminophen administration in acute 
ischemic stroke patients, and consequently, the interaction of acetaminophen with non-febrile Tc 
in humans was not explored further. In this PhD project, the author viewed the animal model 
data from a different perspective; if acetaminophen reduces human Tc in those without a fever, 
this may increase the risk of accidental hypothermia in those who already struggle to maintain 
their Tc during cold exposure. If so, acetaminophen use in these vulnerable people could have 
serious implications in the healthcare sector, especially since there were already 17,500 hospital 
admissions from accidental hypothermia in 2014 (HSCIC 2015). To support this view, there are 
several case reports of acetaminophen induced hypothermia following administration of high 
(Rollstin and Seifert 2012) and therapeutic doses (Van Tittelboom and Govaerts-Lepicard 1989). 
To address this question, a preliminary experiment was developed which investigated if oral 
acetaminophen administration (20 mg∙kg-1 lean body mass) interacted with human Tre during a 
passive exposure to mild cold [Chapter 4, (20°C, 40% r.h for 120 minutes)]. This ambient 
temperature was chosen as it replicated previous experiments in mice which were house beneath 
their thermal neutral zone (Ayoub et al. 2004), and acetaminophen has not been shown to exert a 
hypothermic action in mammals housed at or above their thermal neutral zone. In this 
preliminary trial, the confounding effect of clothing was removed to ensure a more uniform Tsk 
distribution across the body. This mechanistic approach removes the opportunity for behavioural 
thermoregulation and is a useful approach for determining any cause and effect. However, it 
should be noted that, in real life, young adults are fully capable of behavioural adaptations such 
as increasing clothing insulation and increasing the room temperature from the thermostat. 
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However, behavioural thermoregulation is not always possible. Indeed, the mechanistic approach 
used for the following PhD studies can reflect conditions experienced by frail older people who 
are the most vulnerable to accidental hypothermia. Due to medical and socioeconomic issues, 
frail individuals may not be able to readily increase clothing insulation or alter the thermostat of 
the room (Collins, 1995). Although the hypothermic effect of acetaminophen should be 
investigated in this specific population, a clear cause and effect trial was warranted in the first 
instance to build a rationale for future studies investigating this in different population groups.  
Although Tre was the primary outcome variable in Study 1, its effects on Tsk were also of interest. 
A raised Tsk is evident of increased heat transfer from the skin to the environment, since an 
augmented skin blood flow will increase the local temperature of the skin (Romanovsky 2014). 
If acetaminophen reduced Tre during the 120-minute exposure, a concomitant increase in Tsk 
would suggest that this effect is due to a reduction in the autonomic vasoconstrictor response to 
cold. Participant’s TS was an additional marker of interest throughout this thesis. The ability to 
perceive changes in Tre and Tsk is indispensable for adequate behavioural thermoregulation, such 
that appropriate changes in clothing or the ambient temperature can be made to keep Tre at 
~37°C. If there was a reduction in Tre without an associated decrease in TS, it suggests that 
participants do not perceive they are colder with acetaminophen, placing that at an even greater 
risk of accidental hypothermia. Study 1 (Chapter 4) was to be the first experiment in humans 
which maps these thermoregulatory variables following acetaminophen administration, while 
controlling the clothing insulation, ambient temperature, and gastric emptying rate of 
acetaminophen (by controlling food consumption prior to its ingestion). As a dose was 
administered relative to lean body mass, the plasma response to first documented (Study 1, part 
a) to ensure that plasma concentrations were in line with that seen previously. In part b (where 
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the thermoregulatory response was examined), young adults were chosen as participants in place 
of older people as they generally maintain their Tre during cold exposure. Because skin cooling 
may already decrease the Tre of older people without acetaminophen administration, it would be 
difficult to know acetaminophen’s independent influence on Tre, even if an effect existed.  
In Study 1 part a, it was demonstrated that oral acetaminophen administered at 20 mg·kg of lean 
body mass reached maximal plasma concentrations [14 ± 4 μg/ml, (range, 8-19 μg/ml)] at 80 to 
100-minutes post-ingestion. These concentrations were in line with prior pharmacokinetic work, 
where acetaminophen was orally administered at a 1 g or 2 g dose (Singla et al. 2012). An 
interesting finding in part b was that acetaminophen reduced Tre in all 13 participants relative to 
the baseline value (0.19 ± 0.09°C decrease at 120 minutes), an effect not seen when participants 
were administered a sugar placebo. There are several reasons why there was a consistent effect 
on Tre. in this experiment compared with prior work in stroke patients. Firstly, the 20°C 
environment in Study 1 was sufficient to reduce Tsk to 27°C, a temperature which activates 
metabolic pathways required thermogenesis (Gosselin and Haman 2013). Although the ambient 
temperature in hospital wards may be ~22°C, the clothing insulation and bedding is sufficient to 
ensure that the Tsk is maintained within a thermoneutral range. Thus, it can be concluded that the 
hypothermic response to acetaminophen depends on whether participants are exposed to an 
environment beneath their thermal neutral zone. Secondly, Tre was continuously monitored in 
Study 1b, whereas it was only measured after 24 hours in the PAIS trial (de Ridder et al. 2013). 
Based on our results, the hypothermic action of acetaminophen could occur rapidly after its 
appearance in the systemic circulation, such that previous likely missed an initial reduction in 
Tre. This is pertinent since Tre on hospital admission is a key predictor of neurological outcome 
following an acute traumatic brain injury (Titus et al. 2015). Thirdly, acetaminophen was 
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administered as a 1 g oral or rectal dose in the PAIS trial. Since the hypothermic action of 
acetaminophen is highly dose dependent (Gentry et al. 2015), a 1 g dose may not have been 
sufficient to induce a reduction in Tre. A final limitation of the PAIS trial was the use of tympanic 
temperature in an unknown quantity of patients. Although the same method was used at baseline, 
there can be substantial variability with tympanic temperature and rectal temperature depending 
on the model of the sensor and the inter-rater reliability.  
In experimental Chapter 5 (Study 2), the influence of acetaminophen on thermoregulation during 
uncompensable dry and humid heat stress was examined. Prior work has demonstrated negative 
effects of over-the-counter drugs aspirin (oral) and ketorolac (intradermal infusion) on heat loss 
effector responses in older and young males, respectively (Bruning et al. 2013; Fujii et al. 
2014b). For example, Bruning et al (2013) showed that a 7-day regimen of low dose aspirin (81 
mg·day-1) caused the threshold for heat loss effector responses to increase by ~0.3ºC. In the 
present acute study, the administration time was 100 minutes prior to entry into the 
environmental chamber so that Cmax was attained at this point, in line with Study 1a. The dry and 
humid heat exposures caused Tre to rise at a rate of ~0.02 and 0.005°C∙min-1, respectively, but Tre 
and other thermoregulatory responses were not different between the acetaminophen and placebo 
group, suggesting that acetaminophen does not alter these responses or effect the thresholds for 
heat loss activation. An important limitation of the study was that Tre was the only variable 
associated with any change in body heat storage. Indeed, many studies demonstrate that the Tre 
likely underestimates absolute heat storage compared with those attained using direct calorimetry 
(Larose et al. 2014). Although direct calorimeters are not commercially available, an improved 
estimated of heat storage could have been attained with additional Tre measurement sites (i.e. 
oesophageal), and through measurement of whole body sweat losses. The reason that 
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acetaminophen was examined for both dry and humid heat stress was due to evidence that COX 
may only be involved in the sweating response at low heat loads (Fujii et al. 2014b). The lack of 
effect for acetaminophen during heat stress supports previous work which drew similar 
conclusions (Coombs et al. 2015).     
In experimental Chapter 6 (Study 3), the strength of acetaminophen induced hypothermia was 
compared between exposure to a thermoneutral environment (25°C) and severe cold stress 
(10°C). Since acetaminophen had no effect on Tre during heat stress (Chapter 4), but reduced Tre 
during mild cold stress (Chapter 5), it is likely that acetaminophen depresses thermogenesis, 
while exerting little to no effect on active heat loss mechanisms. Because autonomic 
thermogenesis is governed by initial changes in Tsk, and acetaminophen may reduce efferent 
drive for this response, it was hypothesised that the strength of acetaminophen induced 
hypothermia would increase in line with requirement for thermogenesis. Thus, it was predicted 
that there would be no acetaminophen induced hypothermia in thermoneutral conditions, but a 
significant effect on Tre would occur during cold stress. In that study, the experimental 
hypothesis was accepted because acetaminophen had a hypothermic side-effect during cold 
stress, but not in thermoneutral conditions. Indeed, Tre fell by ~0.4ºC at 120 minutes compared 
with baseline, while Tre was well maintained in the placebo condition. These findings have 
implications for accidental hypothermia, especially because older people have the highest 
hospital admission rates in the UK (HSCIC 2015) and commonly use acetaminophen for the 
management of chronic pain (Koponen et al. 2013).  
In Study 4, it was demonstrated that ibuprofen, a non-selective COX inhibitor, had no influence 
on thermogenesis during an acute exposure to cold (10ºC for 120-minutes). Prior to this work, 
there was considerable evidence both for (Section 2.4.3) and against (Aronoff and Romanovsky 
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2007) such a role for COX. In the present work, ibuprofen did not influence metabolic heat 
production, shivering at the vastus medialis, thermometry (Tsk, Tre), or thermal perception of cold 
(p > 0.05). The thermometric and metabolic responses were comparable to the placebo condition 
in Study 3, and prior studies where healthy humans were exposed to 10ºC for over ~120-minutes 
(Blondin et al. 2010; Gosselin and Haman 2013; Haman et al. 2004a; Lee and Haymes 1995; 
Murray et al. 2011a). For example, when Gosselin and Haman (2013) exposed young males to 
10ºC for 2 hours, Tre remained stable at ~37ºC, and EE increased to ~130 kJ·kg-1·min-1; these 
responses were mirrored in the present study. Shivering activity of the vastus medialis peaked at 
~1.5% MVC, which is relatively low when compared with previous work. For example, when 
Haman et al. (2004a) exposed young adult males to 10ºC for 2 hours, vastus medialis shivering 
activity rose to ~3.5% MVC at the end of the trial. Although the mean Tsk response was similar in 
both studies, methodological differences may explain the lower shivering response in the present 
study. Since Haman et al. (2004a) used a suit perfused with 10ºC water, so ~95% of the body 
surface area would be exposed to cold, whereas participants laid supine in Study 4 while exposed 
to 10ºC air. Here, only ~50% of body surface area (the anterior side) would have been exposed to 
the cold, so less cold thermoreceptors would have been activated to activate thermogenesis. It is 
also worth noting that local Tsk measurements can be confounded if they come into contact with 
the water perfused garment (communications with experts), perhaps explaining why Tsk was 
similar in both studies despite changes in body surface area exposed to cold. Based on prior 
work, it is most likely that COX is involved in chronic adaptations to cold rather than acute 
responses. For example, COX-2 release of PGE2 is involved in the browning of white adipose 
tissue and the induction of UCP-1 in these beige cells (Madsen et al. 2010; Vegiopoulos et al. 
2010). One day after transfer into a cold environment, blockade of COX-2 expression with 
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indomethacin caused Tre to fall by 2ºC, whereas Tre only fell by 1ºC in mice treated with saline 
(Madsen et al. 2010). While use of COX inhibitors do not augment heat loss in acutely cold 
exposed humans (Study 4), they may reduce beige cell following cold acclimation, but this 
should be determined in future work. Overall, these results suggest that the use of COX 
inhibitors (NSAIDS & Coxibs) does not represent a risk for accidental hypothermia during 
winter months. The results also suggest that acetaminophen induced hypothermia is independent 
of COX inhibition in humans, which contradicts prior work where this side effect was largely 
reduced in COX-1-/- mice  (Ayoub et al. 2004).  
8.2 Limitations 
The use of rectal temperature as a surrogate for Tc is widely used, but it may not reflect whole 
body heat loss since it measures the temperature of a specific tissue. In addition, there may be a 
lagged effect regarding the Tre response to heat stress compared with oesophageal temperature 
and intestinal temperature (Lee et al. 2000). Although measuring heat balance in real time is only 
available with direct calorimetry, additional Tc measurement sites would provide a greater 
estimation of internal temperature. In this project, rectal temperature was chosen since it allows 
comparisons with previous work in mice (Ayoub et al. 2011) and is also efficient from a 
logistical point of view. Secondly, the lack of circulating plasma acetaminophen concentrations 
in Study 1b, Study 2, and Study 3 is a major limitation since it is still unknown what 
concentration is required to mediate the demonstrated physiological responses. However, since 
the plasma response to 20 mg∙kg-1 lean body mass was mapped in Study 1a, the concentrations 
attained in the subsequent experiments can be predicted with reasonable confidence, as there 
were no changes to the study design which would influence the pharmacokinetics of 
acetaminophen. Thirdly, Study 2 adopted a design which required acetaminophen to be 
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administered 100 minutes prior to heat exposure. This approach ensured therapeutic plasma 
concentrations were attained during the humid heat exposure (45°C, 70% r.h.), since this trial 
was only 45 minutes in duration. For example, if acetaminophen was administered at rest, 
concentrations would only be ~5 to 10 µg∙ml-1 at the end of the humid exposure, as informed by 
Study 1a. In retrospect, administration of acetaminophen immediately prior to chamber entry in 
the dry heat stress trial (45°C, 30% r.h.) would have improved the comparison with Study 1 and 
3. It would also have demonstrated how physiological changes occur as a product of increase 
acetaminophen concentrations (if an effect existed). Fourthly, the major rationale for 
investigating whether over-the-counter drugs impact Tc regulation during thermal stress is linked 
to vulnerable populations, such as the elderly and neonates. These two age groups are the most 
vulnerable to accidental hypothermia (Collins 1995; Onalo 2013), yet the experimental subjects 
in this series of studies used healthy young males. However, such an effect needed to be 
investigated in a healthy model prior to work in vulnerable populations. Indeed, the work 
demonstrated in Study 1 and 3 serves as a rationale for future investigations into the contribution 
of acetaminophen to hospital admission rates for accident hypothermia. Fifth, heat production 
(indirect calorimetry) and shivering (sEMG) responses to cold were only measured in Study 4. 
The lack of these measures in Study 1 and 3 make it difficult to know if acetaminophen induced 
hypothermia was due to activated heat loss effectors or increase in basal vasodilation, or through 
a reduction in heat production. The primary aim of these studies was to determine if 
acetaminophen reduced Tc, since this was most relevant to clinicians. The data from Study 1 and 
3 warrant further work which should measure expired air and shivering responses to 
acetaminophen during cold exposure. Sixth, the posture of the participants was different in Study 
4 (supine), compared with experiments 1-3 (seated). Participants were in a supine position in the 
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final study because this decreased the potential for subtle behavioural responses i.e. adjusting 
their position for comfort. The limitation to this is that ~50% of the body surface area is in 
contact with a non-conductive hospital bed, contributing to an elevated mean Tsk (~2ºC) 
compared with Study 3. The elevated requirement for thermogenesis in Study 3 may have 
contributed to a greater hypothermic effect of the experimental drug.     
8.3 Conclusions 
In conclusions, this project has demonstrated that acetaminophen reduces Tc during cold stress, 
and this effect is unlikely to be mediated by COX inhibition, at least in isolation. Despite its 
ability to inhibit COX in endothelial cells, and thus inhibition of vasodilatory prostaglandins 
(Boutaud et al. 2002), acetaminophen did not affect the rate of Tc rise during exposure to dry and 
humid passive heat stress. Future work should determine the factors that influence the 
hypothermic response to acetaminophen i.e. age, body morphology, dose administered, drug 
tolerance, ambient temperature, and prior acclimatisation to cold. Moreover, the mechanism of 
acetaminophens hypothermic should be confirmed in humans because it may lead to the 
development of drugs used for the induction of therapeutic hypothermia.  
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